<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12753621</article-id><article-id pub-id-type="pmcid-ver">PMC12753621.1</article-id><article-id pub-id-type="pmcaid">12753621</article-id><article-id pub-id-type="pmcaiid">12753621</article-id><article-id pub-id-type="pmid">41315111</article-id><article-id pub-id-type="doi">10.1007/s12672-025-04188-2</article-id><article-id pub-id-type="publisher-id">4188</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zubair</surname><given-names initials="A">Akmal</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wdidi</surname><given-names initials="S">Safa</given-names></name><address><email>safaahmedwdidi@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04s9hft57</institution-id><institution-id institution-id-type="GRID">grid.412621.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2215 1297</institution-id><institution>Department of Biotechnology, </institution><institution>Quaid-i-Azam University, </institution></institution-wrap>Islamabad, 45320 Pakistan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ghc4a37</institution-id><institution-id institution-id-type="GRID">grid.442427.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 5984 622X</institution-id><institution>Faculty of Medical Laboratory Science, Oncology Research Center, </institution><institution>University of Shendi, </institution></institution-wrap>Khartoum, Sudan </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>2343</elocation-id><history><date date-type="received"><day>22</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-01 00:25:15.337"><day>01</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12672_2025_Article_4188.pdf"/><abstract id="Abs1" abstract-type="unstructured"><p id="Par1">Recent advancements in cancer treatment, including targeted therapy, tailored vaccines, immunotherapy, and bacteriotherapy, have demonstrated remarkable potential in addressing various types of cancer. However, the pursuit of novel therapeutic strategies remains challenged by significant obstacles, including toxicity to healthy tissues, limited penetration into malignant tissues, and the potential for tumor cell resistance to pharmacological agents. This study explored the potential of tailored vaccinations, immunotherapy, CRISPR/Cas9, and bacteriotherapy for cancer treatment. Randomized and non-randomized studies were reviewed using the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed (NCBI), Scopus (ELSEVIER), and Web of Science (CLAVIRATE) databases. This research highlights the promising use of personalized cancer vaccines, which induce tumor-specific immune responses targeting neoantigens unique to each patient. Immunotherapy, which enhances the ability of the immune system to identify and destroy cancer cells, has revitalized tumor immunology. While the effectiveness of immunotherapies, such as immune checkpoint inhibitors (ICIs) and adoptive cell transfer (ACT), is variable, certain cancer patients show substantial benefits. Bacteriotherapy has also proven effective in promoting tumor remission and inhibiting metastasis, either alone or in combination with conventional treatments, by reducing tumor proliferation and metastasis. Additionally, bacteriotherapy serves as a potential platform for delivering therapeutics, genes, or medications directly to tumors. The CRISPR-Cas9 genome-editing technique shows promise for advancing cancer treatment, with the potential to target and treat genetic mutations at the tumor level, although its application in human cancer therapy is still under development. This study highlights the potential of these innovative approaches in the fight against cancer.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Adoptive cell transfer (ACT)</kwd><kwd>CRISPR/Cas9</kwd><kwd>Cancer treatment</kwd><kwd>Immune checkpoint inhibitors (ICIs)</kwd><kwd>Immunotherapy</kwd><kwd>Personalized cancer therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2"> The 2023 cancer statistics report released by the American Cancer Society revealed a substantial 33% reduction in the death rate attributed to cancer since 1991 and a modest 1.5% decline in the period from 2019 to 2020 [<xref ref-type="bibr" rid="CR1">1</xref>]. This decline in mortality rates has been observed across various types of tumors, including leukemia, melanoma, and renal cancer, despite an increase in the incidence of these cancers. Anticipated new cancer cases for the year 2023 stand at approximately 2 million, with prostate, lung, and colorectal cancer (CRC) being the predominant diagnoses in men, comprising a total of 48% of cases [<xref ref-type="bibr" rid="CR2">2</xref>]. In women, breast, lung, and (CRC) (CRC) account for 52% of diagnoses. Among these, prostate cancer is projected to be the most prevalent among men at 29%, while breast cancer is expected to have the highest incidence rate among women at 31%. Improved survival rates have been steadily rising, with a 68% 5-year survival rate for patients diagnosed between 2012 and 2018, in contrast to the 49% survival rate for those diagnosed in the 1970s [<xref ref-type="bibr" rid="CR3">3</xref>]. One contributing factor to these improvements is the enhanced categorization of patients for treatments that target specific driver mutations [<xref ref-type="bibr" rid="CR4">4</xref>] Common treatments for cancer are surgery, chemotherapy, or radiation therapy but there are complications associated such as the destruction of normal body cells, Anemia, bleeding, and infection. These treatment options are not working in a good manner due to adverse side effects. Novel therapeutic options such as personalized cancer vaccines, immunotherapy, bacteriotherapy, and CRISPR-CAS9 are the modern options due to its accuracy, long-term memorization, and complete elimination of the cancer microenvironment with minimum side effects. This review aims to combine all novel therapeutic options and current progress on these treatments [<xref ref-type="bibr" rid="CR5">5</xref>]. Personalized cancer vaccines bacteriotherapy, immunotherapy, and CRISPR-CAS9 are the most suitable and highly advanced treatment options for eliminating cancer. the goal of developing individualized cancer vaccines is to reduce side effects while increasing the likelihood of a strong immune response targeting tumor-specific neoantigens and establishing long-term protection against cancer [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Bacteria have the ability to multiply in tissues, their distinct virulence factors that can be used to fight tumors, and their antibiotic-controlled population, bacteria are being considered as potential micro-medication for cancer treatments [<xref ref-type="bibr" rid="CR8">8</xref>]. Cancer treatment includes immunotherapy. It boosts the immune system and helps find and kill cancer cells using body-produced or lab-made chemicals. Immunotherapy treats many cancers. It can be used alone or with chemotherapy. Because of its precision and accuracy, CRISPR/Cas9 is being considered as a cancer treatment. It treats brain, colorectal, hepatocellular, renal cell, and urinary bladder cancers worldwide. The trails vaccines of cancer are represented in Table <xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par3">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Represent the class of different vaccines under trial for various cancers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>) the table represent different trials of vaccines, common side effects and number of doses</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Personalized vaccine (study, trial, name)</th><th align="left" colspan="1" rowspan="1">Cancer types</th><th align="left" colspan="1" rowspan="1">Treatment</th><th align="left" colspan="1" rowspan="1">Study evaluation</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>Personalized Peptide Vaccine for Pancreatic Cancer or Colorectal Cancer</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02600949">NCT02600949</ext-link></p></td><td align="left" colspan="1" rowspan="1">colorectal d pancreatic ductal adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Subcutaneously pembrolizumab injection</td><td align="left" colspan="1" rowspan="1">Toxicity, PFS, RR, tumour biomarker CA19-9,</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02999646">NCT02999646</ext-link></p></td><td align="left" colspan="1" rowspan="1">Squamous Cell Carcinoma (HNSCC)</td><td align="left" colspan="1" rowspan="1">MVXONCO-1 subcutaneous vaccination</td><td align="left" colspan="1" rowspan="1">Assess OS at 26 weeks, time to next treatment, response duration, AEs, PFS, and OS.</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Personalized Tumor Vaccine Follicular Lymphoma</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03121677">NCT03121677</ext-link></p></td><td align="left" colspan="1" rowspan="1">Follicular Lymphoma</td><td align="left" colspan="1" rowspan="1">subcutaneously injection</td><td align="left" colspan="1" rowspan="1">Review response time and select OS and PFS.</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>mRNA Vaccine Encoding Neoantigen in Patients with Advanced Digestive System Neoplasms</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03468244">NCT03468244</ext-link></p></td><td align="left" colspan="1" rowspan="1">squamous carcinoma, gastric adenocarcinoma, pancreatic colorectal</td><td align="left" colspan="1" rowspan="1">Subcutaneous mRNA injection</td><td align="left" colspan="1" rowspan="1">Assess tumour vaccine&#8217;s safety, tolerability, and effectiveness.</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Neoantigen Vaccine for Pancreatic Tumor</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03645148">NCT03645148</ext-link></p></td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Subcutaneous Personalized neoantigen vaccine</td><td align="left" colspan="1" rowspan="1">Use ELISPOT to assess neoantigen immune response.</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03606967">NCT03606967</ext-link></p></td><td align="left" colspan="1" rowspan="1">breast carcinoma,</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Evaluate PFS</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Smoldering Multiple Myeloma</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06574126">NCT06574126</ext-link></p></td><td align="left" colspan="1" rowspan="1">Multiple myeloma</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection</td><td align="left" colspan="1" rowspan="1">Assess the feasibility, intensity and longevity</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Neo-antigen Vaccine (NeoPepVac)</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03715985">NCT03715985</ext-link></p></td><td align="left" colspan="1" rowspan="1">lung cancer (NSCLC),</td><td align="left" colspan="1" rowspan="1">Subcutaneous with 5 doses successively</td><td align="left" colspan="1" rowspan="1">Incidence of treatment related Ages</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>NeoAntigen Cancer Vaccine Combined with Anti-PD-1 in</p><p>Melanoma</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04072900">NCT04072900</ext-link></p></td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Administration of a personalized neoantigen cancer vaccine.</td><td align="left" colspan="1" rowspan="1">Assess AEs, complete remission rate.</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Neoantigen Vaccination With Dendritic Cells</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04912765">NCT04912765</ext-link></p></td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer (TNBC)</td><td align="left" colspan="1" rowspan="1">Subcutaneous</td><td align="left" colspan="1" rowspan="1">Assess AEs and safety</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>PCV13</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04613375">NCT04613375</ext-link></p></td><td align="left" colspan="1" rowspan="1">Diffuse large-cell lymphoma,</td><td align="left" colspan="1" rowspan="1">3 times injection of intramuscular injection</td><td align="left" colspan="1" rowspan="1">Determine humoral RR to PCV13 vaccine.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec2"><title>Personalized vaccine for cancer treatment</title><p id="Par4">A tailored neoantigen-based vaccination called NEO-PV-01 was coupled with PD-1 therapy in the first open-label phase IB clinical study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02897765">NCT02897765</ext-link>) of 122 advanced solid tumor patients. Out of 82 patients, the median progression-free survival (PFS) for vaccinated melanoma was 23.5 months, NSCLC was 8.5 months, and bladder cancer was 5.8 months. Melanoma and NSCLC patients did not attain the median overall survival (OS) of 20.7 months for vaccinated people. However, bladder cancer patients had a 20.7-month OS. The research focused on NEO-PV-01 and nivolumab safety and tolerability. The vaccine&#8217;s most prevalent side effects were injection site responses (52% of patients) and flu-like symptoms (35%). No significant medication adverse effects were detected. This treatment was safe and effective for advanced solid tumours [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par5">Individualized neoantigen-specific immunotherapy (iNeST) RO7198457 was tested in 144 locally or metastatic solid tumor patients in a phase IB research (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03289962">NCT03289962</ext-link>) utilizing atezolizumab. RO7198457, an mRNA vaccine, has 20 neoantigens. Of the 108 patients evaluated, one had a complete response (CR) among the nine who responded to medication (ORR 8%), and 54 (49%) had stable illness. Vaccination produced neoantigen-specific T cells in 77% of people. Infusion-related reactions, tiredness, cytokine release syndrome, nausea, and pyrexia were the most common combined side effects, affecting over 10% of patients. Many people tolerated the drug. Compared to anti-PD-1 monotherapy, immune-mediated adverse effects were unchanged. RO7198457 with atezolizumab may induce a strong neoantigen-specific immune response [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par6">In a second phase I multicenter research (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03313778">NCT03313778</ext-link>), mRNA-4157 and pembrolizumab will be tested for safety, immunogenicity, and tolerability in 13 solid tumor patients who have undergone surgery and 20 untreated patients. Indications include melanoma, bladder cancer, non-small cell small cell carcinoma, (CRC) with metastases, and non-small cell lung cancer&#8212;neoantigen-based lipid-encapsulated RNA vaccination mRNA-4157. After eight months of follow-up, twelve of thirteen patients are disease-free. One complete response (CR), two partial responses (PR), five progressive diseases (PD), two newly detected immune-unconfirmed progressive illnesses, and one patient who could not be tested were found among the other twenty patients. No drug-related severe adverse events (SAEs) or AAEs above grade 3 were recorded. Treatment-related AEs are usually mild and short-lived. These findings move mRNA-4157 to phase 2 by confirming that pembrolizumab and neoantigen-specific T cells are safe and effective against tumours [<xref ref-type="bibr" rid="CR12">12</xref>]. The ADXS-NEO-02 Phase 1 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03265080">NCT03265080</ext-link>) is testing ADXSNEO&#8217;s effectiveness and safety in solid tumors alone or conjunction with anti-PD-1 antibody radiation treatment. Listeriolysin O (tLLO) and 20-21mer peptides make up the ADXS-NEO-tailored tumour antigen system. The best and safest ADXS-NEO dosage is shown by this early finding. The only mild to moderate, controllable, and transient side effects at this dosage were chills, fever, and tachycardia. Chemokines that promote T-cell trafficking into the tumour microenvironment were released at a greater rate, and many CD8 + T cells were primed against most neoantigens soon. The synergy between ADXS-NEO and anti-PD-1 antibody treatment is currently being studied [<xref ref-type="bibr" rid="CR10">10</xref>]. GEN-009 and anti-PD-1/L1 are being tested in another phase I/IIA research (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03633110">NCT03633110</ext-link>) to treat advanced cancers. GEN-009, a customized neoantigen vaccine, uses poly-ICLC to synthesize four to twenty synthetic long peptides. The first solid tumor research using GEN-009 alone showed persistent peripheral neoantigen-specific CD4 + and CD8 + responses in all eight patients. Multiple doses have caused mild local pain, but no dosing-related adverse effects (DLT). We eagerly await vaccine-PD-1 inhibitor research outcomes for advanced tumour patients [<xref ref-type="bibr" rid="CR13">13</xref>].</p><sec id="Sec3"><title>Whole tumor cell vaccines admixed with adjuvant</title><p id="Par7">An essential first step toward the development of tailored vaccinations for use in therapeutic settings is the isolation of tumor cells from a patient and their subsequent use in the production of an autologous whole tumor cell vaccine [<xref ref-type="bibr" rid="CR14">14</xref>]. By introducing a wide variety of tumor antigens, including tumor-associated antigens (TAAs) and neoantigens unique to the individual patient, this strategy aims to trigger a potent and precise immune response against the tumor [<xref ref-type="bibr" rid="CR15">15</xref>]. Additionally, this strategy aims to prevent immune evasion by the tumor. In several clinical studies spanning phases I and II, the efficacy of autologous cell vaccines against advanced metastatic cancers such as prostate, lung, colorectal, melanoma, and renal cell carcinoma (RCC) has been investigated [<xref ref-type="bibr" rid="CR16">16</xref>]. These are just a few of the advanced malignancies that have been investigated. In this research, therapeutic immunological responses and excellent safety profiles have been observed [<xref ref-type="bibr" rid="CR17">17</xref>]. The tumor cell lysate vaccination, known as Reniale, has shown promising results when used in cases of locally limited renal cell carcinoma [<xref ref-type="bibr" rid="CR18">18</xref>]. Reniale substantially improved the 5-year (PFS) in patients with non-metastatic (RCC) across all tumor stages when administered post-nephrectomy [<xref ref-type="bibr" rid="CR19">19</xref>]. The improvement increased the (PFS) rate to 77.4% from 67.8% in the control group. One other method for boosting the immunogenicity of tumor cell vaccines is to use immunomodulatory adjuvants in combination with the vaccinations [<xref ref-type="bibr" rid="CR20">20</xref>].</p><sec id="Sec4"><title>Genetically modified tumor cells as vaccines</title><p id="Par8">Several methods have been found to be effective in developing vaccines that utilize genetically modified tumor cells. Combining chemotherapy with Autologous tumor cell&#8211;based vaccines (ATVs) improves objective responses in ovarian cancer patients [<xref ref-type="bibr" rid="CR21">21</xref>]. Hydrogels and microneedle patches have been employed in both preventative and curative mouse models to encode foreign dendritic cells (DCs), cytosine-phosphodiester-guanine oligodeoxynucleotide, or even whole tumor cells or lysates. However, postoperative malignancies still do not respond to ATVs-based therapy when T cell induction is the only strategy used [<xref ref-type="bibr" rid="CR22">22</xref>]. It is advised that modified ATVs be made in an easy way to accommodate the limited period between getting autologous cell sources and giving postoperative immunization [<xref ref-type="bibr" rid="CR23">23</xref>]. It is possible that enhancing the immunogenicity of autologous tumor cells through genetic modification to include immunostimulatory components could be advantageous [<xref ref-type="bibr" rid="CR20">20</xref>]. A Phase I clinical trial utilized autologous tumor cells engineered to produce the co-stimulatory B7-1 (CD80) molecule to vaccinate patients with metastatic (mRCC) using systemic interleukin (IL)-12 [<xref ref-type="bibr" rid="CR24">24</xref>]. In the treated group, there were a total of 15 people. Out of these 15 individuals, two cases of disease stability and two instances of partial response were observed [<xref ref-type="bibr" rid="CR25">25</xref>]. Numerous preclinical and clinical studies have utilized autologous tumor cells transformed to express GM-CSF (GVAX) [<xref ref-type="bibr" rid="CR26">26</xref>]. These genetically modified cells attract and grow dendritic cells (DCs), which transmit tumor antigens and stimulate cytotoxic CD8 + T lymphocytes [<xref ref-type="bibr" rid="CR27">27</xref>]. Table <xref rid="Tab1" ref-type="table">1</xref> represents various vaccine trials conducted between 2010 and 2021. The autologous vaccine against (OC) known as Vigil, which is a product of Gradalis<sup>&#174;</sup>, utilizes modified cells that express and block GM-CSF. There is some evidence, which is cause for optimism, that this immunization may enhance (PFS) in individuals with advanced r (OC) [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec></sec><sec id="Sec5"><title>Cell-derived exosomes as vaccines</title><p id="Par9">Exosomes are released into the extracellular environment by a variety of cell types, including normal cells, malignant cells, and (DCs) [<xref ref-type="bibr" rid="CR29">29</xref>]. They play a crucial role in the processes that occur within the cell, such as the transportation and communication of molecules. Tumor cells produce exosomes containing numerous tumor antigens, MHC, HSPs, and inducible costimulatory molecules [<xref ref-type="bibr" rid="CR30">30</xref>]. Exosomes produced from tumors, in conjunction with the appropriate immunostimulatory drugs, have been shown in several studies to be capable of inducing potent anti-tumor responses in CD8 + T cells [<xref ref-type="bibr" rid="CR31">31</xref>]. During the Phase I clinical investigation, immunotherapy was administered subcutaneously once per week for a total of four weeks to forty patients with advanced (CRC). Both GM-CSF (granulocyte-macrophage colony-stimulating factor) and Aex (autologous ascites-derived exosomes) were used in the administration of these immunizations [<xref ref-type="bibr" rid="CR32">32</xref>]. Following vaccination, there was a noticeable increase in the number of cytotoxic T lymphocytes (CTL) that responded favorably to tumors, and patients had a positive response to the therapy itself [<xref ref-type="bibr" rid="CR33">33</xref>]. Similarly, in a Phase I study, autologous dendritic cell-derived exosomes (DEX) expressing MAGE-3 peptides were used to immunize individuals with stage III/IV melanoma. These individuals received four doses of the exosome immunization; however, only mild grade 1 adverse effects were reported after the treatment [<xref ref-type="bibr" rid="CR34">34</xref>]. Two out of the fifteen patients exhibited signs of disease stability (SD), while one patient showed signs of a partial response (PR) [<xref ref-type="bibr" rid="CR35">35</xref>]. Patients with advanced cases of non-small cell lung cancer (NSCLC) received a vaccination containing DEX, which included peptides from MAGEA3, MAGEA4, MAGEA10, and MAGE-3DPO4 as part of a phase II clinical trial [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec6"><title>DNA and RNA-based vaccines derived from tumor cells</title><p id="Par10">There is reason to be optimistic about the potential of using nucleic acid vaccines as a means of protecting multiple tumor antigens simultaneously. They are both safe and effective in clinical trials for eliciting antitumor immune responses at both the humoral and cellular levels [<xref ref-type="bibr" rid="CR37">37</xref>]. The target genes for DNA vaccines are inserted into bacterial plasmids or viruses, which subsequently function as vectors for delivering the genes and enabling vaccine production [<xref ref-type="bibr" rid="CR38">38</xref>]. They can be produced in large quantities at a low cost and do not require a refrigerated supply network [<xref ref-type="bibr" rid="CR39">39</xref>]. It has been shown that DNA vaccines may elicit immune responses; however, the magnitude of these responses is often lower when compared to those generated by cell-based cancer vaccines [<xref ref-type="bibr" rid="CR40">40</xref>]. At least a portion of this issue might be attributed, at least in part, to the difficulty DNA vaccines face in effectively stimulating the body&#8217;s immune system, or to the inefficiency with which DNA plasmids are transported into the nucleus of target cells. Figure <xref rid="Fig1" ref-type="fig">1</xref> represent different bases of vaccines development [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par11">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Represent the different ways vaccine development for cancer. There were six different approaches utilized in the development of personalized cancer vaccines such as (a) autologous molecules (RNA, DNA) (b) autologous (neo) antigen peptides (c), autologous subunits (d) autologous whole tumor lysates (e), genetically modified autologous tumor cells (f), autologous tumor cells and adjuvants to treat the cancer</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e510" position="float" orientation="portrait" xlink:href="12672_2025_4188_Fig1_HTML.jpg"/></fig>
</p><p id="Par12">Since RNA cannot be integrated into the host genome, RNA vaccines are rapidly translated into the host cytoplasm without activating oncogenes. PCR can amplify RNA from even small amounts of tumor or stroma [<xref ref-type="bibr" rid="CR42">42</xref>]. Because RNA is less stable than DNA, additional measures must be taken during the first biopsy. To evaluate the success of RNA vaccines in treating melanoma, prostate cancer, and (RCC), several clinical studies have been conducted [<xref ref-type="bibr" rid="CR43">43</xref>]. The major issue with RNA based vaccine is that they are rapidly degraded by RNases and crossing cell membrane barrier. One of the most promising ways to deliver messenger RNA (mRNA) is using liposome complexes or liposome nanoparticles (LNPs), which can transport both hydrophobic and hydrophilic molecules. These molecules can include small molecules, proteins, and nucleic acids. The first liposome delivery materials were cationic liposomes, which protected messenger RNA (mRNA) against RNase breakdown [<xref ref-type="bibr" rid="CR44">44</xref>]. Production of pH-responsive cationic lipids is underway with the aim of improving the efficacy of mRNA delivery. This is because, in addition to lipids, immune cells may take in additional substances with negative charges that interact with them [<xref ref-type="bibr" rid="CR45">45</xref>]. A vaccine against neoantigen mutations in melanoma, based on RNA, has successfully completed Phase I of its clinical trials [<xref ref-type="bibr" rid="CR46">46</xref>]. Two synthetic RNAs generated in the lab were used to encode a total of five large synthetic peptides, which were then combined to create the vaccine. The vaccine was then administered to patients. Patients exhibited T cell responses against numerous vaccine-encoded neoepitopes, and they displayed selective tumor cell death after receiving the vaccination [<xref ref-type="bibr" rid="CR47">47</xref>]. One patient who experienced a cancer relapse achieved tumor remission after receiving combination therapy with an anti-PD-1 antibody, and eleven out of thirteen patients remained disease-free for up to 26 months [<xref ref-type="bibr" rid="CR48">48</xref>]. At the moment, ModernaTX Inc. is conducting a Phase II trial in melanoma patients to investigate the efficacy of an RNA vaccine named mRNA-4157. This vaccine encodes 20 neoantigens. The mechanism of DNA/RNA based are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref> [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par13">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Immunotherapy of cancer: DNA and RNA-based vaccines for tumor antigen targeting</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e550" position="float" orientation="portrait" xlink:href="12672_2025_4188_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec7"><title>Tumor neoantigen peptides</title><p id="Par14">As discussed previously, the genomic instability of tumor cells has been shown to potentially trigger the generation of neoantigens. Tumor antigens, on the other hand, are exclusively expressed by malignant neoplasms [<xref ref-type="bibr" rid="CR49">49</xref>]. This contrasts with self-tumor-associated antigens, or TAAs. Since they are not regulated by thymic selection or central tolerance mechanisms, they have the potential to activate highly reactive T cells [<xref ref-type="bibr" rid="CR50">50</xref>]. Using prediction algorithms and cutting-edge technologies such as mass spectrometry, it may be possible to determine which neoantigen candidates offer the greatest potential for personalized vaccination [<xref ref-type="bibr" rid="CR51">51</xref>]. Chen and colleagues&#8217; novel research has demonstrated that synthesized long peptides are safe and effective in human clinical trials [<xref ref-type="bibr" rid="CR52">52</xref>]. Four out of six cancer patients in the phase I clinical trial showed no recurrence at 25 months after receiving NeoVax (comprising up to 20 long synthetic tailored neoantigen peptides mixed with Poly IC: LC as an adjuvant) [<xref ref-type="bibr" rid="CR53">53</xref>]. Neon Therapeutics has initiated a Phase I clinical research study to combat melanoma, (NSCLC), and bladder cancer by combining nivolumab with synthetic personalized peptides (at least 20 peptides per vaccination) [<xref ref-type="bibr" rid="CR54">54</xref>]. A Phase I clinical research study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03673020">NCT03673020</ext-link>) of the AutoSynVax (ASV<sup>&#174;</sup>) AGEN2017 vaccine has been initiated by Agenus Inc. in patients with advanced cancers that have shown resistance to traditional therapies [<xref ref-type="bibr" rid="CR54">54</xref>]. The AutoSynVax (ASV<sup>&#174;</sup>) was developed by coupling synthetic peptides isolated from a patient&#8217;s cancer neoantigens with HSP70 to enhance the immune system&#8217;s capacity to process and recognize antigens (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02992977">NCT02992977</ext-link>) [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par15">Tumor neoantigen peptides have garnered interest for their capacity to enhance the specificity and personalization of cancer therapy; yet, they are accompanied by many limits and drawbacks. A significant issue is tumor heterogeneity, cancer cells within the same tumor may possess distinct mutations, indicating that a neoantigen vaccination tailored for one subset of cells may not efficiently target others, resulting in partial tumor eradication. A further problem involves the identification of appropriate neoantigens, necessitating intricate and time-intensive bioinformatics analyses, sequencing, and predictive algorithms that are not consistently reliable. Furthermore, not all anticipated neoantigens elicit a robust immune response, and some ones may not be effectively presented by the patient&#8217;s HLA molecules [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par16">Moreover, tumor immune evasion might diminish efficacy; cancer cells may downregulate antigen presentation mechanisms or establish an immunosuppressive tumor microenvironment that impedes T cell functionality. The production of tailored neoantigen vaccines is both expensive and time-consuming, hence restricting accessibility and prompt therapy, particularly for patients with aggressive malignancies. Safety issues exist, including the potential for causing autoimmunity if a neoantigen closely mimics a normal human peptide. Currently, clinical data on neoantigen peptide vaccines are scarce; several studies demonstrate encouraging immune activation but provide modest clinical results, suggesting that while the idea is potent, its conversion into a reliable and successful treatment poses a considerable obstacle [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec8"><title>Virus-like particle vaccines</title><p id="Par17">A groundbreaking therapeutic cancer vaccine has been created, harnessing the power of P22 VLPs to showcase the crucial B and T epitopes of ovalbumin (OVAB peptide and OVAT peptide). These OVAB and OVAT peptides are intriguing tumor-specific neoantigens that result from somatic mutations within tumor cells. They possess an impressive skill in stimulating cytotoxic lymphocytes (CTLs), which initiates a potent immune response against tumors. When the adjuvant poly (I: C) was used in combination with the OVAB-P22 VLPs, a robust immune response against the OVAB antigen was observed. In addition, the OVAT-P22 VLPs successfully inhibited the growth of tumors by promoting immune responses that specifically target the tumor cells. Testing was conducted on mice with a melanoma model using PLPs, which have a connection to polyomaviruses. By combining the primary coat protein VP1 with two antigens, namely ovalabumin (OVA257-264) and tyrosinase-related protein (TRP2180-188), both of which are H2-Kb-restricted T-cell epitopes, CD8 T cells can be generated. We conducted experiments using VP1-OVA252-270 and VP1-TRP2180-188 on C57BL/6 mice with MO5 (B16-OVA) melanoma to evaluate their efficacy as therapeutic agents. The VP1-OVA252-270 treatment significantly improved survival rates by 80&#8211;100%, while the VP1-TRP2180-188 treatment showed a 60% increase in survival [<xref ref-type="bibr" rid="CR57">57</xref>]. The HBV surface antigen is their basis. Three vaccines that protect against human papillomaviruses&#8212;Cervarix, Gardasil-4, and Gardasil-9&#8212;have been approved globally based on virus-like particle (VLP) technology. The majority of cervical cancer cases are caused by two to seven different types of HPV, notably HPV16, 18, 31, 33, 45, 52, and 58 [<xref ref-type="bibr" rid="CR58">58</xref>]. These VLPs derive from the primary capsid protein L1 and provide protection against these types of HPV. They also protect against the two types of human papillomavirus (HPV) that are associated with over 90% of genital warts: HPV6 and HPV11. Cervarix and Gardasil-4 need an immune response that lasts 13 years, but Gardasil-9 just needs a 6-year duration. There is a 21&#8211;64% chance that the Cervarix vaccine will continue to protect against HPV35, 31, 33, 45, and 58 after 11 years. Nevertheless, 52% of Gardasil-4 vaccinees had antibodies against HPV18, and 90% had antibodies against heterologous HPV types (HPV6, 11, and 16) after 14 years [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>] .</p></sec></sec><sec id="Sec9"><title>Immunotherapy</title><sec id="Sec10"><title>CAR-T cell therapy</title><p id="Par18">CAR-T cell therapy is a groundbreaking treatment that uses a patient&#8217;s own immune cells to fight cancer. Doctors start by collecting T cells, a type of white blood cell, from the patient&#8217;s blood. These cells are then genetically modified in the laboratory to carry a special receptor called a Chimeric Antigen Receptor (CAR) [<xref ref-type="bibr" rid="CR61">61</xref>]. The CAR works like a tracking device, allowing the T cell to recognize and attach to proteins on cancer cells. Once re-infused into the patient, these engineered T cells can find cancer cells more effectively, activate themselves, multiply, and release toxic substances that directly destroy the tumor [<xref ref-type="bibr" rid="CR62">62</xref>]. CAR-T cells do not require cancer cells to display antigens by a mechanism that utilises MHC molecules as the tumour does (as normal T cells do), but instead home in on the tumour itself. The remarkable success of this unique mechanism has already been achieved in the treatment of certain blood cancers such as leukaemia and lymphoma [<xref ref-type="bibr" rid="CR63">63</xref>]. Several CAR-T therapies are approved and in clinical practice. In 2017, the first to be approved was called Tisagenlecleucel (Kymriah), which targets CD19 in B-cell cancers. It has been applied in the treatment of children and young adults with acute lymphoblastic leukemia (ALL) and in the treatment of adults with some forms of lymphoma [<xref ref-type="bibr" rid="CR64">64</xref>]. This was followed by Axicabtagene ciloleucel (Yescarta), which is also based on CD19, and is commonly used in large B-cell lymphoma. Brexucabtagene autoleucel (Tecartus) is licensed for mantle cell lymphoma and B-cell precursor ALL, whereas Idecabtagene vicleucel (Abecma) and Lisocabtagene maraleucel (Breyanzi) were licensed for large B-cell lymphoma and multiple myeloma, respectively [<xref ref-type="bibr" rid="CR65">65</xref>]. More recently, Ciltacabtagene autoleucel (Carvykti) was given the green light in relapsing or refractory multiple myeloma. These treatment methods have demonstrated good response rates, and many patients were brought to complete remission, even after other treatments had failed [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p id="Par19">There are numerous benefits of CAR-T cell therapy, but it is not safe. CRS occurs when the CAR-T cells become hyperactive and produce huge doses of chemical messengers called cytokines. These cytokines play a crucial role in combating cancer, but when produced out of control, they cause an unregulated inflammatory reaction commonly known as the cytokine storm [<xref ref-type="bibr" rid="CR67">67</xref>]. CRS causes the patient to experience the symptoms of a flu, such as fever, fatigue, and muscle aches, as the first signs [<xref ref-type="bibr" rid="CR68">68</xref>]. The reaction can get bad to such an extent that it can lead to very low blood pressure, difficulty breathing, and even organ failure. CRS is very common (the majority of patients have mild symptoms and about 10&#8211;20% develop severe cases requiring urgent care) [<xref ref-type="bibr" rid="CR69">69</xref>]. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which is a brain and nervous system side effect, is another serious side effect [<xref ref-type="bibr" rid="CR70">70</xref>]. ICANS has been believed to be a result of injury to the blood-brain barrier and diffusion of inflammatory cytokines into the brain. The initial symptoms in patients may include confusion, inability to communicate (either verbally or in writing), tremors, or headache. In even more severe cases, there may be seizures, consciousness loss or even swelling of the brain. ICANS typically occurs a few days following CRS, but may occur independently. Doctors use standardized grading systems developed by the American Society for Transplantation and Cellular Therapy (ASTCT) to manage these complications. CRS is rated as mild (gets a fever but does not need any other medications); to life-threatening (needs more than one medication to stabilise blood pressure or a ventilator to breathe) [<xref ref-type="bibr" rid="CR71">71</xref>]. ICANS can be evaluated by a test known as the ICE score, which evaluates the ability of a patient to respond to orientation questions, write a sentence, name things, and count in reverse. The normal score is 4 and below corresponds to a higher degree of severity [<xref ref-type="bibr" rid="CR72">72</xref>]. Treatment depends on the severity of symptoms. For mild CRS, supportive care such as fluids, fever reducers, and oxygen is usually enough. If symptoms worsen, the first-line treatment is tocilizumab, a drug that blocks IL-6, one of the main cytokines responsible for CRS. Steroids may also be used if symptoms do not improve quickly. ICANS is treated differently because tocilizumab does not cross into the brain. Instead, steroids like dexamethasone are the main therapy, along with seizure prevention and, in severe cases, intensive neurological monitoring [<xref ref-type="bibr" rid="CR73">73</xref>].</p></sec><sec id="Sec11"><title>Immune checkpoint inhibitors (CPIs)in cancer treatment</title><p id="Par20">Immunological checkpoints are receptors found on the surface of immune cells that play a crucial role in regulating the activation or suppression of the immune response. Immunotherapy, specifically immune checkpoint inhibitors (CPIs), enhances the immune response against tumors by obstructing the receptors on T cells&#8217; surface. This class of immunotherapy is extremely important in the treatment of numerous types of cancers, and it has been extensively researched compared to any other class so far [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>]. In the past decade, blocking programmed cell death protein-1 and its ligand-1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) molecules has emerged as highly effective and widely employed strategies for checkpoint suppression. There are several other potential targets that can be considered, such as inhibitory receptors like Tim-3, VISTA, Lag-3, and GITR, as well as activating molecules such as OX40 (CD134) and glucocorticoid-induced TNFR-related protein. Through its interaction with ligands B7-1 (CD80) and B7-2 (CD86), CTLA-4, a member of the immunoglobulin superfamily and a molecule that inhibits immune response, regulates T cell activation in a negative manner. The genes for CTLA-4 and CD28 are found in proximity on chromosome 2q33, and their protein sequences exhibit significant similarities. They both bind the same ligands in homodimers, but their affinities vary. Negative signaling of T cells happens due to the higher affinity binding and ligand scavenging of CTLA-4 compared to CD28. CTLA-4 plays a crucial role in the early stage of the T-cell response in the lymph nodes, specifically in the context of tumor immunoregulation. This suggests additional evidence that the absence of CTLA-4 could result in unregulated multiplication of T cells, providing a fresh perspective on the potential of CTLA-4 inhibition to bolster the immune response against tumors. A member of the immunoglobulin superfamily, PD-1, reacts to a process controlled by T cells by inducing programmed cell death. It is prevalent in several immune cell types inside the tumor microenvironment (TME) and expresses itself more broadly than CTLA-4. The death of T cells is caused by an inhibitory signal sent when PD-1 and its ligand PD-L1 (B7-H1) bind. While CTLA-4 regulates T-cell activity during the priming phase, PD-1 mostly suppresses T-cell activity in peripheral tissues as tumors progress.</p><p id="Par21">Researchers have shown that inhibiting PD-1 successfully counteracts tumor cells in several types of cancer, including colon, melanoma, and pancreatic ductal adenocarcinoma. Pembrolizumab, nivolumab, and cemiplimab are the three PD-1 inhibitors that have been approved by the FDA after extensive clinical studies [<xref ref-type="bibr" rid="CR77">77</xref>&#8211;<xref ref-type="bibr" rid="CR79">79</xref>] .</p><p id="Par22">When PD-1 interacts with PD-L1 and PD-L2, it can potentially hinder the function of activated immune cells. Various types of tumors and immune cells express PD-L1, while normal dendritic cells typically express PD-L2. When cancer cells utilize the PD-1/PD-L1 pathway to dampen T-cell-mediated immunity, it can result in abnormal cell growth. Through extensive research, it has been discovered that PD-L1 can interact with certain entities, thus presenting itself as a promising candidate for immunotherapy. There are three PD-L1 inhibitors that have been approved by the Food and Drug Administration: Atezolizumab, durvalumab, and avelumab. In 2016, the treatment for urothelial cancer called atezolizumab, a humanized IgG1 anti-PD-L1 mAb, received approval. Due to the improved response rate, the indication was later expanded to include small cell lung cancer, melanoma, hepatocellular carcinoma, non-small cell lung cancer, and melanoma. It is worth mentioning that the therapy was originally developed for TNBC. However, due to the unsuccessful outcome of the IMpassion130 clinical trial, it is no longer considered a viable treatment option [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par23">Immune checkpoint inhibitors (ICIs) such as anti&#8211;CTLA-4, anti&#8211;PD-1, and anti&#8211;PD-L1 antibodies have transformed cancer treatment by unlocking the body&#8217;s immune system to attack tumors [<xref ref-type="bibr" rid="CR81">81</xref>]. By removing the &#8220;brakes&#8221; on T cells, they allow a stronger and longer-lasting immune response. However, this same mechanism can also cause the immune system to attack healthy tissues, leading to a wide range of side effects known as immune-related adverse events (irAEs) [<xref ref-type="bibr" rid="CR82">82</xref>]. These toxicities are different from those seen with chemotherapy or targeted drugs, and they require a specific approach to recognition and management [<xref ref-type="bibr" rid="CR83">83</xref>]. irAEs can affect nearly every organ system. The most widespread of them are skin reactions (including rash and itching), gastrointestinal (including diarrhoea and colitis), and endocrine (including thyroid disorders, hypophysitis, and adrenal insufficiency) conditions. Inflammation of the liver and the lungs (pneumonitis) also occurs, with rarer but life-threatening complications such as heart inflammation (myocarditis), neurological (encephalitis or myasthenia gravis-like syndromes), and kidney inflammation [<xref ref-type="bibr" rid="CR84">84</xref>]. Most irAEs are mild to moderate but others may become severe or even life threatening when they are not detected early [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p id="Par24">The Common Terminology Criteria for Adverse Events (CTCAE) often characterises the severity of irAEs on a scale of 1 (mild) to 4 (life-threatening). The timing also differs according to the organ system [<xref ref-type="bibr" rid="CR86">86</xref>]. Skin toxicities are usually evident in the first few weeks, and gastrointestinal and liver side effects are seen in the first three months. Later, the endocrine problems can occur and become permanent [<xref ref-type="bibr" rid="CR87">87</xref>]. Neurological and cardiac complications are particularly dangerous and prone to manifest themselves at an early stage and develop rapidly. Both severity and recovery determine the decision to resume the ICIs on an irAE. Mild cases can often be managed without stopping therapy, but severe or life-threatening toxicities generally require permanent discontinuation, especially if they involve the brain, heart, or lungs [<xref ref-type="bibr" rid="CR88">88</xref>]. Managing irAEs requires a thoughtful, organ-specific approach. Corticosteroids remain the backbone of treatment for most moderate to severe cases, but the details matter. For skin reactions, topical creams and antihistamines may be enough for mild cases, while severe blistering diseases may require high-dose steroids and discontinuation of therapy [<xref ref-type="bibr" rid="CR89">89</xref>]. Diarrhea and colitis are usually treated with systemic steroids, and if symptoms do not improve, additional drugs such as infliximab or vedolizumab can be used [<xref ref-type="bibr" rid="CR90">90</xref>]. Liver inflammation is treated with high-dose steroids, and in resistant cases, mycophenolate may be considered, but infliximab is avoided due to its risk of worsening liver injury. Endocrine toxicities are often irreversible, meaning hormone replacement (such as thyroid hormone or insulin) becomes the mainstay rather than steroids [<xref ref-type="bibr" rid="CR91">91</xref>]. Pneumonitis is managed with steroids, but severe cases frequently require permanent cessation of ICIs. Neurologic and cardiac toxicities are medical emergencies, treated immediately with high-dose intravenous steroids, sometimes alongside intravenous immunoglobulin or plasmapheresis. In these cases, rechallenge with ICIs is generally not safe [<xref ref-type="bibr" rid="CR92">92</xref>]. While most immune-related side effects improve with timely treatment, some are fatal or irreversible. Myocarditis and severe neurological toxicities carry some of the highest mortality rates, sometimes exceeding 30&#8211;50% despite aggressive care [<xref ref-type="bibr" rid="CR92">92</xref>]. Endocrine disorders like hypothyroidism, adrenal insufficiency, and diabetes usually do not resolve and require lifelong hormone replacement. On the other hand, many patients recover fully from skin, gastrointestinal, or hepatic events, and there is evidence that patients who experience irAEs may actually have better cancer outcomes, suggesting a link between immune activation and treatment success [<xref ref-type="bibr" rid="CR93">93</xref>]. Nevertheless, the long-term effects of ICIs are still being studied, and careful follow-up is critical for survivors who may face chronic fatigue, hormonal issues, or other lasting effects [<xref ref-type="bibr" rid="CR94">94</xref>].</p></sec></sec><sec id="Sec12"><title>Precise cancer treatment using clustered regularly interspaced short palindromic repeats (CRISPR-CAS9)</title><p id="Par25">Three components that constitute the CRISPR/Cas9 system. These include a DNA-specific guide RNA (sgRNA), the Cas9 protein, which can endonuclease DNA, and an interaction between Cas9 and tracrRNA. Just like a biologist, the 20-base-pair gRNA forms a binding with the precise genomic location, providing instructions to the Cas9 protein [<xref ref-type="bibr" rid="CR95">95</xref>]. Having a deep understanding of the gRNA sequence is crucial to maximize the effectiveness, precision, and reliability of CRISPR/Cas9-mediated genome editing. The seed sequence, found at the 3&#8242; end of gRNA and adjacent to a protospacer adjacent motif (PAM), plays a vital role in determining the binding specificity to the target sequence. By utilizing truncated gRNAs with fewer than 20 complementary nucleotides, the potential for off-target effects can be reduced by a remarkable 5000-fold, all while ensuring a strong on-target efficiency. Furthermore, extending the length of the gRNA duplex by 5 base pairs has been demonstrated to significantly improve the efficiency of the knockout procedure [<xref ref-type="bibr" rid="CR96">96</xref>]. Proto-oncogenes, which regulate cell formation, also have the potential to control cell proliferation and differentiation. If these proto-oncogenes undergo mutations and transform into oncogenes, the conversion of typically dividing cells into cancerous cells is theoretically possible [<xref ref-type="bibr" rid="CR97">97</xref>]. There is a possibility that this change led to the development of cancer. On the other hand, genes that function as tumor suppressors can be utilized to inhibit abnormal cell divisions, thus averting the onset of cancer [<xref ref-type="bibr" rid="CR98">98</xref>]. Proteins known as tumor suppressors may prevent oncogenes from promoting abnormal tissue growth [<xref ref-type="bibr" rid="CR99">99</xref>]. Tumor suppressor genes provide a defense mechanism against cancer by inhibiting the overexpression of the cell cycle in normal human cells [<xref ref-type="bibr" rid="CR100">100</xref>]. They keep track of the rates at which different types of cells proliferate, die off, and repair damage to their DNA. The BRCA1 and BRCA2 genes, along with the TP53 gene, are the three most well-known tumor suppressor genes. These genes play a role in regulating various stages throughout the cell cycle [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. The process by which tumors develop as a consequence of mutations in the DNA of the affected cells is known as carcinogenesis. Incubation, growth, transition to a malignant state, and spread are the four stages that constitute cancer progression [<xref ref-type="bibr" rid="CR102">102</xref>]. Even if a single mutation in a cell is not harmful, the accumulation of mutations that naturally occurs with aging might increase carcinogenesis and the development of malignancies [<xref ref-type="bibr" rid="CR96">96</xref>]. This is because age naturally causes mutations to arise. Cancer cells can exhibit a characteristic known as genetic instability. The most common type of genetic instability is chromosomal instability, which occurs when the structure of chromosomes frequently changes [<xref ref-type="bibr" rid="CR103">103</xref>]. Chromosomal instability may be defined as the frequent shifting of chromosome structures. It is still not completely understood when exactly during the progression of cancer this genetic instability will manifest itself [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Because cells with unstable genes divide at a quicker pace, they may bypass the usual checkpoints that occur during the cell cycle. It is possible that this will transform cancer cells into more aggressive forms of the disease [<xref ref-type="bibr" rid="CR105">105</xref>]. If the factors contributing to the development of cancer are better understood, novel strategies to block or delay the expansion of malignant cells may be uncovered [<xref ref-type="bibr" rid="CR106">106</xref>]. The purpose of CRISPR technology and other gene editing approaches used to regulate or prevent carcinogenesis is to modify DNA nucleotides by deleting defective genes and replacing them with functional equivalents. This is accomplished by replacing the faulty genes with functional counterparts [<xref ref-type="bibr" rid="CR107">107</xref>]. CRISPR/Cas9 technology may be used in oncology to create cancer models, identify targetable genes, and more [<xref ref-type="bibr" rid="CR108">108</xref>] The clarification of resistance mechanisms and the improvement of immunotherapies. As checkpoint inhibitors and T-cell therapies become first-line treatments, enhancing their efficacy is crucial. CRISPR/Cas9 can address challenging tumor microenvironment issues, such as T-cell depletion and immunosuppression [<xref ref-type="bibr" rid="CR108">108</xref>]. The technology&#8217;s ability to create very effective gene knockouts allows this. The ability of CRISPR/Cas9 to modify genes holds promise for personalized cancer therapies. Previous and ongoing preclinical and clinical investigations have established that CRISPR/Cas9 systems work. Different genes of cancer are knock down via CRISPR-CAS9 as shown in Table <xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR109">109</xref>].</p><p id="Par26">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Represent different targets genes of cancer in a CRISPR-CAS9. The various genes such as TERT, TR53, PKC, CTLA-4, EGFR, and non-metastatic cancer cell in various cancer tissue were knocked-down through CRISPR-CAS9</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Target genes</th><th align="left" colspan="1" rowspan="1">Cancer types</th><th align="left" colspan="1" rowspan="1">CRISPR-CAS9</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TERT</td><td align="left" colspan="1" rowspan="1">Glioblastoma</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">TP53</italic>
</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">PKC</italic>
</td><td align="left" colspan="1" rowspan="1">Colon cancer</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Genes on non-metastatic cancer cell line</td><td align="left" colspan="1" rowspan="1">Lung metastases</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Colorectal cancer driver genes</td><td align="left" colspan="1" rowspan="1">Intestinal tumors</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CTLA-4</td><td align="left" colspan="1" rowspan="1">Bladder cancer</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR115">115</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">EGFR</italic>
</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR116">116</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">KRAS</italic>,<italic toggle="yes"> BRAF</italic>
</td><td align="left" colspan="1" rowspan="1">Colorectal</td><td align="left" colspan="1" rowspan="1">. knockdown</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par27">T-cell depletion is particularly problematic in immunosuppressive microenvironments because it significantly impairs the effectiveness of CAR-T cells and the body&#8217;s endogenous anticancer responses [<xref ref-type="bibr" rid="CR118">118</xref>]. People with persistent or chronic lymphocytic leukemia (CLL) who received CD19-targeted chimeric-antigen receptor (CAR) T-cell therapy showed clinical improvement in T-cell depletion following apheresis [<xref ref-type="bibr" rid="CR119">119</xref>]. It is conceivable to achieve improved clinical outcomes by modifying CAR T cells using the gene-editing tool CRISPR/Cas9 to eliminate regulators of T cell activity and persistence [<xref ref-type="bibr" rid="CR120">120</xref>]. Table <xref rid="Tab3" ref-type="table">3</xref> represents different genes and CRISPR-Cas9 trials for the treatment of cancer. EGFR is mainly expressed in lung tissue and neurogenic tissue. Eliminating EGFR mutations using CRISPR may limit lung cancer cell growth in vitro and in mice [<xref ref-type="bibr" rid="CR121">121</xref>]. Genome-wide CRISPR screening, using extensive libraries of guide RNAs targeting numerous genes of interest, has unveiled promising therapeutic targets in preclinical (CRC) research [<xref ref-type="bibr" rid="CR122">122</xref>]. These laboratory achievements establish the framework for studying how CRISPR/Cas9 may help in creating cancer treatments [<xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par28">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Represent The clinical trial of CRISPR-CAS9. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>). The table represent different clinical trials of phase 1 in various cancer using CRISPR-CAS9 system</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinical Trial</th><th align="left" colspan="1" rowspan="1">CANCER TYPE</th><th align="left" colspan="1" rowspan="1">Related CRISPR Method</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1">Refractory cancers</td><td align="left" colspan="1" rowspan="1">Delete two genes that encode TCR and a gene encoding PD-1</td></tr><tr><td align="left" colspan="1" rowspan="1">Advanced NSCLC</td><td align="left" colspan="1" rowspan="1">Edite PD-1 on T cells</td></tr><tr><td align="left" colspan="1" rowspan="1">Mesothelin-positive solid tumors</td><td align="left" colspan="1" rowspan="1">PD-L1 possible target for knockout</td></tr><tr><td align="left" colspan="1" rowspan="1">Refractory solid cancers</td><td align="left" colspan="1" rowspan="1">Knockout two (TCR) gene</td></tr></tbody></table></table-wrap>
</p><p id="Par29">Since 2018, researchers have started utilizing CRISPR/Cas9 technology to develop personalized therapy options for different types of cancer. Several potential therapies currently in development are based on proteins suspected of having oncogenic properties [<xref ref-type="bibr" rid="CR124">124</xref>]. Overexpression of the large ribosomal subunit component RPL15 has been associated with breast cancer metastasis. These genes can be identified through CRISPR/Cas9 genome screening. CRISPR/Cas9-mediated deletion of the estrogen receptor signaling gene FASN may reduce breast cancer cell proliferation and metastasis [<xref ref-type="bibr" rid="CR125">125</xref>]. It is known that BRCA1 mutations are responsible for 80% of triple-negative breast cancer cases. However, there are currently no CRISPR/Cas9 applications for treating TNBC [<xref ref-type="bibr" rid="CR126">126</xref>]. The poly (ADP-ribose) polymerase 1 (PARP1) gene may be targeted using CRISPR/Cas9 to treat various types of breast cancer. This gene causes synthetic lethality in BRCA1-deficient cells and mechanism of cancer is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref> [<xref ref-type="bibr" rid="CR127">127</xref>].</p><p id="Par30">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Virus-like particle vaccines and the CRISPR-Cas9 mechanism for gene editing in cancer therapeutics</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1046" position="float" orientation="portrait" xlink:href="12672_2025_4188_Fig3_HTML.jpg"/></fig>
</p><p id="Par31">Additionally, the estrogen receptor (ER) gene was found in prostate cancer and was effectively excised from the patient&#8217;s genome using CRISPR. The signaling of androgen receptors is largely responsible for controlling the development and function of the prostate [<xref ref-type="bibr" rid="CR128">128</xref>]. However, estrogen receptors (ER) help in the formation of prostatic epithelial cells and inhibit the growth of prostate cancer cells. ER signaling is still poorly understood, but this suggests another potential cancer therapy utilizing CRISPR [<xref ref-type="bibr" rid="CR129">129</xref>]. Stadtmauer et al. generated T cells using CRISPR-Cas9 in phase I. CRISPR/Cas9 was used to delete two natural. (TCR) genes in three refractory cancer patients, reducing TCR mispairing and increasing cancer-specific TCR transgenic expression. The PD-1 gene was removed to improve antitumor immunity. The CRISPR/Cas9 technology may edit genes for immunotherapies, since all three T cell transplants were successful and lasted nine months. This innovative experiment enabled focused treatment research and immunotherapy efficacy improvements [<xref ref-type="bibr" rid="CR130">130</xref>]. Both phase I lung cancer trials indicated CRISPR/Cas9 T cell editing is safe and effective. Lu et al. treated 12 advanced NSCLC patients with CRISPR/Cas9-edited T cells for PD-1. Edited T cells injected into peripheral blood had no significant side effects. Median progression-free and overall survival were 7.7 and 42.6 weeks. Next-generation sequencing detected off-target events, and median mutation frequency was 0.05%, indicating CRISPR/Cas9 modified T cells are safe and practical. Most recently, Wang et al. recruited 15 mesothelin-positive solid tumor patients and used CRISPR/Cas9 to produce PD-1 and TCR-deficient mesothelin-specific CAR-T cells and evaluated dose escalation [<xref ref-type="bibr" rid="CR131">131</xref>] Two patients had stable disease; circulating changed T cells peaked at days 7&#8211;14 and were undetectable after one month without any side effects or toxicity, indicating CRISPR/Cas9 altered T cells are safe and practical. In osteosarcoma patients, Liao et al. found that CRISPR/Cas9 could knock down PD-L1. The PD-1/PD-L1 axis is crucial to cancer immune evasion and therapy, therefore our results are the first steps toward proving CRISPR/Cas9&#8217;s safety and efficacy in treating NSCLC, sarcoma, and other cancers [<xref ref-type="bibr" rid="CR132">132</xref>].</p><sec id="Sec13"><title>CRISPR in cancer therapy: real-world translational and clinical hurdles</title><p id="Par32">CRISPR has changed how we think about treating cancer, but moving from elegant lab experiments to safe, effective patient care is not straightforward [<xref ref-type="bibr" rid="CR133">133</xref>]. The first practical barrier is <bold>delivery</bold>. Ex vivo editing (for example, editing a patient&#8217;s T cells outside the body and reinfusing them) is relatively controllable and already in trials, but it is expensive and logistically complex [<xref ref-type="bibr" rid="CR134">134</xref>]. Getting CRISPR components to solid tumours in vivo is far more difficult. AAV vectors have poor cargo capacity and can integrate at low frequency; lipid nanoparticles can be concentrated in the liver and spleen; and local injections do not yet cover multi-site or metastatic disease [<xref ref-type="bibr" rid="CR135">135</xref>]. Tumours are also located under physical and biological obstacles of dense stroma, high interstitial pressure, and irregularity of blood flow that dulls delivery to the very cells we must edit [<xref ref-type="bibr" rid="CR136">136</xref>]. The second is the issue of precision and safety. Even high-fidelity nucleases and better guide design do not eliminate off-target edits. More importantly, on-target, off-tumour editing has the potential to damage normal cells that contain the target gene [<xref ref-type="bibr" rid="CR137">137</xref>]. Large deletions, translocations, or p53-mediated stress could be induced by a double-strand break and, ironically, favour the survival of p53-deficient (more aggressive) clones. Base and prime editors do not require DNA cutting; however, they do have their own editing windows as well as bystander effects, which need to be well-mapped and monitored over the long term [<xref ref-type="bibr" rid="CR138">138</xref>].</p><p id="Par33">The real-life issues are immunogenicity and re-dose. Most human beings have prior immunity against Cas proteins or viral vectors. Edited cells may be cleared by immune recognition, or repeat dosing may be unsafe and ineffective. LNPs can be re-dosed more easily than viral vectors and can induce complement. In the case of ex vivo, patients might require lymphodepletion to allow proliferation of the edited cells-increasing both toxicity and cost [<xref ref-type="bibr" rid="CR139">139</xref>].</p><p id="Par34">Even tumour biology rebels. Cancer is a heterogeneous and rapidly evolving disease. You can edit works in one subclone and still have another escape [<xref ref-type="bibr" rid="CR140">140</xref>]. Since a single edit can be eroded by redundant pathways, copy-number variation, and the immunosuppressive tumour microenvironment, it can be easily eroded. Combination (e.g., editing T cells and using them with checkpoint blockade) is a promising approach, but it creates new questions regarding timing, dosing, and compounded toxicity [<xref ref-type="bibr" rid="CR141">141</xref>]. CRISPR therapies put pressure on existing systems on the clinical operations side. Production should be GMP-level, repeatable, and fast with a closed chain-of-identity on customised products [<xref ref-type="bibr" rid="CR142">142</xref>]. Without delaying treatment too long, release testing must establish potency, specificity, residual nuclease/guide levels, and absence of contamination. It is expensive and uneven in access, particularly where specialised facilities are limited [<xref ref-type="bibr" rid="CR143">143</xref>].</p><p id="Par35">Lastly, regulatory and ethical authorities consider CRISPR a form of gene therapy, and there is greater concern about long-term risks, including genotoxicity, unintentional germline introduction (but highly unlikely in the oncology setting), and delayed adverse events. Trials should be developed with long-period monitoring, excellent off-target analytics, and explicit stop rules. Patient selection, biomarker strategies (to show editing actually happened and mattered), and clinically meaningful endpoints (beyond molecular editing rates) are all essential to convince regulators, clinicians, and payers [<xref ref-type="bibr" rid="CR144">144</xref>].</p></sec></sec><sec id="Sec14"><title>Cancer treatment through bacteria</title><p id="Par36">Because cancer is a complex illness with many different manifestations, effective treatment of the disease necessitates the use of several therapeutic modalities [<xref ref-type="bibr" rid="CR145">145</xref>]. Bacteria have been the subject of intensive research for more than a century, to determine their potential for use as therapeutic agents in the treatment of cancer. In the beginning, cancer patients were treated with live bacteria such as Streptococci and Clostridia by medical professionals [<xref ref-type="bibr" rid="CR146">146</xref>]. There are certain challenges in bacteriotherapy such immune response against anti-tumours bacteria, cytotoxicity of bacteria. To overcome with challenges bacteria are modified so that they are unable to detect by our immune system by masking the pathogen associated molecular patterns (PAMP) receptors. The second approach is using attenuated bacteria of the treatment such bacille Calmette-Guerin (BCG) vaccine. The third approach to use probiotics and gut microflora for bacteriotherapy for cancer because they not recognized by immune as foreign antigens [<xref ref-type="bibr" rid="CR147">147</xref>]. However, in today&#8217;s modern times, this task is often accomplished through the use of genetically engineered microorganisms [<xref ref-type="bibr" rid="CR148">148</xref>]. The use of bacteria in the treatment of cancer encompasses several different strategies, including the expression of antigens specific to tumors, facilitating gene transfer, utilizing RNA interference, and enabling the activation of pro-drugs, as shown in Table <xref rid="Tab4" ref-type="table">4</xref> [<xref ref-type="bibr" rid="CR149">149</xref>]. Some of these strategies include harnessing the bacteria&#8217;s intrinsic toxicity, integrating them with complementary therapeutic methods, using bacteria that have the ability to control the production of anticancer substances, and integrating them with complementary therapeutic methods [<xref ref-type="bibr" rid="CR150">150</xref>]. The study of cancer has utilized a wide variety of experimental models, including the examination of whole live bacteria, attenuated strains, and genetically modified versions, either individually or in conjunction with conventional therapies [<xref ref-type="bibr" rid="CR151">151</xref>]. <italic toggle="yes">Salmonella</italic>,<italic toggle="yes"> Clostridium</italic>,<italic toggle="yes"> Bifidobacterium</italic>,<italic toggle="yes"> Lactobacillus</italic>,<italic toggle="yes"> Escherichia coli</italic>,<italic toggle="yes"> Pseudomonas aeruginosa</italic>,<italic toggle="yes"> Caulobacter</italic>,<italic toggle="yes"> Listeria</italic>,<italic toggle="yes"> Proteus</italic>, and <italic toggle="yes">Streptococcus</italic> are among the most often described bacterial genera in this setting. The potential of Clostridia, Bifidobacteria, and Salmonellae as vectors for delivering or expressing tumor suppressor genes, anti-angiogenic genes, suicide genes, and (TAAs) has been extensively studied in animal models with a wide range of malignancies [<xref ref-type="bibr" rid="CR152">152</xref>]. These bacteria might potentially carry or express these genes. Due to the limited results shown in the ongoing clinical studies, additional research involving human subjects is necessary [<xref ref-type="bibr" rid="CR153">153</xref>]. Imaging techniques such as MRI and PET can identify genetically modified bacteria. This indicates that besides their therapeutic benefits, these microorganisms also have diagnostic applications [<xref ref-type="bibr" rid="CR154">154</xref>].</p><sec id="Sec15"><title>Genetically modified bacteria in cancer therapy</title><p id="Par37">Gene therapy is a cutting-edge method that holds enormous therapeutic promise for the treatment of cancer. The high degree of specificity with which this method eradicates cancer cells is the key benefit of using it [<xref ref-type="bibr" rid="CR155">155</xref>]. Cancer therapy using genetically altered bacteria has the potential to be more effective and less harmful to the host [<xref ref-type="bibr" rid="CR156">156</xref>]. In recent years, a unique approach to treating cancer has emerged: the use of genetically engineered bacteria to produce reporter genes, cytotoxic proteins, anticancer drugs, and tumor-specific antigens [<xref ref-type="bibr" rid="CR157">157</xref>].</p><p id="Par38">According to the findings of several studies, genetically engineered bacteria may reproduce more quickly inside tumor tissue than they do within normal cells [<xref ref-type="bibr" rid="CR158">158</xref>]. Tumor-colonizing bacteria have been utilized as delivery vehicles in animal tumor models, however this strategy has been met with poor results and unwanted side effects [<xref ref-type="bibr" rid="CR56">56</xref>]. This has been achieved without the use of conventional chemotherapy. Salmonella typhimurium serovar <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VNP20009">VNP20009</ext-link> and Clostridium butyricum M55 are two of the microorganisms that make up this group. Nevertheless, the results of not all of the research have been favorable [<xref ref-type="bibr" rid="CR159">159</xref>].</p><p id="Par39">The anticancer properties shown by genetically modified <italic toggle="yes">Clostridium strains (C. acetobutylicum</italic> and <italic toggle="yes">C. beijerinckii</italic>), which express genes encoding bacterial enzymes (cytosine deaminase and nitroreductase, respectively), have exhibited promising outcomes [<xref ref-type="bibr" rid="CR160">160</xref>]. Moreover, scientific investigations have shown that bacteria possess the capability to generate antibodies that may effectively attach themselves to hypoxia-inducible factor 1, a pivotal transcription factor that is associated with the formation of malignancies [<xref ref-type="bibr" rid="CR161">161</xref>]. Experiments conducted in clinical settings have shown that modified S. typhimurium and Clostridium novyi-NT have the potential to promote tumor regression and necrosis by stimulating the immune system of the host. The production of cytokines, including (IL-2), IL-4, IL-18, and CC chemokine-21, facilitates this process. These results imply that bacteriotherapy, when combined with other cancer treatments such as radiation therapy, immunotherapy, or chemotherapy, may offer an innovative and effective strategy for combating the illness when utilized in combination with these other treatments as shown in Table <xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par40">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Different bacteria used for cancer as a therapeutic purpose. The tables represent different types of bacteria used in various types of cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Treatment Options</th><th align="left" colspan="1" rowspan="1">Types of bacteria</th><th align="left" colspan="1" rowspan="1">Results</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"> Immunotherapeutic agents </td><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Streptococcus pyogenes</italic>, <italic toggle="yes">Clostridium spp</italic>,</p><p>
<italic toggle="yes">Salmonella typhimurium</italic> Salmonella typhimurium</p></td><td align="left" colspan="1" rowspan="1"><p>Rapid tumor regression</p><p>Reduced frequency of cancer</p><p>Tumor regression</p><p>An antitumor effect</p></td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR162">162</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"> Vectors/spores to carry tumoricidal agent </td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Clostridium novyi-NT</italic>, <italic toggle="yes">C novyi&#8208;NT and C. sporogenes</italic>, <italic toggle="yes">C novyi&#8208;NT</italic>,</td><td align="left" colspan="1" rowspan="1"><p>Elimination of tumors</p><p>Hemorrhagic necrosis of tumors</p></td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR163">163</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"> Bacterial toxins/enzymes </td><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Salmonella enterica Serovar Typhimurium</italic>,</p><p>
<italic toggle="yes">Streptococci and Serratia marcescens</italic>, <italic toggle="yes">Serratia marcescens</italic> (Coley&#8217;s Toxin)</p><p>
<italic toggle="yes">E coli</italic> BM2-1 strain)</p></td><td align="left" colspan="1" rowspan="1">Vaccine as an adjuvant against different types of cancer.</td><td align="left" colspan="1" rowspan="1"><p> [<xref ref-type="bibr" rid="CR164">164</xref>]</p><p> [<xref ref-type="bibr" rid="CR165">165</xref>]</p></td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Clostridium novyi-NT</italic>
</td><td align="left" colspan="1" rowspan="1">Injection 3 &#215; 108 spores of C novyi-NT</td><td align="left" colspan="1" rowspan="1"><p>C novyi-NT plus external beam radiation led to tumor shrinkage in mice bearing HCT116</p><p>tumors</p></td><td align="left" colspan="1" rowspan="1"><p> [<xref ref-type="bibr" rid="CR166">166</xref>]</p><p> [<xref ref-type="bibr" rid="CR167">167</xref>]</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec16"><title>Bacteria as immunotherapeutic agents in cancer therapy</title><p id="Par41">The efficacy of immunotherapy in cancer treatment stems from its ability to stimulate the immune system to specifically target malignant cells. The proposed methodology primarily focuses on the activation and stimulation of CD8 + and CD4 + T lymphocytes, which possess the ability to recognize tumor antigens. Upon activation, these immune cells will actively participate in the process of identifying tumor cells and eradicating them [<xref ref-type="bibr" rid="CR168">168</xref>]. Following infection by bacteria such as C. novyi, necrotic cells possess the capacity to produce pathogen-associated molecular patterns (PAMPs) and heat shock proteins, including Hsp70. The Hsp70 protein is of significant importance in the dendritic cell maturation process, which is vital for the effective initiation of immune responses targeted towards antigens [<xref ref-type="bibr" rid="CR169">169</xref>]. The synthesis of pro-inflammatory cytokines and costimulatory molecules is triggered by the interaction between pathogen-associated molecular patterns (PAMPs) and toll-like receptors. The mediators in question induce the production of interferon gamma (IFN- &#945;), which subsequently initiates a cellular immune response that is primarily driven by CD8 + effector cells and is reliant on Th1 cells. The treatment of Clostridium novyi NT to mice has shown the capacity to induce tumor-specific acquired immunity via the mediation of CD8 + cells [<xref ref-type="bibr" rid="CR170">170</xref>]. The capacity of intracellular bacteria, namely S. typhimurium, to invade host cells plays a pivotal role in the efficacy of the melanoma immunotherapy strategy presented by Avogadri et al. The use of a type-3 secretion system (T3SS) by Salmonella typhimurium in order to facilitate the invasion of neoplastic cells has been shown. Both in vivo and in vitro studies have provided empirical data indicating that mutant strains missing the type III secretion system (T3SS) exhibit an inability to infiltrate tumor cells [<xref ref-type="bibr" rid="CR171">171</xref>]. The elimination of infected tumor cells by Salmonella does not occur by direct means. Rather, the presence of bacterial antigens facilitates the activation of T lymphocytes that specifically recognize Salmonella, so acting as targets for immune response. Nevertheless, more investigation is required to fully understand the intricate mechanism behind this process [<xref ref-type="bibr" rid="CR172">172</xref>].</p><p id="Par42">Clostridia strains may generate cell suicide genes like cytosine deaminase or eukaryotic host molecules like TNF-&#945; [<xref ref-type="bibr" rid="CR61">61</xref>]. C. novyi-NT has RecA, a DNA repair and maintenance protein, which boosts host immunity and pro-inflammatory cytokines and chemokines, which shrink tumors.</p><p id="Par43">Engineering less virulent Salmonella and Listeria may lower dose toxicity and infection. Three commonly used attenuated Salmonella strains for therapy are <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VNP20009">VNP20009</ext-link>, AR-1, and &#916;ppGpp. By eliminating purI and msbB genes, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VNP20009">VNP20009</ext-link> lowers septic shock and boosts antibiotic sensitivity A phase I clinical trial found better tumor colonization without severe toxicity or side effects and quick bloodstream clearance throughout experimental testing [<xref ref-type="bibr" rid="CR173">173</xref>].</p><p id="Par44">A study by Yun et al. observed that mice treated with &#916;ppGpp showed reduced cytoskeletal components and increased iron and heme metabolism, suggesting that bacteria proliferation might disturb tumor tissues and give free heme and iron for growth [<xref ref-type="bibr" rid="CR174">174</xref>] without maintenance treatment. The live-attenuated double-deleted (LADD) strain of Listeria exhibits lower liver toxicity and fast liver and spleen clearance, making it the main vaccine candidate in clinical trials. The XFL-7 serovar indicates that prfA gene deletions greatly reduce Lm strains. A tumor-associated antigen-cloned PrfA plasmid recovers immunogenic partial virulence. A plasmid alone may partially restore virulence in the &#916;dal/&#916;dat (Lmdd) strain, which lacks peptidoglycan genes and needs alanine co-administration. Medical trials use Lmdd and XFL-7 strains [<xref ref-type="bibr" rid="CR175">175</xref>].</p><p id="Par45">The regression of B16F10 melanoma tumors in mice is seen in its entirety when (DCs) are activated by bacterial compounds, namely CpG oligonucleotides, which are recognized for their capacity to initiate the immune response [<xref ref-type="bibr" rid="CR176">176</xref>]. Nearly thirty years have elapsed since the first use of recombinant Escherichia coli strains in the realm of molecular biology and the synthesis of recombinant proteins [<xref ref-type="bibr" rid="CR177">177</xref>]. These strains have the potential to serve as vehicles for the delivery of tumor antigens to dendritic cells. Upon internalization by macrophages, the OVA Kb-restricted epitope, SIINFEKL, is presented by MHC class I molecules after the concurrent synthesis of listeriolysin O (LLO) and ovalbumin (OVA) inside a single Escherichia coli strain. After the process of phagocytosis and subsequent breakdown inside phagocytic vesicles, LLO, along with the proteins that are co-expressed, is released into the cytosol [<xref ref-type="bibr" rid="CR158">158</xref>]. Following that, it proceeds through processing and presentation via the major histocompatibility complex (MHC) class I route. Bacterial species are involved in the synthesis of LLO, a protein that is mostly located inside the cytoplasmic compartment. Based on current study findings, the use of a distinct assemblage of pathogen-associated molecular patterns (PAMPs) has shown promise in achieving comprehensive elimination of solid tumors in mice suffering from cancer [<xref ref-type="bibr" rid="CR178">178</xref>].</p></sec><sec id="Sec17"><title>Bacterial toxins or enzymes in cancer therapy</title><p id="Par46">Several types of pathogenic bacteria are capable of producing and secreting protein toxins in order to weaken the immune system of the host. Researchers have investigated the idea of using a few of these carcinogens as potential cancer treatments [<xref ref-type="bibr" rid="CR179">179</xref>]. They do this by accelerating covalent modifications in the target proteins, which in turn prevents the production of antibodies and cytokines [<xref ref-type="bibr" rid="CR180">180</xref>]. These toxins not only prevent macrophages from migrating, but they also prevent epithelial cells from performing their barrier role. Many of these toxins are potent enzymes with incredible selectivity, and the biological substrates that they target are often signaling molecules. These enzymatic poisons are created by bacteria after they have successfully infiltrated a host cell [<xref ref-type="bibr" rid="CR154">154</xref>]. They have the potential to modify the cytosolic substrates of the host cell, which may result in a change in the function of the cell or even cell death [<xref ref-type="bibr" rid="CR181">181</xref>]. These toxins have been used to investigate or alter a variety of mammalian cell signaling pathways because of the familiarity of their structures, cellular receptors, molecular processes, and absorption routes [<xref ref-type="bibr" rid="CR182">182</xref>].</p><p id="Par47">Cytotoxins produced by bacteria are among the most lethal substances on the earth. Cytolysin A, also known as ClyA or HlyE, is an enzyme toxin that is generated by bacteria. It causes the membranes of eukaryotic cells to become perforated, which then leads to the caspase cascade causing the cells to die [<xref ref-type="bibr" rid="CR183">183</xref>]. According to the findings of a number of research, mice who were given Escherichia coli or Salmonella typhimurium strains that released the ClyA toxin had much less development of tumors than mice that were not given the treatment. The tumor necrosis factor (TNF), also known as TRAIL, and the FAS ligand, also known as FAS-L, are all examples of cytokines that belong to the TNF superfamily. Caspases 3 and 8 are examples of apoptotic mediators that are activated when these proteins preferentially induce programmed cell death via pathways associated with death receptors. Various types of bacteria use for use cancer which are shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref> [<xref ref-type="bibr" rid="CR184">184</xref>].</p><p id="Par48">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Represent different bacteria used for cancer treatment. The figure represent various of bacterial strains specially modified to remove the cancer cell from the tissue</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1448" position="float" orientation="portrait" xlink:href="12672_2025_4188_Fig4_HTML.jpg"/></fig>
</p><p id="Par49">Carbon nitride (C3N4) and an E. coli strain with the ability to produce nitric oxide (NO) were used in the creation of a &#8220;photo-controlled bacterial metabolite therapy&#8221; that was recently created by Zheng and colleagues. When C3N4-containing bacteria were introduced into a mouse model tumor, this resulted to a substantial anticancer impact as well as an approximately 80% reduction in the growth of the tumor. Toxins produced by bacteria may either inhibit or stimulate the cell cycle progression of eukaryotic organisms. Cell-cycle stimulators, on the other hand, cause cells to divide more quickly than they would if the stimulant were not there, while cell-cycle inhibitors, often referred to as &#8220;cyclomodulins,&#8221; are toxic substances that prevent cells from dividing [<xref ref-type="bibr" rid="CR185">185</xref>]. The secretion of CNF by some bacteria, such as E. coli, has been seen to enhance the progression from the G1 to the S phase of the cell cycle and promote DNA replication, leading to the formation of multinucleated cells. There is a potential for toxins such as Cif and CDTs, produced by many Gram-negative bacterial species like Salmonella typhi and Campylobacter jejuni, to inhibit the clonal proliferation of lymphocytes. Cif is found in both enterohemorrhagic E. coli and enteropathogenic E. coli. CDT toxins are synthesized by a wide range of Gram-negative bacterial species [<xref ref-type="bibr" rid="CR186">186</xref>]. It&#8217;s possible that treating cancer using bacterial toxins has fewer adverse effects than conventional therapy does. It is possible that the treatment of cancer might be improved by combining the use of these poisons with conventional chemotherapy or radiation therapy [<xref ref-type="bibr" rid="CR187">187</xref>].</p></sec><sec id="Sec18"><title>Bacteriotherapy in cancer: real-world translational and clinical hurdles</title><p id="Par50">Therapeutic bacteria promise to do things drugs cannot&#8212;find hypoxic tumor cores, remodel the microenvironment, and deliver payloads locally. But turning this promise into routine care faces unique obstacles [<xref ref-type="bibr" rid="CR188">188</xref>]. The former is strain selection and control. Attenuated Salmonella, Clostridium, Listeria, or modified E. coli may colonise tumours, but may also disseminate, mutate, or cause sepsis, risks that are aggravated in immunocompromised cancer patients. Biocontainment design (auxotrophy, kill switches, quorum-sensing lysis circuits) is beneficial, but genetic circuits may fail in a selective environment, and horizontal genetic transfer to commensal or pathogen hosts is a practical consideration. The issue of safety and dosing is not a trifle. In contrast to conventional medicines, live bacteria replicate unpredictably, and their pharmacokinetics are influenced by the immune state of the patient, antibiotics, tumour perfusion, and oxygen levels in the region. Inflammation mediated by endotoxins may lead to high fevers or hemodynamic instability; aggressive antibiotic rescue may, on the other hand, eliminate the treatment effect. Tumor targeting and efficacy remain variable. While hypoxic or necrotic regions attract some strains, many solid tumors are patchy; incomplete colonization leads to uneven payload delivery and mixed responses [<xref ref-type="bibr" rid="CR189">189</xref>]. The tumor microenvironment (TME) is a double-edged sword: it provides niches for bacterial growth but also contains dense stroma, abnormal vasculature, and immune suppressive cells that limit penetration and durable control [<xref ref-type="bibr" rid="CR190">190</xref>]. When bacteria are used as delivery vehicles for cytokines, checkpoint inhibitors, or toxins, the payload control (how much, where, and when) must be precise to avoid systemic toxicity. Bacteriotherapy is a living product about manufacturing and logistics: it has to be sterilised to a high level (GMP), it has to maintain a consistent genotype, it has to be predictable in CFU, it has to be free of phage contamination, and it has to be closely regulated in terms of temperature during shipping and storage [<xref ref-type="bibr" rid="CR191">191</xref>]. This is because it is difficult to test the batch-to-batch reproducibility and real-time release without slowing down care. Hospitals must also have infection-control measures such as patient isolation, environmental shedding, and waste management information, which is critical to regulators and institutional review boards [<xref ref-type="bibr" rid="CR192">192</xref>]. There must be a change in clinical trial design. Conventional oncology dose-escalation (in search of a maximum tolerated dose) might not identify the biologically effective dose at which colonisation and payload expression capabilities occur. Trials require an imaging or molecular readout of colonization of the tumor, shedding measurements to control environmental risk, and an objective definition of when the antibiotics are to be removed [<xref ref-type="bibr" rid="CR193">193</xref>]. A combination of bacteriotherapy, radiotherapy, chemotherapy, or immunotherapy is desirable but creates scheduling issues, drug-microbe interactions (e.g., antibiotics blunting effect), and overlapping toxicities [<xref ref-type="bibr" rid="CR194">194</xref>]. Lastly, regulatory and public acceptance are substantial hurdles. Engineered microbes are regulated as live biotherapeutic products and genetically modified organisms (GMOs), with additional biosafety requirements and environmental risk assessments [<xref ref-type="bibr" rid="CR195">195</xref>]. Long-term follow-up is needed to monitor persistence, resistance, and microbiome disruption. On the access and equity side, specialized manufacturing, containment infrastructure, and monitoring increase cost and limit availability, particularly outside major centers [<xref ref-type="bibr" rid="CR196">196</xref>].</p></sec></sec><sec id="Sec19"><title>Combined therapies for cancer</title><p id="Par51">Using a combination of different agents is a key strategy for effectively treating the disease. Various types of combination therapy are currently being used in both clinical settings and ongoing clinical trials. Many creative combinations have been developed. Given the surge in popularity of this treatment, it is reasonable to anticipate that technological advancements will lead to the development of even more innovative approaches. Furthermore, information from fields like nanotechnology, DNA sequencing technologies, and computational analysis can be employed to improve different combination approaches. Combination therapies have significant advantages over monotherapies. It&#8217;s important to highlight that there are still challenges to address, including preventing drug resistance, managing toxicity and drug interactions, and conducting more comprehensive survival analysis [<xref ref-type="bibr" rid="CR197">197</xref>]. Furthermore, it is essential to carefully adjust combination therapies based on the unique reactions of patients. Having a deep understanding of the different combination approaches used in clinical settings or trials is essential for assessing the most effective treatment options for patients. Utilizing a variety of therapeutic agents is crucial in the battle against cancer, as it allows for a more effective approach known as combination therapy. When different anti-cancer drugs are combined, they synergistically enhance their effectiveness, surpassing the efficacy of using a single drug alone. These pathways are targeted in a manner that either works together or adds up. This approach holds great promise in reducing drug resistance and providing therapeutic advantages in the fight against cancer. These advantages encompass the deceleration of tumor growth and the inhibition of cancer cell proliferation, as well as the decrease in the population of cancer stem cells and the initiation of cellular demise [<xref ref-type="bibr" rid="CR198">198</xref>]. Survival rates for most metastatic cancers are unfortunately still quite low, and the process of developing new anti-cancer drugs is both expensive and time-consuming. Thus, scientists are investigating alternative approaches that prioritize the pathways for survival to attain the best outcomes at a reasonable expense. Another approach involves using therapeutic agents that were initially created to treat diseases other than cancer. This method is most efficient when the FDA-approved substance focuses on pathways that are also found in cancer. By incorporating an FDA-approved drug into combination therapy, the expenses associated with research are greatly diminished. By optimizing the cost efficiency of therapy, it ensures that individuals with limited access to medical services can also reap the benefits. In addition, a technique that combines repurposed pharmaceutical agents with other therapeutics has shown promising results in reducing tumor burden [<xref ref-type="bibr" rid="CR199">199</xref>].</p></sec><sec id="Sec20"><title>Comparative study of four therapeutics options for cancer</title><p id="Par52">Cancer vaccines. Therapeutic cancer vaccines (not preventive vaccines like HPV) have generally produced modest clinical outcomes to date [<xref ref-type="bibr" rid="CR200">200</xref>]. The clearest real-world example is sipuleucel-T for metastatic prostate cancer, which in the pivotal trial prolonged median overall survival by roughly 4 months versus control [<xref ref-type="bibr" rid="CR201">201</xref>]. This statistically significant but clinically modest benefit established proof of principle rather than a broad cure [<xref ref-type="bibr" rid="CR202">202</xref>]. Several tumor-antigen and neoantigen vaccine platforms are in development (peptide, dendritic cell, viral vectors, mRNA), and some early-phase trials show immunologic responses and occasional durable remissions when combined with other therapies. However, single-agent vaccine response rates remain low in most solid tumors, and success has been limited to niche indications or combination strategies [<xref ref-type="bibr" rid="CR203">203</xref>]. Key limitations are the generally weak magnitude of induced T-cell responses in the hostile tumor microenvironment (TME), antigen heterogeneity and loss, and the difficulty of generating neoantigen vaccines quickly and cost-effectively for each patient. Immune checkpoint inhibitors (ICIs) and cell therapies. ICIs (anti-PD-1/PD-L1 and anti-CTLA-4) are the most broadly impactful immunotherapies so far [<xref ref-type="bibr" rid="CR204">204</xref>]. In immunologically &#8220;hot&#8221; tumors such as melanoma and some lung cancers, single-agent anti-PD-1 therapies produce objective response rates (ORRs) often in the 20&#8211;45% range and durable long-term survival for a subset of patients; combinations (e.g., nivolumab + ipilimumab) push response and long-term survival rates even higher in melanoma, with multi-year survivors now well documented [<xref ref-type="bibr" rid="CR205">205</xref>]. In non-small cell lung cancer (NSCLC), trials show ORRs around 20% overall but much higher in PD-L1-high tumors, and 5-year survival benchmarks are now in the low-to-mid-20% range for some populations. CAR-T cell therapy for hematologic cancers has shown very high complete-remission rates in relapsed/refractory B-cell malignancies (often &gt;50&#8211;80% in certain trials), but its success in solid tumors is far more limited [<xref ref-type="bibr" rid="CR206">206</xref>, <xref ref-type="bibr" rid="CR207">207</xref>]. Limitations across ICIs and CAR-T include primary and acquired resistance (driven by the TME, antigen loss, and immune exclusion), immune-related toxicities that can be severe or fatal, and variable biomarkers to reliably predict responders [<xref ref-type="bibr" rid="CR208">208</xref>]. The clinical payoff is real and sometimes dramatic, but benefits are heterogeneous and patient selection remains an unmet need.</p><p id="Par53">CRISPR/Cas9-based approaches.</p><p id="Par54">Clinical use of CRISPR in oncology is still nascent and mainly experimental. Most early clinical work involves ex vivo editing of patient immune cells (for example, knocking out PD-1 in T cells or inserting engineered receptors) and reinfusing them; a few bespoke trials have shown safety signals and hints of anti-tumor activity in small cohorts, but objective response rates are low and follow-up is short [<xref ref-type="bibr" rid="CR209">209</xref>]. In vivo CRISPR editing of tumor cells remains largely preclinical because of delivery challenges. Key translational hurdles are safe, tumor-specific delivery (avoiding liver/spleen accumulation), limiting off-target edits and large genomic rearrangements, managing immune responses to CRISPR components, and building GMP manufacturing and long-term monitoring for genotoxicity [<xref ref-type="bibr" rid="CR210">210</xref>]. Regulatory and ethical scrutiny is high, and clinical evidence of meaningful, reproducible cancer cures from CRISPR is still pending. In short, strong biological potential, but early, small, and cautious clinical signals so far.</p><p id="Par55">Bacteriotherapy (engineered/attenuated bacteria). Using bacteria to treat cancer is attractive because some microbes naturally home to hypoxic tumor niches and can be engineered to deliver drugs, immune modulators, or provoke local inflammation [<xref ref-type="bibr" rid="CR211">211</xref>]. Clinical experience is mixed: several Listeria- or Salmonella-based vaccines and Clostridium or C. novyi-NT intratumoral approaches have shown safety in phase I&#8211;II studies and immunologic activity, and a handful of trials reported encouraging survival signals in specific settings [<xref ref-type="bibr" rid="CR212">212</xref>]. But robust, reproducible objective response rates across large trials are still rare. Major limitations include controlling bacterial replication and preventing systemic infection (especially in immunocompromised patients), ensuring predictable tumor colonization, biocontainment and horizontal gene transfer risks, and complex manufacturing and infection-control logistics [<xref ref-type="bibr" rid="CR213">213</xref>]. Like CRISPR, bacteriotherapy is promising in principle, but translation to routine, widely used therapy requires solving safety, dosing, and regulatory challenges. Comparative takeaways. ICIs (and, in a few cases, CAR-T) are at the forefront with respect to current clinical maturity and established population value, as they have already achieved long-term remissions and survival advantages in large patient groups [<xref ref-type="bibr" rid="CR214">214</xref>]. There have been isolated, small successes with cancer vaccines, and they are best combined with other agents rather than acting alone. CRISPR and bacteriotherapy are promising experimental platforms. CRISPR has exciting potential in terms of precise editing, but must address delivery, safety, and regulatory challenges; bacteriotherapy has the capacity to target unique tumour niches and deliver payload locally, but must overcome safety, reproducibility, and manufacturing challenges.</p><p id="Par56">In all modalities, overarching themes that hinder success are the tumour microenvironment, tumour heterogeneity, technology of delivery, patient selection/biomarkers, and scalable manufacturing [<xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR216">216</xref>]. Immune checkpoint blockade and CAR-T therapy have produced the clearest and most reproducible clinical benefits to date, with durable remissions in subsets of patients (notably melanoma, some lung cancers, and B-cell malignancies) [<xref ref-type="bibr" rid="CR217">217</xref>]. Therapeutic cancer vaccines have delivered modest survival gains in selected settings and are likely to be most useful in combination with other immunotherapies. CRISPR-based cancer therapies remain early-stage: ex vivo edited immune cells have shown safety and preliminary activity in small trials, but in vivo editing faces major delivery and safety challenges. Bacteriotherapy shows promise for targeting difficult tumor niches, but it requires reliable control of live organisms, tight biocontainment, and clear strategies to prevent systemic infection [<xref ref-type="bibr" rid="CR218">218</xref>].</p></sec><sec id="Sec21"><title>Conclusion</title><p id="Par57">Personalized cancer vaccines are a promising strategy for enhancing the precision and efficacy of tumor targeting in individual cancer patients. The progress and enhancement of cancer vaccines have made significant advancements, while not achieving the same remarkable efficacy and results as immune checkpoint inhibitors and T-cell therapy. The CRISPR/Cas9 system has garnered significant attention because of its potential to revolutionize the treatment of cancer and other diseases in the preclinical domain. This is now recognized as an advanced technique for genome editing. The potential medicinal applications of phases 1 and 2 are currently under investigation. The CRISPR/Cas9 system represents a promising and transformative advancement in the realm of immunological oncology and its associated disciplines. However, further research and development are required to ensure its widespread use. Tumor-targeting bacteria have favorable characteristics for the transportation of cancer therapeutic payloads, mostly attributed to their selectivity towards tumors and their ability to efficiently encapsulate genes. The remarkable capacity of unlimited gene packaging not only facilitates the activation of many or sizable target genes but also establishes the foundation for the manipulation of signaling networks in bacteria, thereby empowering them to perform intricate functions in the realm of cancer therapy. Cancer immunotherapy has recently seen significant advancements with the introduction of cancer vaccines, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). These breakthroughs have brought about the long-anticipated promise of cancer immunotherapy. The cellular composition of the tumor microenvironment (TME) encompasses various cell types, including cancer, stromal, and immune cells. Various cell types have the potential to engage in interactions that may modify the tumor microenvironment (TME) and exert control over the proliferation of cancerous cells. Emphasizing this significance lies in acknowledging the collaborative efforts of immune cells residing inside tumors in regulating the progression of cancer. Synchronized reactions from both innate and adaptive immune cells play a pivotal role in determining the efficacy of immunotherapeutic interventions. Integration of different omics techniques for cancer treatment and biomarker identification is a promising and expanding field. It provides significant information regarding the biological processes and therapies of diseases. Integrating data from DNA, RNA, proteins, metabolites, and epigenetic markings is necessary to understand the complex interactions in living systems. This multi-omics technique holistically shows complex systems. Multi-omics has been used in biomedical research to identify new diseases, explore new medications, customize treatments, and optimize cancer therapies.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>A.Z. wrote the manuscript. Data curation was done by S.W.</p><sec id="d33e1588"><title>Disclosure</title><p id="Par58">This paper has been uploaded to [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.authorea.com/">https://www.authorea.com/</ext-link>] as a preprint: [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.authorea.com/users/854474/articles/1239719-unlocking-the-potential-and-myth-of-personalized-vaccines-crispr-cas9-and-bacteriotherapy-as-therapeuticoptions-for-cancer">https://www.authorea.com/users/854474/articles/1239719-unlocking-the-potential-and-myth-of-personalized-vaccines-crispr-cas9-and-bacteriotherapy-as-therapeuticoptions-for-cancer</ext-link>]</p></sec></notes><notes notes-type="funding-information"><title>Funding statement</title><p>This study received no government or private financial support.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data used to support the findings of this study are included in this article.</p></notes><notes><title>Declarations</title><notes id="FPar4"><title><bold>Ethics approval and consent to participate</bold></title><p id="Par59">Not applicable.</p></notes><notes id="FPar5"><title><bold>Informed consent</bold></title><p id="Par60">Not applicable.</p></notes><notes id="FPar6" notes-type="COI-statement"><title>Competing interests</title><p id="Par61">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Colombet</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Pi&#241;eros</surname><given-names>M</given-names></name><name name-style="western"><surname>Znaor</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer statistics for the year 2020: an overview</article-title><source>Int J Cancer</source><year>2021</year><volume>149</volume><issue>4</issue><fpage>778</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/ijc.33588</pub-id><pub-id pub-id-type="pmid">33818764</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi&#241;eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778&#8211;89.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33588</pub-id><pub-id pub-id-type="pmid">33818764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Wagle</surname><given-names>NS</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2023</article-title><source>Ca Cancer J Clin</source><year>2023</year><volume>73</volume><issue>1</issue><fpage>17</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">36633525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17&#8211;48.<pub-id pub-id-type="pmid">36633525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>GP</given-names></name><name name-style="western"><surname>Old</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>The immunobiology of cancer immunosurveillance and immunoediting</article-title><source>Immunity</source><year>2004</year><volume>21</volume><issue>2</issue><fpage>137</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.07.017</pub-id><pub-id pub-id-type="pmid">15308095</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137&#8211;48.<pub-id pub-id-type="pmid">15308095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2004.07.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Rethinking cancer nanotheranostics</article-title><source>Nat Reviews Mater</source><year>2017</year><volume>2</volume><issue>7</issue><fpage>17024</fpage><pub-id pub-id-type="doi">10.1038/natrevmats.2017.24</pub-id><pub-id pub-id-type="pmcid">PMC5654564</pub-id><pub-id pub-id-type="pmid">29075517</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. Nat Reviews Mater. 2017;2(7):17024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/natrevmats.2017.24</pub-id><pub-id pub-id-type="pmcid">PMC5654564</pub-id><pub-id pub-id-type="pmid">29075517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name></person-group><article-title>Allergen-specific immunotherapy induces monocyte&#8208;derived dendritic cells but attenuates their maturation and cytokine production in the lesional skin of an atopic dermatitis mouse model</article-title><source>J Dermatol</source><year>2022</year><volume>49</volume><issue>12</issue><fpage>1310</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.16582</pub-id><pub-id pub-id-type="pmid">36117445</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Feng S, Song G, Liu L, Liu W, Liang G, Song Z. Allergen-specific immunotherapy induces monocyte&#8208;derived dendritic cells but attenuates their maturation and cytokine production in the lesional skin of an atopic dermatitis mouse model. J Dermatol. 2022;49(12):1310&#8211;9.<pub-id pub-id-type="pmid">36117445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.16582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells</article-title><source>Pharmacol Res</source><year>2022</year><volume>181</volume><fpage>106270</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106270</pub-id><pub-id pub-id-type="pmid">35605812</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Pan L, Feng F, Wu J, Fan S, Han J, Wang S, et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022;181:106270.<pub-id pub-id-type="pmid">35605812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2022.106270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><name name-style="western"><surname>Pei</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>23</issue><fpage>23998</fpage><lpage>4011</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c08875</pub-id><pub-id pub-id-type="pmid">37988029</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Shen W, Pei P, Zhang C, Li J, Han X, Liu T, et al. A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano. 2023;17(23):23998&#8211;4011.<pub-id pub-id-type="pmid">37988029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c08875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gut Microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation</article-title><source>Cell Host Microbe</source><year>2022</year><volume>30</volume><issue>10</issue><fpage>1450</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.09.004</pub-id><pub-id pub-id-type="pmid">36228585</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tian Z, Zhang Y, Zheng Z, Zhang M, Zhang T, Jin J, et al. Gut Microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. Cell Host Microbe. 2022;30(10):1450&#8211;63. e8.<pub-id pub-id-type="pmid">36228585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2022.09.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>F</given-names></name><name name-style="western"><surname>Long</surname><given-names>D</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Introduction of exogenous wild&#8211;type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor&#8211;&#954;B in non&#8211;small cell lung cancer NCI&#8211;H1299 cells</article-title><source>Oncol Rep</source><year>2019</year><volume>41</volume><issue>3</issue><fpage>2051</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30628717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.6964</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Chen S, Zhao Y, Shen F, Long D, Yu T, Lin X. Introduction of exogenous wild&#8211;type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor&#8211;&#954;B in non&#8211;small cell lung cancer NCI&#8211;H1299 cells. Oncol Rep. 2019;41(3):2051&#8211;9.<pub-id pub-id-type="pmid">30628717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.6964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shemesh</surname><given-names>CS</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>I</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B-Q</given-names></name><name name-style="western"><surname>Rotte</surname><given-names>A</given-names></name><name name-style="western"><surname>Twomey</surname><given-names>P</given-names></name><etal/></person-group><article-title>Personalized cancer vaccines: clinical landscape, challenges, and opportunities</article-title><source>Mol Ther</source><year>2021</year><volume>29</volume><issue>2</issue><fpage>555</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.09.038</pub-id><pub-id pub-id-type="pmid">33038322</pub-id><pub-id pub-id-type="pmcid">PMC7854282</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Shemesh CS, Hsu JC, Hosseini I, Shen B-Q, Rotte A, Twomey P, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555&#8211;70.<pub-id pub-id-type="pmid">33038322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2020.09.038</pub-id><pub-id pub-id-type="pmcid">PMC7854282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blass</surname><given-names>E</given-names></name><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name></person-group><article-title>Advances in the development of personalized neoantigen-based therapeutic cancer vaccines</article-title><source>Nat Reviews Clin Oncol</source><year>2021</year><volume>18</volume><issue>4</issue><fpage>215</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id><pub-id pub-id-type="pmid">33473220</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Reviews Clin Oncol. 2021;18(4):215&#8211;29.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id><pub-id pub-id-type="pmid">33473220</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Danilova</surname><given-names>ND</given-names></name><name name-style="western"><surname>Soltani</surname><given-names>M</given-names></name><name name-style="western"><surname>Savvateeva</surname><given-names>LV</given-names></name><name name-style="western"><surname>Tarasov</surname><given-names>VV</given-names></name><name name-style="western"><surname>Ganjalikhani-Hakemi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cancer vaccine in cold tumors: clinical Landscape, Challenges, and opportunities</article-title><source>Curr Cancer Drug Targets</source><year>2022</year><volume>22</volume><issue>6</issue><fpage>437</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.2174/1568009622666220214103533</pub-id><pub-id pub-id-type="pmid">35156572</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Rezaei M, Danilova ND, Soltani M, Savvateeva LV, Tarasov VV, Ganjalikhani-Hakemi M, et al. Cancer vaccine in cold tumors: clinical Landscape, Challenges, and opportunities. Curr Cancer Drug Targets. 2022;22(6):437&#8211;53.<pub-id pub-id-type="pmid">35156572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1568009622666220214103533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name></person-group><article-title>The clinical landscape of therapeutic cancer vaccines: the next breakthrough in cancer immunotherapy?</article-title><source>Eur J Cancer</source><year>2023</year><volume>181</volume><fpage>38</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.12.007</pub-id><pub-id pub-id-type="pmid">36634388</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zhao G, Jiang Y, Ma P, Wang S, Nie G, Li N. The clinical landscape of therapeutic cancer vaccines: the next breakthrough in cancer immunotherapy? Eur J Cancer. 2023;181:38&#8211;41.<pub-id pub-id-type="pmid">36634388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.12.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;</given-names></name></person-group><article-title>Personalized vaccines for cancer immunotherapy</article-title><source>Science</source><year>2018</year><volume>359</volume><issue>6382</issue><fpage>1355</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1126/science.aar7112</pub-id><pub-id pub-id-type="pmid">29567706</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sahin U, T&#252;reci &#214;. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355&#8211;60.<pub-id pub-id-type="pmid">29567706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aar7112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>D</given-names></name><name name-style="western"><surname>Geoffroy</surname><given-names>K</given-names></name><name name-style="western"><surname>Marguerie</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Martin</surname><given-names>N</given-names></name><name name-style="western"><surname>Kmiecik</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>2626</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22929-z</pub-id><pub-id pub-id-type="pmid">33976179</pub-id><pub-id pub-id-type="pmcid">PMC8113265</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Roy D, Geoffroy K, Marguerie M, Khan S, Martin N, Kmiecik J, et al. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat Commun. 2021;12(1):2626.<pub-id pub-id-type="pmid">33976179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22929-z</pub-id><pub-id pub-id-type="pmcid">PMC8113265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>AS</given-names></name><name name-style="western"><surname>Koshy</surname><given-names>ST</given-names></name><name name-style="western"><surname>Stafford</surname><given-names>AG</given-names></name><name name-style="western"><surname>Bastings</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>DJ</given-names></name></person-group><article-title>Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for cancer vaccination</article-title><source>Small</source><year>2016</year><volume>12</volume><issue>17</issue><fpage>2321</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/smll.201600061</pub-id><pub-id pub-id-type="pmid">26953489</pub-id><pub-id pub-id-type="pmcid">PMC5074529</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Cheung AS, Koshy ST, Stafford AG, Bastings MM, Mooney DJ. Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for cancer vaccination. Small. 2016;12(17):2321&#8211;33.<pub-id pub-id-type="pmid">26953489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201600061</pub-id><pub-id pub-id-type="pmcid">PMC5074529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></name><name name-style="western"><surname>Heath</surname><given-names>MD</given-names></name><name name-style="western"><surname>Cabral-Miranda</surname><given-names>G</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>C</given-names></name><name name-style="western"><surname>Zeltins</surname><given-names>A</given-names></name><name name-style="western"><surname>Sande</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vaccination with nanoparticles combined with micro-adjuvants protects against cancer</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><fpage>144</fpage><pub-id pub-id-type="pmid">31027511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0587-z</pub-id><pub-id pub-id-type="pmcid">PMC6485085</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, et al. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. J Immunother Cancer. 2019;7:144.<pub-id pub-id-type="pmid">31027511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0587-z</pub-id><pub-id pub-id-type="pmcid">PMC6485085</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>W</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Najafabadi</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy</article-title><source>J Controlled Release</source><year>2018</year><volume>282</volume><fpage>131</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.04.041</pub-id><pub-id pub-id-type="pmcid">PMC6056764</pub-id><pub-id pub-id-type="pmid">29702142</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kuai R, Sun X, Yuan W, Ochyl LJ, Xu Y, Najafabadi AH, et al. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. J Controlled Release. 2018;282:131&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.04.041</pub-id><pub-id pub-id-type="pmcid">PMC6056764</pub-id><pub-id pub-id-type="pmid">29702142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>W</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>4505</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40207-y</pub-id><pub-id pub-id-type="pmid">37495590</pub-id><pub-id pub-id-type="pmcid">PMC10372023</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Meng J, Lv Y, Bao W, Meng Z, Wang S, Wu Y, et al. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nat Commun. 2023;14(1):4505.<pub-id pub-id-type="pmid">37495590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40207-y</pub-id><pub-id pub-id-type="pmcid">PMC10372023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>KK</given-names></name><name name-style="western"><surname>Geary</surname><given-names>SM</given-names></name><name name-style="western"><surname>Salem</surname><given-names>AK</given-names></name></person-group><article-title>Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines</article-title><source>J Controlled Release</source><year>2017</year><volume>248</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.12.036</pub-id><pub-id pub-id-type="pmcid">PMC5309920</pub-id><pub-id pub-id-type="pmid">28057523</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ahmed KK, Geary SM, Salem AK. Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines. J Controlled Release. 2017;248:1&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2016.12.036</pub-id><pub-id pub-id-type="pmcid">PMC5309920</pub-id><pub-id pub-id-type="pmid">28057523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Xanthohumol, a prenylated flavonoid from Hops, exerts anticancer effects against gastric cancer in vitro</article-title><source>Oncol Rep</source><year>2018</year><volume>40</volume><issue>6</issue><fpage>3213</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">30272303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2018.6723</pub-id><pub-id pub-id-type="pmcid">PMC6196606</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wei S, Sun T, Du J, Zhang B, Xiang D, Li W. Xanthohumol, a prenylated flavonoid from Hops, exerts anticancer effects against gastric cancer in vitro. Oncol Rep. 2018;40(6):3213&#8211;22.<pub-id pub-id-type="pmid">30272303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2018.6723</pub-id><pub-id pub-id-type="pmcid">PMC6196606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gong</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>GH</given-names></name></person-group><article-title>Low expression of miR&#8211;199 in hepatocellular carcinoma contributes to tumor cell hyper&#8211;proliferation by negatively suppressing XBP1</article-title><source>Oncol Lett</source><year>2018</year><volume>16</volume><issue>5</issue><fpage>6531</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30405792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2018.9476</pub-id><pub-id pub-id-type="pmcid">PMC6202493</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lou Z, Gong YQ, Zhou X, Hu GH. Low expression of miR&#8211;199 in hepatocellular carcinoma contributes to tumor cell hyper&#8211;proliferation by negatively suppressing XBP1. Oncol Lett. 2018;16(5):6531&#8211;9.<pub-id pub-id-type="pmid">30405792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2018.9476</pub-id><pub-id pub-id-type="pmcid">PMC6202493</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lalancette</surname><given-names>RA</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>J&#228;kle</surname><given-names>F</given-names></name></person-group><article-title>Near-infrared-absorbing B&#8211;N Lewis pair-functionalized anthracenes: electronic structure tuning, conformational isomerism, and applications in photothermal cancer therapy</article-title><source>J Am Chem Soc</source><year>2022</year><volume>144</volume><issue>41</issue><fpage>18908</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1021/jacs.2c06538</pub-id><pub-id pub-id-type="pmid">36194812</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Liu K, Jiang Z, Lalancette RA, Tang X, J&#228;kle F. Near-infrared-absorbing B&#8211;N Lewis pair-functionalized anthracenes: electronic structure tuning, conformational isomerism, and applications in photothermal cancer therapy. J Am Chem Soc. 2022;144(41):18908&#8211;17.<pub-id pub-id-type="pmid">36194812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.2c06538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name><name name-style="western"><surname>Sayegh</surname><given-names>N</given-names></name><name name-style="western"><surname>Graciotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Kandalaft</surname><given-names>LE</given-names></name></person-group><article-title>Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines</article-title><source>Curr Opin Biotechnol</source><year>2020</year><volume>65</volume><fpage>142</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2020.02.009</pub-id><pub-id pub-id-type="pmid">32240923</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ahmed R, Sayegh N, Graciotti M, Kandalaft LE. Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines. Curr Opin Biotechnol. 2020;65:142&#8211;55.<pub-id pub-id-type="pmid">32240923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.copbio.2020.02.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>DA</given-names></name></person-group><article-title>Gene-modified dendritic cell vaccines for cancer</article-title><source>Cytotherapy</source><year>2016</year><volume>18</volume><issue>11</issue><fpage>1446</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2016.09.009</pub-id><pub-id pub-id-type="pmid">27745604</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Abraham RS, Mitchell DA. Gene-modified dendritic cell vaccines for cancer. Cytotherapy. 2016;18(11):1446&#8211;55.<pub-id pub-id-type="pmid">27745604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2016.09.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kooreman</surname><given-names>NG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>de Almeida</surname><given-names>PE</given-names></name><name name-style="western"><surname>Termglinchan</surname><given-names>V</given-names></name><name name-style="western"><surname>Diecke</surname><given-names>S</given-names></name><name name-style="western"><surname>Shao</surname><given-names>N-Y</given-names></name><etal/></person-group><article-title>Autologous iPSC-based vaccines elicit anti-tumor responses in vivo</article-title><source>Cell Stem Cell</source><year>2018</year><volume>22</volume><issue>4</issue><fpage>501</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.01.016</pub-id><pub-id pub-id-type="pmid">29456158</pub-id><pub-id pub-id-type="pmcid">PMC6134179</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao N-Y, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell. 2018;22(4):501&#8211;13. e7.<pub-id pub-id-type="pmid">29456158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stem.2018.01.016</pub-id><pub-id pub-id-type="pmcid">PMC6134179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></name><name name-style="western"><surname>Kassim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Tran</surname><given-names>TL</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>JS</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SA</given-names></name><etal/></person-group><article-title>A pilot trial using lymphocytes genetically engineered with an NY-ESO-1&#8211;reactive T-cell receptor: long-term follow-up and correlates with response</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><issue>5</issue><fpage>1019</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2708</pub-id><pub-id pub-id-type="pmid">25538264</pub-id><pub-id pub-id-type="pmcid">PMC4361810</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1&#8211;reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019&#8211;27.<pub-id pub-id-type="pmid">25538264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-14-2708</pub-id><pub-id pub-id-type="pmcid">PMC4361810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Miguel A, Sendra L, No&#233; V, Ciudad CJ, Das&#237; F, Hervas D et al. Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma. OncoTargets Therapy. 2017:503&#8211;14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S104393</pub-id><pub-id pub-id-type="pmcid">PMC5271385</pub-id><pub-id pub-id-type="pmid">28176947</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>J</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J</given-names></name></person-group><article-title>Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>152</volume><fpage>113250</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113250</pub-id><pub-id pub-id-type="pmid">35700679</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Xia J, Miao Y, Wang X, Huang X, Dai J. Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomed Pharmacother. 2022;152:113250.<pub-id pub-id-type="pmid">35700679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2022.113250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitt</surname><given-names>JM</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S</given-names></name><name name-style="western"><surname>Soria</surname><given-names>J-C</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Dendritic cell&#8211;derived exosomes for cancer therapy</article-title><source>J Clin Investig</source><year>2016</year><volume>126</volume><issue>4</issue><fpage>1224</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1172/JCI81137</pub-id><pub-id pub-id-type="pmid">27035813</pub-id><pub-id pub-id-type="pmcid">PMC4811123</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Pitt JM, Andr&#233; F, Amigorena S, Soria J-C, Eggermont A, Kroemer G, et al. Dendritic cell&#8211;derived exosomes for cancer therapy. J Clin Investig. 2016;126(4):1224&#8211;32.<pub-id pub-id-type="pmid">27035813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI81137</pub-id><pub-id pub-id-type="pmcid">PMC4811123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name></person-group><article-title>Immune-cell-derived exosomes for cancer therapy</article-title><source>Mol Pharm</source><year>2022</year><volume>19</volume><issue>9</issue><fpage>3042</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00407</pub-id><pub-id pub-id-type="pmid">35876318</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhao Y, Liu T, Zhou M. Immune-cell-derived exosomes for cancer therapy. Mol Pharm. 2022;19(9):3042&#8211;56.<pub-id pub-id-type="pmid">35876318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.2c00407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor Inhibition in vivo</article-title><source>Acta Biomater</source><year>2022</year><volume>138</volume><fpage>491</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2021.10.041</pub-id><pub-id pub-id-type="pmid">34757230</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zhu H, Wang K, Wang Z, Wang D, Yin X, Liu Y, et al. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor Inhibition in vivo. Acta Biomater. 2022;138:491&#8211;504.<pub-id pub-id-type="pmid">34757230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2021.10.041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><name name-style="western"><surname>Gu</surname><given-names>T</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Bode</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M-H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name></person-group><article-title>CRISPR/Cas9&#8211;An evolving biological tool kit for cancer biology and oncology</article-title><source>NPJ Precision Oncol</source><year>2019</year><volume>3</volume><issue>1</issue><fpage>221</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41698-019-0080-7</pub-id><pub-id pub-id-type="pmcid">PMC6423228</pub-id><pub-id pub-id-type="pmid">30911676</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tian X, Gu T, Patel S, Bode AM, Lee M-H, Dong Z. CRISPR/Cas9&#8211;An evolving biological tool kit for cancer biology and oncology. NPJ Precision Oncol. 2019;3(1):221.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41698-019-0080-7</pub-id><pub-id pub-id-type="pmcid">PMC6423228</pub-id><pub-id pub-id-type="pmid">30911676</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naseri</surname><given-names>M</given-names></name><name name-style="western"><surname>Bozorgmehr</surname><given-names>M</given-names></name><name name-style="western"><surname>Z&#246;ller</surname><given-names>M</given-names></name><name name-style="western"><surname>Ranaei Pirmardan</surname><given-names>E</given-names></name><name name-style="western"><surname>Madjd</surname><given-names>Z</given-names></name></person-group><article-title>Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>1779991</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2020.1779991</pub-id><pub-id pub-id-type="pmid">32934883</pub-id><pub-id pub-id-type="pmcid">PMC7466856</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Naseri M, Bozorgmehr M, Z&#246;ller M, Ranaei Pirmardan E, Madjd Z. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology. 2020;9(1):1779991.<pub-id pub-id-type="pmid">32934883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2020.1779991</pub-id><pub-id pub-id-type="pmcid">PMC7466856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai Phung</surname><given-names>C</given-names></name><name name-style="western"><surname>Pham</surname><given-names>TT</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>HT</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TT</given-names></name><name name-style="western"><surname>Ou</surname><given-names>W</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J-H</given-names></name><etal/></person-group><article-title>Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses</article-title><source>Acta Biomater</source><year>2020</year><volume>115</volume><fpage>371</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.08.008</pub-id><pub-id pub-id-type="pmid">32798721</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dai Phung C, Pham TT, Nguyen HT, Nguyen TT, Ou W, Jeong J-H, et al. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses. Acta Biomater. 2020;115:371&#8211;82.<pub-id pub-id-type="pmid">32798721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2020.08.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>B</given-names></name><name name-style="western"><surname>Jing</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models</article-title><source>J Hepatol</source><year>2017</year><volume>67</volume><issue>4</issue><fpage>739</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.05.019</pub-id><pub-id pub-id-type="pmid">28549917</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67(4):739&#8211;48.<pub-id pub-id-type="pmid">28549917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2017.05.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faghfuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Pourfarzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Faghfouri</surname><given-names>AH</given-names></name><name name-style="western"><surname>Abdoli Shadbad</surname><given-names>M</given-names></name><name name-style="western"><surname>Hajiasgharzadeh</surname><given-names>K</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B</given-names></name></person-group><article-title>Recent developments of RNA-based vaccines in cancer immunotherapy</article-title><source>Expert Opin Biol Ther</source><year>2021</year><volume>21</volume><issue>2</issue><fpage>201</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1080/14712598.2020.1815704</pub-id><pub-id pub-id-type="pmid">32842798</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther. 2021;21(2):201&#8211;18.<pub-id pub-id-type="pmid">32842798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14712598.2020.1815704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi Najafabadi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A</given-names></name><name name-style="western"><surname>Aghasadeghi</surname><given-names>MR</given-names></name></person-group><article-title>Tumor cell-based vaccine: an effective strategy for eradication of cancer cells</article-title><source>Immunotherapy</source><year>2022</year><volume>14</volume><issue>8</issue><fpage>639</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2217/imt-2022-0036</pub-id><pub-id pub-id-type="pmid">35481358</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Sadeghi Najafabadi SA, Bolhassani A, Aghasadeghi MR. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy. 2022;14(8):639&#8211;54.<pub-id pub-id-type="pmid">35481358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt-2022-0036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">McNamara MA, Nair SK, Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res. 2015;2015.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/794528</pub-id><pub-id pub-id-type="pmcid">PMC4668311</pub-id><pub-id pub-id-type="pmid">26665011</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahanafrooz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B</given-names></name><name name-style="western"><surname>Mosafer</surname><given-names>J</given-names></name><name name-style="western"><surname>Hashemzaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>T</given-names></name><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of DNA and mRNA vaccines against cancer</article-title><source>Drug Discovery Today</source><year>2020</year><volume>25</volume><issue>3</issue><fpage>552</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.12.003</pub-id><pub-id pub-id-type="pmid">31843577</pub-id><pub-id pub-id-type="pmcid">PMC7080609</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discovery Today. 2020;25(3):552&#8211;60.<pub-id pub-id-type="pmid">31843577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2019.12.003</pub-id><pub-id pub-id-type="pmcid">PMC7080609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M</given-names></name><name name-style="western"><surname>Kloke</surname><given-names>B-P</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title><source>Nature</source><year>2017</year><volume>547</volume><issue>7662</issue><fpage>222</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="pmid">28678784</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, L&#246;wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222&#8211;6.<pub-id pub-id-type="pmid">28678784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature23003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Tomb&#225;cz I, Weissman D, Pardi N. Vaccination with messenger RNA: a promising alternative to DNA vaccination. DNA Vaccines: Methods Protocols. 2021:13&#8211;31.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-0872-2_2</pub-id><pub-id pub-id-type="pmid">32827130</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bidram</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shebardina</surname><given-names>NG</given-names></name><name name-style="western"><surname>Baldin</surname><given-names>AV</given-names></name><name name-style="western"><surname>Bazhin</surname><given-names>AV</given-names></name><name name-style="western"><surname>Ganjalikhany</surname><given-names>MR</given-names></name><etal/></person-group><article-title>mRNA-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><issue>10</issue><fpage>1060</fpage><pub-id pub-id-type="doi">10.3390/vaccines9101060</pub-id><pub-id pub-id-type="pmid">34696168</pub-id><pub-id pub-id-type="pmcid">PMC8540049</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021;9(10):1060.<pub-id pub-id-type="pmid">34696168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9101060</pub-id><pub-id pub-id-type="pmcid">PMC8540049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Akakuru</surname><given-names>OU</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A</given-names></name></person-group><article-title>Nanoscale covalent organic frameworks: from controlled synthesis to cancer therapy</article-title><source>Chem Commun</source><year>2021</year><volume>57</volume><issue>93</issue><fpage>12417</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1039/D1CC04846E</pub-id><pub-id pub-id-type="pmid">34734601</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">He X, Jiang Z, Akakuru OU, Li J, Wu A. Nanoscale covalent organic frameworks: from controlled synthesis to cancer therapy. Chem Commun. 2021;57(93):12417&#8211;35.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d1cc04846e</pub-id><pub-id pub-id-type="pmid">34734601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>KRT17 promotes T-lymphocyte infiltration through the YTHDF2&#8211;CXCL10 axis in colorectal cancer</article-title><source>Cancer Immunol Res</source><year>2023</year><volume>11</volume><issue>7</issue><fpage>875</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0814</pub-id><pub-id pub-id-type="pmid">37129929</pub-id><pub-id pub-id-type="pmcid">PMC10320689</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W, et al. KRT17 promotes T-lymphocyte infiltration through the YTHDF2&#8211;CXCL10 axis in colorectal cancer. Cancer Immunol Res. 2023;11(7):875&#8211;94.<pub-id pub-id-type="pmid">37129929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-22-0814</pub-id><pub-id pub-id-type="pmcid">PMC10320689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. Curr Strategies Cancer Gene Therapy. 2016:61&#8211;85.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-319-42934-2_5</pub-id><pub-id pub-id-type="pmid">28101688</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>PA</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Schauer</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>F</given-names></name><etal/></person-group><article-title>Advances in DNA-and RNA-Based oncolytic viral therapeutics and immunotherapies</article-title><source>Appl Microbiol</source><year>2022</year><volume>2</volume><issue>2</issue><fpage>319</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3390/applmicrobiol2020024</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Johnson PA, Wu A, Johnson JC, Schauer Z, Wu T, Fernandes F, et al. Advances in DNA-and RNA-Based oncolytic viral therapeutics and immunotherapies. Appl Microbiol. 2022;2(2):319&#8211;29.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beyaert</surname><given-names>S</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>S</given-names></name></person-group><article-title>Vaccine-based immunotherapy for head and neck cancers</article-title><source>Cancers</source><year>2021</year><volume>13</volume><issue>23</issue><fpage>6041</fpage><pub-id pub-id-type="doi">10.3390/cancers13236041</pub-id><pub-id pub-id-type="pmid">34885150</pub-id><pub-id pub-id-type="pmcid">PMC8656843</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Beyaert S, Machiels J-P, Schmitz S. Vaccine-based immunotherapy for head and neck cancers. Cancers. 2021;13(23):6041.<pub-id pub-id-type="pmid">34885150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13236041</pub-id><pub-id pub-id-type="pmcid">PMC8656843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Jian</surname><given-names>X</given-names></name><name name-style="western"><surname>Wan</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>DbPepNeo: a manually curated database for human tumor neoantigen peptides</article-title><source>Database</source><year>2020</year><volume>2020</volume><fpage>baaa004</fpage><pub-id pub-id-type="doi">10.1093/database/baaa004</pub-id><pub-id pub-id-type="pmid">32090262</pub-id><pub-id pub-id-type="pmcid">PMC7043295</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Tan X, Li D, Huang P, Jian X, Wan H, Wang G, et al. DbPepNeo: a manually curated database for human tumor neoantigen peptides. Database. 2020;2020:baaa004.<pub-id pub-id-type="pmid">32090262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/database/baaa004</pub-id><pub-id pub-id-type="pmcid">PMC7043295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>F</given-names></name><etal/></person-group><article-title>Neoantigen vaccine: an emerging tumor immunotherapy</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1055-6</pub-id><pub-id pub-id-type="pmid">31443694</pub-id><pub-id pub-id-type="pmcid">PMC6708248</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128.<pub-id pub-id-type="pmid">31443694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-019-1055-6</pub-id><pub-id pub-id-type="pmcid">PMC6708248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulik-Sullivan</surname><given-names>B</given-names></name><name name-style="western"><surname>Busby</surname><given-names>J</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>CD</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>T</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A</given-names></name><etal/></person-group><article-title>Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification</article-title><source>Nat Biotechnol</source><year>2019</year><volume>37</volume><issue>1</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nbt.4313</pub-id><pub-id pub-id-type="pmid">30556813</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol. 2019;37(1):55&#8211;63.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.4313</pub-id><pub-id pub-id-type="pmid">30556813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>13</issue><fpage>6011</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.7150/thno.38742</pub-id><pub-id pub-id-type="pmid">32483434</pub-id><pub-id pub-id-type="pmcid">PMC7255011</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics. 2020;10(13):6011&#8211;23.<pub-id pub-id-type="pmid">32483434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.38742</pub-id><pub-id pub-id-type="pmcid">PMC7255011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>T</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors</article-title><source>Adv Sci</source><year>2022</year><volume>9</volume><issue>22</issue><fpage>2105810</fpage><pub-id pub-id-type="doi">10.1002/advs.202105810</pub-id><pub-id pub-id-type="pmcid">PMC9353440</pub-id><pub-id pub-id-type="pmid">35665491</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Wang W, Yuan T, Ma L, Zhu Y, Bao J, Zhao X, et al. Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors. Adv Sci. 2022;9(22):2105810.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202105810</pub-id><pub-id pub-id-type="pmcid">PMC9353440</pub-id><pub-id pub-id-type="pmid">35665491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>S</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F</given-names></name><etal/></person-group><article-title>Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors</article-title><source>J Clin Investig</source><year>2019</year><volume>129</volume><issue>5</issue><fpage>2056</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1172/JCI99538</pub-id><pub-id pub-id-type="pmid">30835255</pub-id><pub-id pub-id-type="pmcid">PMC6486339</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Chen F, Zou Z, Du J, Su S, Shao J, Meng F, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Investig. 2019;129(5):2056&#8211;70.<pub-id pub-id-type="pmid">30835255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI99538</pub-id><pub-id pub-id-type="pmcid">PMC6486339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menez-Jamet</surname><given-names>J</given-names></name><name name-style="western"><surname>Gallou</surname><given-names>C</given-names></name><name name-style="western"><surname>Rougeot</surname><given-names>A</given-names></name><name name-style="western"><surname>Kosmatopoulos</surname><given-names>K</given-names></name></person-group><article-title>Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines</article-title><source>Annals Translational Med</source><year>2016</year><volume>4</volume><issue>14</issue><fpage>266</fpage><pub-id pub-id-type="doi">10.21037/atm.2016.05.15</pub-id><pub-id pub-id-type="pmcid">PMC4971378</pub-id><pub-id pub-id-type="pmid">27563653</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Annals Translational Med. 2016;4(14):266.<pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2016.05.15</pub-id><pub-id pub-id-type="pmcid">PMC4971378</pub-id><pub-id pub-id-type="pmid">27563653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Abbott M, Ustoyev Y, editors. Cancer and the immune system: the history and background of immunotherapy. Seminars in oncology nursing. Elsevier; 2019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.soncn.2019.08.002</pub-id><pub-id pub-id-type="pmid">31526550</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkman</surname><given-names>M</given-names></name><name name-style="western"><surname>Walter</surname><given-names>J</given-names></name><name name-style="western"><surname>Grein</surname><given-names>S</given-names></name><name name-style="western"><surname>Thies</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>TW</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma</article-title><source>Cancer Immunol Immunother</source><year>2005</year><volume>54</volume><fpage>611</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s00262-004-0655-0</pub-id><pub-id pub-id-type="pmid">15685447</pub-id><pub-id pub-id-type="pmcid">PMC11034281</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Brinkman M, Walter J, Grein S, Thies MJ, Schulz TW, Herrmann M, et al. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol Immunother. 2005;54:611&#8211;22.<pub-id pub-id-type="pmid">15685447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-004-0655-0</pub-id><pub-id pub-id-type="pmcid">PMC11034281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dissecting the roles and clinical potential of YY1 in the tumor microenvironment</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1122110</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1122110</pub-id><pub-id pub-id-type="pmid">37081988</pub-id><pub-id pub-id-type="pmcid">PMC10110844</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Li M, Wei J, Xue C, Zhou X, Chen S, Zheng L, et al. Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. Front Oncol. 2023;13:1122110.<pub-id pub-id-type="pmid">37081988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1122110</pub-id><pub-id pub-id-type="pmcid">PMC10110844</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kheirvari</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name></person-group><article-title>Virus-like particle vaccines and platforms for vaccine development</article-title><source>Viruses</source><year>2023</year><volume>15</volume><issue>5</issue><fpage>1109</fpage><pub-id pub-id-type="doi">10.3390/v15051109</pub-id><pub-id pub-id-type="pmid">37243195</pub-id><pub-id pub-id-type="pmcid">PMC10223759</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kheirvari M, Liu H, Tumban E. Virus-like particle vaccines and platforms for vaccine development. Viruses. 2023;15(5):1109.<pub-id pub-id-type="pmid">37243195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v15051109</pub-id><pub-id pub-id-type="pmcid">PMC10223759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Recent advances in the development of virus-like particle-based flavivirus vaccines</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><issue>3</issue><fpage>481</fpage><pub-id pub-id-type="doi">10.3390/vaccines8030481</pub-id><pub-id pub-id-type="pmid">32867194</pub-id><pub-id pub-id-type="pmcid">PMC7565697</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Zhang N, Li C, Jiang S, Du L. Recent advances in the development of virus-like particle-based flavivirus vaccines. Vaccines. 2020;8(3):481.<pub-id pub-id-type="pmid">32867194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8030481</pub-id><pub-id pub-id-type="pmcid">PMC7565697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanty</surname><given-names>R</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>CR</given-names></name><name name-style="western"><surname>Arega</surname><given-names>S</given-names></name><name name-style="western"><surname>Sen</surname><given-names>P</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>P</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>N</given-names></name></person-group><article-title>CAR T cell therapy: A new era for cancer treatment</article-title><source>Oncol Rep</source><year>2019</year><volume>42</volume><issue>6</issue><fpage>2183</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">31578576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.7335</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment. Oncol Rep. 2019;42(6):2183&#8211;95.<pub-id pub-id-type="pmid">31578576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.7335</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332(22):1924&#8211;35. 10.1001/jama.2024.19462.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.19462</pub-id><pub-id pub-id-type="pmcid">PMC11808657</pub-id><pub-id pub-id-type="pmid">39495525</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Haideri</surname><given-names>M</given-names></name><name name-style="western"><surname>Tondok</surname><given-names>SB</given-names></name><name name-style="western"><surname>Safa</surname><given-names>SH</given-names></name><name name-style="western"><surname>Maleki</surname><given-names>AH</given-names></name><name name-style="western"><surname>Rostami</surname><given-names>S</given-names></name><name name-style="western"><surname>Jalil</surname><given-names>AT</given-names></name><etal/></person-group><article-title>CAR-T cell combination therapy: the next revolution in cancer treatment</article-title><source>Cancer Cell Int</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>365</fpage><pub-id pub-id-type="doi">10.1186/s12935-022-02778-6</pub-id><pub-id pub-id-type="pmid">36419058</pub-id><pub-id pub-id-type="pmcid">PMC9685957</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365.<pub-id pub-id-type="pmid">36419058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-022-02778-6</pub-id><pub-id pub-id-type="pmcid">PMC9685957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braendstrup</surname><given-names>P</given-names></name><name name-style="western"><surname>Levine</surname><given-names>BL</given-names></name><name name-style="western"><surname>Ruella</surname><given-names>M</given-names></name></person-group><article-title>The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19</article-title><source>Cytotherapy</source><year>2020</year><volume>22</volume><issue>2</issue><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2019.12.004</pub-id><pub-id pub-id-type="pmid">32014447</pub-id><pub-id pub-id-type="pmcid">PMC7036015</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22(2):57&#8211;69.<pub-id pub-id-type="pmid">32014447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2019.12.004</pub-id><pub-id pub-id-type="pmcid">PMC7036015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhaskar</surname><given-names>ST</given-names></name><name name-style="western"><surname>Dholaria</surname><given-names>B</given-names></name><name name-style="western"><surname>Savani</surname><given-names>BN</given-names></name><name name-style="western"><surname>Sengsayadeth</surname><given-names>S</given-names></name><name name-style="western"><surname>Oluwole</surname><given-names>O</given-names></name></person-group><article-title>Overview of approved CAR-T products and utility in clinical practice</article-title><source>Clin Hematol Int</source><year>2024</year><volume>6</volume><issue>4</issue><fpage>93</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.46989/001c.124277</pub-id><pub-id pub-id-type="pmid">39469119</pub-id><pub-id pub-id-type="pmcid">PMC11514108</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Bhaskar ST, Dholaria B, Savani BN, Sengsayadeth S, Oluwole O. Overview of approved CAR-T products and utility in clinical practice. Clin Hematol Int. 2024;6(4):93&#8211;9.<pub-id pub-id-type="pmid">39469119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.46989/001c.124277</pub-id><pub-id pub-id-type="pmcid">PMC11514108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>U</given-names></name><name name-style="western"><surname>Zanwar</surname><given-names>S</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>R</given-names></name><name name-style="western"><surname>Khouri</surname><given-names>J</given-names></name><name name-style="western"><surname>Dima</surname><given-names>D</given-names></name></person-group><article-title>Ciltacabtagene autoleucel for the treatment of Relapsed/Refractory multiple myeloma: Efficacy, Safety, and place in therapy</article-title><source>Cancer Manag Res</source><year>2025</year><volume>17</volume><fpage>357</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S510408</pub-id><pub-id pub-id-type="pmid">39990276</pub-id><pub-id pub-id-type="pmcid">PMC11847446</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D. Ciltacabtagene autoleucel for the treatment of Relapsed/Refractory multiple myeloma: Efficacy, Safety, and place in therapy. Cancer Manag Res. 2025;17:357&#8211;72.<pub-id pub-id-type="pmid">39990276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CMAR.S510408</pub-id><pub-id pub-id-type="pmcid">PMC11847446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ping</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>CAR-T cell therapy in cancer: tribulations and road ahead</article-title><source>J Immunol Res</source><year>2020</year><volume>2020</volume><issue>1</issue><fpage>1924379</fpage><pub-id pub-id-type="doi">10.1155/2020/1924379</pub-id><pub-id pub-id-type="pmid">32411789</pub-id><pub-id pub-id-type="pmcid">PMC7201836</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, et al. CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res. 2020;2020(1):1924379.<pub-id pub-id-type="pmid">32411789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/1924379</pub-id><pub-id pub-id-type="pmcid">PMC7201836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grigor</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Fergusson</surname><given-names>D</given-names></name><name name-style="western"><surname>Kekre</surname><given-names>N</given-names></name><name name-style="western"><surname>Montroy</surname><given-names>J</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>H</given-names></name><name name-style="western"><surname>Seftel</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis</article-title><source>Transfus Med Rev</source><year>2019</year><volume>33</volume><issue>2</issue><fpage>98</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.tmrv.2019.01.005</pub-id><pub-id pub-id-type="pmid">30948292</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Grigor EJ, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98&#8211;110.<pub-id pub-id-type="pmid">30948292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tmrv.2019.01.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jogalekar</surname><given-names>MP</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>RL</given-names></name><name name-style="western"><surname>Khan</surname><given-names>F</given-names></name><name name-style="western"><surname>Dmello</surname><given-names>C</given-names></name><name name-style="western"><surname>Gangadaran</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B-C</given-names></name></person-group><article-title>CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>925985</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.925985</pub-id><pub-id pub-id-type="pmid">35936003</pub-id><pub-id pub-id-type="pmcid">PMC9355792</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn B-C. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13:925985.<pub-id pub-id-type="pmid">35936003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.925985</pub-id><pub-id pub-id-type="pmcid">PMC9355792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterner</surname><given-names>RC</given-names></name><name name-style="western"><surname>Sterner</surname><given-names>RM</given-names></name></person-group><article-title>Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>879608</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.879608</pub-id><pub-id pub-id-type="pmid">36081506</pub-id><pub-id pub-id-type="pmcid">PMC9445841</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol. 2022;13:879608.<pub-id pub-id-type="pmid">36081506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.879608</pub-id><pub-id pub-id-type="pmcid">PMC9445841</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sievers</surname><given-names>S</given-names></name><name name-style="western"><surname>Watson</surname><given-names>G</given-names></name><name name-style="western"><surname>Johncy</surname><given-names>S</given-names></name><name name-style="western"><surname>Adkins</surname><given-names>S</given-names></name></person-group><article-title>Recognizing and grading CAR T-Cell toxicities: an advanced practitioner perspective</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>885</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00885</pub-id><pub-id pub-id-type="pmid">32670871</pub-id><pub-id pub-id-type="pmcid">PMC7327099</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Sievers S, Watson G, Johncy S, Adkins S. Recognizing and grading CAR T-Cell toxicities: an advanced practitioner perspective. Front Oncol. 2020;10:885.<pub-id pub-id-type="pmid">32670871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.00885</pub-id><pub-id pub-id-type="pmcid">PMC7327099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neill</surname><given-names>L</given-names></name><name name-style="western"><surname>Rees</surname><given-names>J</given-names></name><name name-style="western"><surname>Roddie</surname><given-names>C</given-names></name></person-group><article-title>Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know</article-title><source>Pract Neurol</source><year>2020</year><volume>20</volume><issue>4</issue><fpage>285</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1136/practneurol-2020-002550</pub-id><pub-id pub-id-type="pmid">32503897</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Neill L, Rees J, Roddie C. Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know. Pract Neurol. 2020;20(4):285&#8211;93.<pub-id pub-id-type="pmid">32503897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/practneurol-2020-002550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riegler</surname><given-names>LL</given-names></name><name name-style="western"><surname>Jones</surname><given-names>GP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DW</given-names></name></person-group><article-title>Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy</article-title><source>Ther Clin Risk Manag</source><year>2019</year><volume>15</volume><fpage>323</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S150524</pub-id><pub-id pub-id-type="pmid">30880998</pub-id><pub-id pub-id-type="pmcid">PMC6400118</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323&#8211;35.<pub-id pub-id-type="pmid">30880998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/TCRM.S150524</pub-id><pub-id pub-id-type="pmcid">PMC6400118</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basudan</surname><given-names>AM</given-names></name></person-group><article-title>The role of immune checkpoint inhibitors in cancer therapy</article-title><source>Clin Pract</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>22</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.3390/clinpract13010003</pub-id><pub-id pub-id-type="pmid">36648843</pub-id><pub-id pub-id-type="pmcid">PMC9844484</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Basudan AM. The role of immune checkpoint inhibitors in cancer therapy. Clin Pract. 2022;13(1):22&#8211;40.<pub-id pub-id-type="pmid">36648843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/clinpract13010003</pub-id><pub-id pub-id-type="pmcid">PMC9844484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hao</surname><given-names>P</given-names></name></person-group><article-title>Usefulness of enzyme-free and enzyme-resistant detection of complement component 5 to evaluate acute myocardial infarction</article-title><source>Sens Actuators B</source><year>2022</year><volume>369</volume><fpage>132315</fpage><pub-id pub-id-type="doi">10.1016/j.snb.2022.132315</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Zhou L, Liu Y, Sun H, Li H, Zhang Z, Hao P. Usefulness of enzyme-free and enzyme-resistant detection of complement component 5 to evaluate acute myocardial infarction. Sens Actuators B. 2022;369:132315.</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">Zhang X, Li H, Wang H, Zhang Q, Deng X, Zhang S, Wang L, Guo C, Zhao F, Yin Y, Zhou T, Zhong J, Feng H, Chen W, Zhang J, Feng H, Hu R. Iron/ROS/Itga3 mediated accelerated depletion of hippocampal neural stem cell pool contributes to cognitive impairment after hemorrhagic stroke. Redox Biol. 2024;71:103086. 10.1016/j.redox.2024.103086.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2024.103086</pub-id><pub-id pub-id-type="pmcid">PMC10883838</pub-id><pub-id pub-id-type="pmid">38367510</pub-id></mixed-citation></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markham</surname><given-names>A</given-names></name></person-group><article-title>Atezolizumab: first global approval</article-title><source>Drugs</source><year>2016</year><volume>76</volume><fpage>1227</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s40265-016-0618-8</pub-id><pub-id pub-id-type="pmid">27412122</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Markham A. Atezolizumab: first global approval. Drugs. 2016;76:1227&#8211;32.<pub-id pub-id-type="pmid">27412122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-016-0618-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>D-Y</given-names></name><name name-style="western"><surname>Ruth He</surname><given-names>A</given-names></name><name name-style="western"><surname>Qin</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L-T</given-names></name><name name-style="western"><surname>Okusaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer</article-title><source>NEJM Evid</source><year>2022</year><volume>1</volume><issue>8</issue><fpage>EVIDoa2200015</fpage><pub-id pub-id-type="doi">10.1056/EVIDoa2200015</pub-id><pub-id pub-id-type="pmid">38319896</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.<pub-id pub-id-type="pmid">38319896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/EVIDoa2200015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizvi</surname><given-names>NA</given-names></name><name name-style="western"><surname>Cho</surname><given-names>BC</given-names></name><name name-style="western"><surname>Reinmuth</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name><name name-style="western"><surname>Luft</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M-J</given-names></name><etal/></person-group><article-title>Durvalumab with or without Tremelimumab vs standard chemotherapy in first-line treatment of metastatic non&#8211;small cell lung cancer: the MYSTIC phase 3 randomized clinical trial</article-title><source>JAMA Oncol</source><year>2020</year><volume>6</volume><issue>5</issue><fpage>661</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0237</pub-id><pub-id pub-id-type="pmid">32271377</pub-id><pub-id pub-id-type="pmcid">PMC7146551</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, et al. Durvalumab with or without Tremelimumab vs standard chemotherapy in first-line treatment of metastatic non&#8211;small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661&#8211;74.<pub-id pub-id-type="pmid">32271377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.0237</pub-id><pub-id pub-id-type="pmcid">PMC7146551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathieu</surname><given-names>L</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S</given-names></name><name name-style="western"><surname>Pai-Scherf</surname><given-names>L</given-names></name><name name-style="western"><surname>Larkins</surname><given-names>E</given-names></name><name name-style="western"><surname>Vallejo</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>FDA approval summary: Atezolizumab and durvalumab in combination with platinum&#8208;based chemotherapy in extensive stage small cell lung cancer</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><issue>5</issue><fpage>433</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/onco.13752</pub-id><pub-id pub-id-type="pmid">33687763</pub-id><pub-id pub-id-type="pmcid">PMC8100557</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, et al. FDA approval summary: Atezolizumab and durvalumab in combination with platinum&#8208;based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433&#8211;8.<pub-id pub-id-type="pmid">33687763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/onco.13752</pub-id><pub-id pub-id-type="pmcid">PMC8100557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiravand</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>F</given-names></name><name name-style="western"><surname>Kashani</surname><given-names>SMA</given-names></name><name name-style="western"><surname>Hosseini-Fard</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sadeghirad</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitors in cancer therapy</article-title><source>Curr Oncol</source><year>2022</year><volume>29</volume><issue>5</issue><fpage>3044</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3390/curroncol29050247</pub-id><pub-id pub-id-type="pmid">35621637</pub-id><pub-id pub-id-type="pmcid">PMC9139602</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044&#8211;60.<pub-id pub-id-type="pmid">35621637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/curroncol29050247</pub-id><pub-id pub-id-type="pmcid">PMC9139602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>C</given-names></name></person-group><article-title>A decade of immune-checkpoint inhibitors in cancer therapy</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>3801</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17670-y</pub-id><pub-id pub-id-type="pmid">32732879</pub-id><pub-id pub-id-type="pmcid">PMC7393098</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.<pub-id pub-id-type="pmid">32732879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17670-y</pub-id><pub-id pub-id-type="pmcid">PMC7393098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>A</given-names></name><name name-style="western"><surname>Mollica</surname><given-names>V</given-names></name><name name-style="western"><surname>Matrana</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rosellini</surname><given-names>M</given-names></name><name name-style="western"><surname>Faloppi</surname><given-names>L</given-names></name><etal/></person-group><article-title>The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study</article-title><source>Crit Rev Oncol/Hematol</source><year>2022</year><volume>170</volume><fpage>103596</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2022.103596</pub-id><pub-id pub-id-type="pmid">35031442</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol/Hematol. 2022;170:103596.<pub-id pub-id-type="pmid">35031442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2022.103596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinmann</surname><given-names>SC</given-names></name><name name-style="western"><surname>Pisetsky</surname><given-names>DS</given-names></name></person-group><article-title>Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors</article-title><source>Rheumatology</source><year>2019</year><volume>58</volume><issue>Supplement7</issue><fpage>vii59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kez308</pub-id><pub-id pub-id-type="pmid">31816080</pub-id><pub-id pub-id-type="pmcid">PMC6900913</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology. 2019;58(Supplement7):vii59&#8211;67.<pub-id pub-id-type="pmid">31816080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/kez308</pub-id><pub-id pub-id-type="pmcid">PMC6900913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name></person-group><article-title>Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis</article-title><source>BMC Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>87</fpage><pub-id pub-id-type="doi">10.1186/s12916-020-01549-2</pub-id><pub-id pub-id-type="pmid">32306958</pub-id><pub-id pub-id-type="pmcid">PMC7169020</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87.<pub-id pub-id-type="pmid">32306958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-020-01549-2</pub-id><pub-id pub-id-type="pmcid">PMC7169020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>S-Q</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L-L</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y-P</given-names></name><name name-style="western"><surname>Li</surname><given-names>W-F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients</article-title><source>Cancer Res Treatment: Official J Korean Cancer Association</source><year>2021</year><volume>53</volume><issue>2</issue><fpage>339</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.4143/crt.2020.790</pub-id><pub-id pub-id-type="pmcid">PMC8053869</pub-id><pub-id pub-id-type="pmid">33171025</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Tang S-Q, Tang L-L, Mao Y-P, Li W-F, Chen L, Zhang Y, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treatment: Official J Korean Cancer Association. 2021;53(2):339&#8211;54.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2020.790</pub-id><pub-id pub-id-type="pmcid">PMC8053869</pub-id><pub-id pub-id-type="pmid">33171025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albandar</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Fuqua</surname><given-names>J</given-names></name><name name-style="western"><surname>Albandar</surname><given-names>JM</given-names></name><name name-style="western"><surname>Safi</surname><given-names>S</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ma</surname><given-names>PC</given-names></name></person-group><article-title>Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to Rechallenge or not?</article-title><source>Cancers</source><year>2021</year><volume>13</volume><issue>5</issue><fpage>989</fpage><pub-id pub-id-type="doi">10.3390/cancers13050989</pub-id><pub-id pub-id-type="pmid">33673446</pub-id><pub-id pub-id-type="pmcid">PMC7956829</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to Rechallenge or not? Cancers. 2021;13(5):989.<pub-id pub-id-type="pmid">33673446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13050989</pub-id><pub-id pub-id-type="pmcid">PMC7956829</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name></person-group><article-title>Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors</article-title><source>Immune Netw</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>e9</fpage><pub-id pub-id-type="doi">10.4110/in.2020.20.e9</pub-id><pub-id pub-id-type="pmid">32158597</pub-id><pub-id pub-id-type="pmcid">PMC7049586</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9.<pub-id pub-id-type="pmid">32158597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4110/in.2020.20.e9</pub-id><pub-id pub-id-type="pmcid">PMC7049586</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolladille</surname><given-names>C</given-names></name><name name-style="western"><surname>Ederhy</surname><given-names>S</given-names></name><name name-style="western"><surname>Sassier</surname><given-names>M</given-names></name><name name-style="western"><surname>Cautela</surname><given-names>J</given-names></name><name name-style="western"><surname>Thuny</surname><given-names>F</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitor Rechallenge after immune-related adverse events in patients with cancer</article-title><source>JAMA Oncol</source><year>2020</year><volume>6</volume><issue>6</issue><fpage>865</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0726</pub-id><pub-id pub-id-type="pmid">32297899</pub-id><pub-id pub-id-type="pmcid">PMC7163782</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor Rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865&#8211;71.<pub-id pub-id-type="pmid">32297899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.0726</pub-id><pub-id pub-id-type="pmcid">PMC7163782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Grizzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Ghidini</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghidini</surname><given-names>A</given-names></name><name name-style="western"><surname>Ratti</surname><given-names>M</given-names></name><name name-style="western"><surname>Panni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis</article-title><source>J Immunother</source><year>2020</year><volume>43</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/CJI.0000000000000300</pub-id><pub-id pub-id-type="pmid">31574022</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43(1):1&#8211;7.<pub-id pub-id-type="pmid">31574022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CJI.0000000000000300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Khan S, Gerber DE, editors. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Seminars in cancer biology. Elsevier; 2020.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.06.012</pub-id><pub-id pub-id-type="pmcid">PMC6980444</pub-id><pub-id pub-id-type="pmid">31330185</pub-id></mixed-citation></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naidoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></name><name name-style="western"><surname>Brahmer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Champiat</surname><given-names>S</given-names></name><name name-style="western"><surname>Feltquate</surname><given-names>D</given-names></name><etal/></person-group><article-title>Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><issue>3</issue><fpage>e006398</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-006398</pub-id><pub-id pub-id-type="pmid">37001909</pub-id><pub-id pub-id-type="pmcid">PMC10069596</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3):e006398.<pub-id pub-id-type="pmid">37001909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2022-006398</pub-id><pub-id pub-id-type="pmcid">PMC10069596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myers</surname><given-names>G</given-names></name></person-group><article-title>Immune-related adverse events of immune checkpoint inhibitors: a brief review</article-title><source>Curr Oncol</source><year>2018</year><volume>25</volume><issue>5</issue><fpage>342</fpage><pub-id pub-id-type="doi">10.3747/co.25.4235</pub-id><pub-id pub-id-type="pmid">30464684</pub-id><pub-id pub-id-type="pmcid">PMC6209551</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018;25(5):342.<pub-id pub-id-type="pmid">30464684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/co.25.4235</pub-id><pub-id pub-id-type="pmcid">PMC6209551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DB</given-names></name></person-group><article-title>Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><issue>1</issue><fpage>306</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0805-8</pub-id><pub-id pub-id-type="pmid">31730012</pub-id><pub-id pub-id-type="pmcid">PMC6858629</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.<pub-id pub-id-type="pmid">31730012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0805-8</pub-id><pub-id pub-id-type="pmcid">PMC6858629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Q-q</given-names></name><name name-style="western"><surname>Jv</surname><given-names>X-h</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X-z</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W-t</given-names></name><etal/></person-group><article-title>Cell senescence induced by toxic interaction between &#945;-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of parkinson&#8217;s disease</article-title><source>Acta Pharmacol Sin</source><year>2024</year><volume>45</volume><issue>2</issue><fpage>268</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/s41401-023-01153-z</pub-id><pub-id pub-id-type="pmid">37674042</pub-id><pub-id pub-id-type="pmcid">PMC10789811</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Shen Q-q, Jv X-h, Ma X-z, Li C, Liu L, Jia W-t, et al. Cell senescence induced by toxic interaction between &#945;-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of parkinson&#8217;s disease. Acta Pharmacol Sin. 2024;45(2):268&#8211;81.<pub-id pub-id-type="pmid">37674042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-023-01153-z</pub-id><pub-id pub-id-type="pmcid">PMC10789811</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name></person-group><article-title>Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment</article-title><source>Clin Genet</source><year>2020</year><volume>97</volume><issue>1</issue><fpage>73</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/cge.13589</pub-id><pub-id pub-id-type="pmid">31231788</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Jiang C, Meng L, Yang B, Luo X. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment. Clin Genet. 2020;97(1):73&#8211;88.<pub-id pub-id-type="pmid">31231788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cge.13589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>H</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L-h</given-names></name></person-group><article-title>CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment</article-title><source>Acta Pharmacol Sin</source><year>2020</year><volume>41</volume><issue>5</issue><fpage>583</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41401-019-0322-9</pub-id><pub-id pub-id-type="pmid">31792341</pub-id><pub-id pub-id-type="pmcid">PMC7468325</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Xing H, Meng L-h. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Acta Pharmacol Sin. 2020;41(5):583&#8211;7.<pub-id pub-id-type="pmid">31792341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-019-0322-9</pub-id><pub-id pub-id-type="pmcid">PMC7468325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Saber</surname><given-names>A</given-names></name><name name-style="western"><surname>Haisma</surname><given-names>HJ</given-names></name></person-group><article-title>CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment</article-title><source>Drug Discovery Today</source><year>2019</year><volume>24</volume><issue>4</issue><fpage>955</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.02.011</pub-id><pub-id pub-id-type="pmid">30849442</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Liu B, Saber A, Haisma HJ. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discovery Today. 2019;24(4):955&#8211;70.<pub-id pub-id-type="pmid">30849442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2019.02.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Lage</surname><given-names>M</given-names></name><name name-style="western"><surname>Puig-Serra</surname><given-names>P</given-names></name><name name-style="western"><surname>Menendez</surname><given-names>P</given-names></name><name name-style="western"><surname>Torres-Ruiz</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodriguez-Perales</surname><given-names>S</given-names></name></person-group><article-title>CRISPR/Cas9 for cancer therapy: hopes and challenges</article-title><source>Biomedicines</source><year>2018</year><volume>6</volume><issue>4</issue><fpage>105</fpage><pub-id pub-id-type="doi">10.3390/biomedicines6040105</pub-id><pub-id pub-id-type="pmid">30424477</pub-id><pub-id pub-id-type="pmcid">PMC6315587</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Martinez-Lage M, Puig-Serra P, Menendez P, Torres-Ruiz R, Rodriguez-Perales S. CRISPR/Cas9 for cancer therapy: hopes and challenges. Biomedicines. 2018;6(4):105.<pub-id pub-id-type="pmid">30424477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines6040105</pub-id><pub-id pub-id-type="pmcid">PMC6315587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hazafa</surname><given-names>A</given-names></name><name name-style="western"><surname>Mumtaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Farooq</surname><given-names>MF</given-names></name><name name-style="western"><surname>Bilal</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>SN</given-names></name><name name-style="western"><surname>Firdous</surname><given-names>M</given-names></name><etal/></person-group><article-title>CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions</article-title><source>Life Sci</source><year>2020</year><volume>263</volume><fpage>118525</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118525</pub-id><pub-id pub-id-type="pmid">33031826</pub-id><pub-id pub-id-type="pmcid">PMC7533657</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, et al. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020;263:118525.<pub-id pub-id-type="pmid">33031826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118525</pub-id><pub-id pub-id-type="pmcid">PMC7533657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>FA</given-names></name><name name-style="western"><surname>Pandupuspitasari</surname><given-names>NS</given-names></name><name name-style="western"><surname>Chun-Jie</surname><given-names>H</given-names></name><name name-style="western"><surname>Ao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>M</given-names></name><name name-style="western"><surname>Zohaib</surname><given-names>A</given-names></name><etal/></person-group><article-title>CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>32</issue><fpage>52541</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9646</pub-id><pub-id pub-id-type="pmid">27250031</pub-id><pub-id pub-id-type="pmcid">PMC5239572</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Khan FA, Pandupuspitasari NS, Chun-Jie H, Ao Z, Jamal M, Zohaib A, et al. CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget. 2016;7(32):52541&#8211;52.<pub-id pub-id-type="pmid">27250031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.9646</pub-id><pub-id pub-id-type="pmcid">PMC5239572</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>An</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1186/s12943-021-01431-6</pub-id><pub-id pub-id-type="pmid">34598686</pub-id><pub-id pub-id-type="pmcid">PMC8484294</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021;20:1&#8211;22.<pub-id pub-id-type="pmid">34598686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01431-6</pub-id><pub-id pub-id-type="pmcid">PMC8484294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>H</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>Z</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W</given-names></name></person-group><article-title>Precision cancer mouse models through genome editing with CRISPR-Cas9</article-title><source>Genome Med</source><year>2015</year><volume>9</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s13073-015-0178-7</pub-id><pub-id pub-id-type="pmcid">PMC4460969</pub-id><pub-id pub-id-type="pmid">26060510</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Mou H, Kennedy Z, Anderson DG, Yin H, Xue W. Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med. 2015;9(1):53.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-015-0178-7</pub-id><pub-id pub-id-type="pmcid">PMC4460969</pub-id><pub-id pub-id-type="pmid">26060510</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M, editors. CRISPR/Cas9 for cancer research and therapy. Seminars in cancer biology. Elsevier; 2019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2018.04.001</pub-id><pub-id pub-id-type="pmid">29673923</pub-id></mixed-citation></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollanoori</surname><given-names>H</given-names></name><name name-style="western"><surname>Shahraki</surname><given-names>H</given-names></name><name name-style="western"><surname>Rahmati</surname><given-names>Y</given-names></name><name name-style="western"><surname>Teimourian</surname><given-names>S</given-names></name></person-group><article-title>CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment</article-title><source>Hum Immunol</source><year>2018</year><volume>79</volume><issue>12</issue><fpage>876</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2018.09.007</pub-id><pub-id pub-id-type="pmid">30261221</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018;79(12):876&#8211;82.<pub-id pub-id-type="pmid">30261221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2018.09.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Applications of CRISPR/Cas9 technology in the treatment of lung cancer</article-title><source>Trends Mol Med</source><year>2019</year><volume>25</volume><issue>11</issue><fpage>1039</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2019.07.007</pub-id><pub-id pub-id-type="pmid">31422862</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Jiang C, Lin X, Zhao Z. Applications of CRISPR/Cas9 technology in the treatment of lung cancer. Trends Mol Med. 2019;25(11):1039&#8211;49.<pub-id pub-id-type="pmid">31422862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2019.07.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez-Rivera</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Jacks</surname><given-names>T</given-names></name></person-group><article-title>Applications of the CRISPR&#8211;Cas9 system in cancer biology</article-title><source>Nat Rev Cancer</source><year>2015</year><volume>15</volume><issue>7</issue><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nrc3950</pub-id><pub-id pub-id-type="pmid">26040603</pub-id><pub-id pub-id-type="pmcid">PMC4530801</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">S&#225;nchez-Rivera FJ, Jacks T. Applications of the CRISPR&#8211;Cas9 system in cancer biology. Nat Rev Cancer. 2015;15(7):387&#8211;93.<pub-id pub-id-type="pmid">26040603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3950</pub-id><pub-id pub-id-type="pmcid">PMC4530801</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>G</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>AR</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-S</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>C</given-names></name></person-group><article-title>CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases</article-title><source>Mol Ther</source><year>2021</year><volume>29</volume><issue>2</issue><fpage>571</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.09.028</pub-id><pub-id pub-id-type="pmid">33238136</pub-id><pub-id pub-id-type="pmcid">PMC7854284</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Sharma G, Sharma AR, Bhattacharya M, Lee S-S, Chakraborty C. CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther. 2021;29(2):571&#8211;86.<pub-id pub-id-type="pmid">33238136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2020.09.028</pub-id><pub-id pub-id-type="pmcid">PMC7854284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasul</surname><given-names>MF</given-names></name><name name-style="western"><surname>Hussen</surname><given-names>BM</given-names></name><name name-style="western"><surname>Salihi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ismael</surname><given-names>BS</given-names></name><name name-style="western"><surname>Jalal</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Zanichelli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01487-4</pub-id><pub-id pub-id-type="pmid">35241090</pub-id><pub-id pub-id-type="pmcid">PMC8892709</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Rasul MF, Hussen BM, Salihi A, Ismael BS, Jalal PJ, Zanichelli A, et al. Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Mol Cancer. 2022;21(1):64.<pub-id pub-id-type="pmid">35241090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01487-4</pub-id><pub-id pub-id-type="pmcid">PMC8892709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azangou-Khyavy</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khanali</surname><given-names>J</given-names></name><name name-style="western"><surname>Boroomand-Saboor</surname><given-names>M</given-names></name><name name-style="western"><surname>Jamalkhah</surname><given-names>M</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>M</given-names></name><etal/></person-group><article-title>CRISPR/Cas: from tumor gene editing to T cell-based immunotherapy of cancer</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>2062</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.02062</pub-id><pub-id pub-id-type="pmid">33117331</pub-id><pub-id pub-id-type="pmcid">PMC7553049</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Azangou-Khyavy M, Ghasemi M, Khanali J, Boroomand-Saboor M, Jamalkhah M, Soleimani M, et al. CRISPR/Cas: from tumor gene editing to T cell-based immunotherapy of cancer. Front Immunol. 2020;11:2062.<pub-id pub-id-type="pmid">33117331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.02062</pub-id><pub-id pub-id-type="pmcid">PMC7553049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><mixed-citation publication-type="other">Takeda H, Kataoka S, Nakayama M, Ali MA, Oshima H, Yamamoto D et al. CRISPR-Cas9&#8211;mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proceedings of the National Academy of Sciences. 2019;116(31):15635-44.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1904714116</pub-id><pub-id pub-id-type="pmcid">PMC6681705</pub-id><pub-id pub-id-type="pmid">31300537</pub-id></mixed-citation></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>P</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>Disruption of CTLA-4 expression on peripheral blood CD8&#8201;+&#8201;T cell enhances anti-tumor efficacy in bladder cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2019</year><volume>83</volume><fpage>911</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00280-019-03800-x</pub-id><pub-id pub-id-type="pmid">30848330</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Zhang W, Shi L, Zhao Z, Du P, Ye X, Li D, et al. Disruption of CTLA-4 expression on peripheral blood CD8&#8201;+&#8201;T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83:911&#8211;20.<pub-id pub-id-type="pmid">30848330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-019-03800-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><mixed-citation publication-type="other">Zhang X, Cheng C, Sun W, Wang H. Engineering T cells using CRISPR/Cas9 for cancer therapy. RNA Interference and CRISPR Technologies: Technical Advances and New Therapeutic Opportunities. 2020:419&#8201;&#8211;&#8201;33.</mixed-citation></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuzbrokh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ragi</surname><given-names>SD</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>SH</given-names></name></person-group><article-title>Gene therapy for inherited retinal diseases</article-title><source>Annals Translational Med</source><year>2021</year><volume>9</volume><issue>15</issue><fpage>1278</fpage><pub-id pub-id-type="doi">10.21037/atm-20-4726</pub-id><pub-id pub-id-type="pmcid">PMC8421966</pub-id><pub-id pub-id-type="pmid">34532415</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Nuzbrokh Y, Ragi SD, Tsang SH. Gene therapy for inherited retinal diseases. Annals Translational Med. 2021;9(15):1278.<pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-20-4726</pub-id><pub-id pub-id-type="pmcid">PMC8421966</pub-id><pub-id pub-id-type="pmid">34532415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanoudakis</surname><given-names>D</given-names></name><name name-style="western"><surname>Kathuria-Prakash</surname><given-names>N</given-names></name><name name-style="western"><surname>Sun</surname><given-names>AW</given-names></name><name name-style="western"><surname>Abel</surname><given-names>M</given-names></name><name name-style="western"><surname>Drolen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ashbaugh</surname><given-names>C</given-names></name><etal/></person-group><article-title>The potential revolution of cancer treatment with CRISPR technology</article-title><source>Cancers</source><year>2023</year><volume>15</volume><issue>6</issue><fpage>1813</fpage><pub-id pub-id-type="doi">10.3390/cancers15061813</pub-id><pub-id pub-id-type="pmid">36980699</pub-id><pub-id pub-id-type="pmcid">PMC10046289</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers. 2023;15(6):1813.<pub-id pub-id-type="pmid">36980699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15061813</pub-id><pub-id pub-id-type="pmcid">PMC10046289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Salinas</surname><given-names>F</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>R</given-names></name><name name-style="western"><surname>Martinez-Amador</surname><given-names>C</given-names></name><name name-style="western"><surname>Herrera-Gamboa</surname><given-names>J</given-names></name><name name-style="western"><surname>Trevino</surname><given-names>V</given-names></name></person-group><article-title>Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show Inhibition of aggressive characteristics in breast cancer cells</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><volume>529</volume><issue>2</issue><fpage>321</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.05.172</pub-id><pub-id pub-id-type="pmid">32703430</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Gonzalez-Salinas F, Rojo R, Martinez-Amador C, Herrera-Gamboa J, Trevino V. Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show Inhibition of aggressive characteristics in breast cancer cells. Biochem Biophys Res Commun. 2020;529(2):321&#8211;7.<pub-id pub-id-type="pmid">32703430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.05.172</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Mao</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name></person-group><article-title>CRISPR-Cas9 for cancer therapy: opportunities and challenges</article-title><source>Cancer Lett</source><year>2019</year><volume>447</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.01.017</pub-id><pub-id pub-id-type="pmid">30684591</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. CRISPR-Cas9 for cancer therapy: opportunities and challenges. Cancer Lett. 2019;447:48&#8211;55.<pub-id pub-id-type="pmid">30684591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2019.01.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S-W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y-M</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J-C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X-Y</given-names></name><etal/></person-group><article-title>Current applications and future perspective of CRISPR/Cas9 gene editing in cancer</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s12943-022-01518-8</pub-id><pub-id pub-id-type="pmid">35189910</pub-id><pub-id pub-id-type="pmcid">PMC8862238</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Wang S-W, Gao C, Zheng Y-M, Yi L, Lu J-C, Huang X-Y, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57.<pub-id pub-id-type="pmid">35189910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-022-01518-8</pub-id><pub-id pub-id-type="pmcid">PMC8862238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oldrini</surname><given-names>B</given-names></name><name name-style="western"><surname>Curiel-Garc&#237;a</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Marques</surname><given-names>C</given-names></name><name name-style="western"><surname>Matia</surname><given-names>V</given-names></name><name name-style="western"><surname>Ulu&#231;kan</surname><given-names>&#214;</given-names></name><name name-style="western"><surname>Gra&#241;a-Castro</surname><given-names>O</given-names></name><etal/></person-group><article-title>Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>1466</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03731-w</pub-id><pub-id pub-id-type="pmid">29654229</pub-id><pub-id pub-id-type="pmcid">PMC5899147</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Oldrini B, Curiel-Garc&#237;a &#193;, Marques C, Matia V, Ulu&#231;kan &#214;, Gra&#241;a-Castro O, et al. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun. 2018;9(1):1466.<pub-id pub-id-type="pmid">29654229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-03731-w</pub-id><pub-id pub-id-type="pmcid">PMC5899147</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>L</given-names></name><name name-style="western"><surname>Tong</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xue</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>Advancements and Obstacles of CRISPR-Cas9 technology in translational research</article-title><source>Mol Therapy-Methods Clin Dev</source><year>2019</year><volume>13</volume><fpage>359</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2019.02.008</pub-id><pub-id pub-id-type="pmcid">PMC6447755</pub-id><pub-id pub-id-type="pmid">30989086</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">You L, Tong R, Li M, Liu Y, Xue J, Lu Y. Advancements and Obstacles of CRISPR-Cas9 technology in translational research. Mol Therapy-Methods Clin Dev. 2019;13:359&#8211;70.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtm.2019.02.008</pub-id><pub-id pub-id-type="pmcid">PMC6447755</pub-id><pub-id pub-id-type="pmid">30989086</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>MK</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>K</given-names></name></person-group><article-title>CRISPR/Cas9 and cancer targets: future possibilities and present challenges</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>11</issue><fpage>12305</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.7104</pub-id><pub-id pub-id-type="pmid">26840090</pub-id><pub-id pub-id-type="pmcid">PMC4914286</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">White MK, Khalili K. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget. 2016;7(11):12305.<pub-id pub-id-type="pmid">26840090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.7104</pub-id><pub-id pub-id-type="pmcid">PMC4914286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacinto</surname><given-names>FV</given-names></name><name name-style="western"><surname>Link</surname><given-names>W</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>BI</given-names></name></person-group><article-title>CRISPR/Cas9-mediated genome editing: from basic research to translational medicine</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><issue>7</issue><fpage>3766</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14916</pub-id><pub-id pub-id-type="pmid">32096600</pub-id><pub-id pub-id-type="pmcid">PMC7171402</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Jacinto FV, Link W, Ferreira BI. CRISPR/Cas9-mediated genome editing: from basic research to translational medicine. J Cell Mol Med. 2020;24(7):3766&#8211;78.<pub-id pub-id-type="pmid">32096600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.14916</pub-id><pub-id pub-id-type="pmcid">PMC7171402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koo</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>A-R</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S</given-names></name><name name-style="western"><surname>Yun</surname><given-names>C-O</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-S</given-names></name></person-group><article-title>Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>13</issue><fpage>7897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx490</pub-id><pub-id pub-id-type="pmid">28575452</pub-id><pub-id pub-id-type="pmcid">PMC5570104</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Koo T, Yoon A-R, Cho H-Y, Bae S, Yun C-O, Kim J-S. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression. Nucleic Acids Res. 2017;45(13):7897&#8211;908.<pub-id pub-id-type="pmid">28575452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx490</pub-id><pub-id pub-id-type="pmcid">PMC5570104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guernet</surname><given-names>A</given-names></name><name name-style="western"><surname>Grumolato</surname><given-names>L</given-names></name></person-group><article-title>CRISPR/Cas9 editing of the genome for cancer modeling</article-title><source>Methods</source><year>2017</year><volume>121</volume><fpage>130</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2017.03.007</pub-id><pub-id pub-id-type="pmid">28288827</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Guernet A, Grumolato L. CRISPR/Cas9 editing of the genome for cancer modeling. Methods. 2017;121:130&#8211;7.<pub-id pub-id-type="pmid">28288827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymeth.2017.03.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao-Jie</surname><given-names>L</given-names></name><name name-style="western"><surname>Hui-Ying</surname><given-names>X</given-names></name><name name-style="western"><surname>Zun-Ping</surname><given-names>K</given-names></name><name name-style="western"><surname>Jin-Lian</surname><given-names>C</given-names></name><name name-style="western"><surname>Li-Juan</surname><given-names>J</given-names></name></person-group><article-title>CRISPR-Cas9: a new and promising player in gene therapy</article-title><source>J Med Genet</source><year>2015</year><volume>52</volume><issue>5</issue><fpage>289</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102968</pub-id><pub-id pub-id-type="pmid">25713109</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet. 2015;52(5):289&#8211;96.<pub-id pub-id-type="pmid">25713109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2014-102968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pellagatti</surname><given-names>A</given-names></name><name name-style="western"><surname>Dolatshad</surname><given-names>H</given-names></name><name name-style="western"><surname>Valletta</surname><given-names>S</given-names></name><name name-style="western"><surname>Boultwood</surname><given-names>J</given-names></name></person-group><article-title>Application of CRISPR/Cas9 genome editing to the study and treatment of disease</article-title><source>Arch Toxicol</source><year>2015</year><volume>89</volume><fpage>1023</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/s00204-015-1504-y</pub-id><pub-id pub-id-type="pmid">25827103</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Pellagatti A, Dolatshad H, Valletta S, Boultwood J. Application of CRISPR/Cas9 genome editing to the study and treatment of disease. Arch Toxicol. 2015;89:1023&#8211;34.<pub-id pub-id-type="pmid">25827103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-015-1504-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><issue>9</issue><fpage>4254</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/cam4.2257</pub-id><pub-id pub-id-type="pmid">31199589</pub-id><pub-id pub-id-type="pmcid">PMC6675705</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Gao Q, Dong X, Xu Q, Zhu L, Wang F, Hou Y, et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy. Cancer Med. 2019;8(9):4254&#8211;64.<pub-id pub-id-type="pmid">31199589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2257</pub-id><pub-id pub-id-type="pmcid">PMC6675705</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachdeva</surname><given-names>M</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>N</given-names></name><name name-style="western"><surname>Pal</surname><given-names>M</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>M</given-names></name><etal/></person-group><article-title>CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer</article-title><source>Cancer Gene Ther</source><year>2015</year><volume>22</volume><issue>11</issue><fpage>509</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/cgt.2015.54</pub-id><pub-id pub-id-type="pmid">26494554</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Sachdeva M, Sachdeva N, Pal M, Gupta N, Khan I, Majumdar M, et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther. 2015;22(11):509&#8211;17.<pub-id pub-id-type="pmid">26494554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cgt.2015.54</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Hao</surname><given-names>M</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>D</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing of HSV-1 virus in human cells</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>34531</fpage><pub-id pub-id-type="doi">10.1038/srep34531</pub-id><pub-id pub-id-type="pmid">27713537</pub-id><pub-id pub-id-type="pmcid">PMC5054376</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Lin C, Li H, Hao M, Xiong D, Luo Y, Huang C, et al. Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing of HSV-1 virus in human cells. Sci Rep. 2016;6(1):34531.<pub-id pub-id-type="pmid">27713537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep34531</pub-id><pub-id pub-id-type="pmcid">PMC5054376</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stadtmauer</surname><given-names>EA</given-names></name><name name-style="western"><surname>Fraietta</surname><given-names>JA</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MM</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Weber</surname><given-names>KL</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>E</given-names></name><etal/></person-group><article-title>CRISPR-engineered T cells in patients with refractory cancer</article-title><source>Science</source><year>2020</year><volume>367</volume><issue>6481</issue><fpage>eaba7365</fpage><pub-id pub-id-type="doi">10.1126/science.aba7365</pub-id><pub-id pub-id-type="pmid">32029687</pub-id><pub-id pub-id-type="pmcid">PMC11249135</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.<pub-id pub-id-type="pmid">32029687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aba7365</pub-id><pub-id pub-id-type="pmcid">PMC11249135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Feng</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors</article-title><source>Cell Mol Immunol</source><year>2021</year><volume>18</volume><issue>9</issue><fpage>2188</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/s41423-021-00749-x</pub-id><pub-id pub-id-type="pmid">34381179</pub-id><pub-id pub-id-type="pmcid">PMC8429583</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188&#8211;98.<pub-id pub-id-type="pmid">34381179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-021-00749-x</pub-id><pub-id pub-id-type="pmcid">PMC8429583</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name><name name-style="western"><surname>Lander</surname><given-names>ES</given-names></name></person-group><article-title>Genetic screens in human cells using the CRISPR-Cas9 system</article-title><source>Science</source><year>2014</year><volume>343</volume><issue>6166</issue><fpage>80</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1126/science.1246981</pub-id><pub-id pub-id-type="pmid">24336569</pub-id><pub-id pub-id-type="pmcid">PMC3972032</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343(6166):80&#8211;4.<pub-id pub-id-type="pmid">24336569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1246981</pub-id><pub-id pub-id-type="pmcid">PMC3972032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khorramian-Ghahfarokhi</surname><given-names>M</given-names></name><name name-style="western"><surname>Shafieizadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Mahmoudi</surname><given-names>E</given-names></name><name name-style="western"><surname>Eskandari</surname><given-names>F</given-names></name><etal/></person-group><article-title>Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy</article-title><source>Mol Cancer</source><year>2024</year><volume>23</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01925-5</pub-id><pub-id pub-id-type="pmid">38195537</pub-id><pub-id pub-id-type="pmcid">PMC10775503</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23(1):9.<pub-id pub-id-type="pmid">38195537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01925-5</pub-id><pub-id pub-id-type="pmcid">PMC10775503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhokisham</surname><given-names>N</given-names></name><name name-style="western"><surname>Laudermilch</surname><given-names>E</given-names></name><name name-style="western"><surname>Traeger</surname><given-names>LL</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>TD</given-names></name><name name-style="western"><surname>Ruiz-Estevez</surname><given-names>M</given-names></name><name name-style="western"><surname>Becker</surname><given-names>JR</given-names></name></person-group><article-title>CRISPR-Cas system: the current and emerging translational landscape</article-title><source>Cells</source><year>2023</year><volume>12</volume><issue>8</issue><fpage>1103</fpage><pub-id pub-id-type="doi">10.3390/cells12081103</pub-id><pub-id pub-id-type="pmid">37190012</pub-id><pub-id pub-id-type="pmcid">PMC10136740</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruiz-Estevez M, Becker JR. CRISPR-Cas system: the current and emerging translational landscape. Cells. 2023;12(8):1103.<pub-id pub-id-type="pmid">37190012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12081103</pub-id><pub-id pub-id-type="pmcid">PMC10136740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title>Overcoming the delivery challenges in CRISPR/Cas9 gene editing for effective cancer treatment: A review of delivery systems</article-title><source>Int J Med Sci</source><year>2025</year><volume>22</volume><issue>14</issue><fpage>3625</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.7150/ijms.112724</pub-id><pub-id pub-id-type="pmid">40959562</pub-id><pub-id pub-id-type="pmcid">PMC12434829</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Tang S, Chen X, Tong X, Zhu L. Overcoming the delivery challenges in CRISPR/Cas9 gene editing for effective cancer treatment: A review of delivery systems. Int J Med Sci. 2025;22(14):3625&#8211;49.<pub-id pub-id-type="pmid">40959562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.112724</pub-id><pub-id pub-id-type="pmcid">PMC12434829</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>C</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Bench-to-bedside: translational development landscape of biotechnology in healthcare</article-title><source>Health Sci Rev</source><year>2023</year><volume>7</volume><fpage>100097</fpage></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Liao C, Xiao S, Wang X. Bench-to-bedside: translational development landscape of biotechnology in healthcare. Health Sci Rev. 2023;7:100097.</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sowmya</surname><given-names>S</given-names></name><name name-style="western"><surname>Augustine</surname><given-names>D</given-names></name><name name-style="western"><surname>Mushtaq</surname><given-names>S</given-names></name><name name-style="western"><surname>Baeshen</surname><given-names>HA</given-names></name><name name-style="western"><surname>Ashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1383062</fpage><pub-id pub-id-type="doi">10.3389/fonc.2024.1383062</pub-id><pub-id pub-id-type="pmid">38915370</pub-id><pub-id pub-id-type="pmcid">PMC11194394</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Sowmya S, Augustine D, Mushtaq S, Baeshen HA, Ashi H, Hassan RN, et al. Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing. Front Oncol. 2024;14:1383062.<pub-id pub-id-type="pmid">38915370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1383062</pub-id><pub-id pub-id-type="pmcid">PMC11194394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youssef</surname><given-names>E</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>D</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>B</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>R</given-names></name></person-group><article-title>Exosomes in precision oncology and beyond: from bench to bedside in diagnostics and therapeutics</article-title><source>Cancers</source><year>2025</year><volume>17</volume><issue>6</issue><fpage>940</fpage><pub-id pub-id-type="doi">10.3390/cancers17060940</pub-id><pub-id pub-id-type="pmid">40149276</pub-id><pub-id pub-id-type="pmcid">PMC11940788</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Youssef E, Palmer D, Fletcher B, Vaughn R. Exosomes in precision oncology and beyond: from bench to bedside in diagnostics and therapeutics. Cancers. 2025;17(6):940.<pub-id pub-id-type="pmid">40149276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers17060940</pub-id><pub-id pub-id-type="pmcid">PMC11940788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eskandar</surname><given-names>K</given-names></name></person-group><article-title>Nanotechnology in cancer treatment: innovative approaches to overcoming drug resistance in tumors</article-title><source>Indonesian J Cancer Chemoprevention</source><year>2024</year><volume>15</volume><issue>2</issue><fpage>162</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.14499/indonesianjcanchemoprev15iss2pp162-174</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Eskandar K. Nanotechnology in cancer treatment: innovative approaches to overcoming drug resistance in tumors. Indonesian J Cancer Chemoprevention. 2024;15(2):162&#8211;74.</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youssef</surname><given-names>E</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>B</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>D</given-names></name></person-group><article-title>Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology</article-title><source>Front Med</source><year>2025</year><volume>11</volume><fpage>1527600</fpage><pub-id pub-id-type="doi">10.3389/fmed.2024.1527600</pub-id><pub-id pub-id-type="pmcid">PMC11769984</pub-id><pub-id pub-id-type="pmid">39871848</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025;11:1527600.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1527600</pub-id><pub-id pub-id-type="pmcid">PMC11769984</pub-id><pub-id pub-id-type="pmid">39871848</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><mixed-citation publication-type="other">Amen RA, Hassan YM, Essmat RA, Ahmed RH, Azab MM, Shehata NR, Elgazzar MM, El-Sayed WM. Harnessing the microbiome: CRISPR-based gene editing and antimicrobial peptides in combating antibiotic resistance and cancer. Probiotics Antimicrob Proteins. 2025;17(4):1938&#8211;68. 10.1007/s12602-025-10573-8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12602-025-10573-8</pub-id><pub-id pub-id-type="pmcid">PMC12405046</pub-id><pub-id pub-id-type="pmid">40377870</pub-id></mixed-citation></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thuret</surname><given-names>I</given-names></name><name name-style="western"><surname>Ruggeri</surname><given-names>A</given-names></name><name name-style="western"><surname>Angelucci</surname><given-names>E</given-names></name><name name-style="western"><surname>Chabannon</surname><given-names>C</given-names></name></person-group><article-title>Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia</article-title><source>Stem Cells Translational Med</source><year>2022</year><volume>11</volume><issue>4</issue><fpage>407</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/stcltm/szac007</pub-id><pub-id pub-id-type="pmcid">PMC9052404</pub-id><pub-id pub-id-type="pmid">35267028</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Thuret I, Ruggeri A, Angelucci E, Chabannon C. Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia. Stem Cells Translational Med. 2022;11(4):407&#8211;14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/stcltm/szac007</pub-id><pub-id pub-id-type="pmcid">PMC9052404</pub-id><pub-id pub-id-type="pmid">35267028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><mixed-citation publication-type="other">Khan G, Hussain MS. Expanding the potential of gene therapy for duchenne muscular dystrophy. Curr Pharm Des. 2025. 10.2174/0113816128386290250507101412.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0113816128386290250507101412</pub-id><pub-id pub-id-type="pmid">40357789</pub-id></mixed-citation></ref><ref id="CR144"><label>144.</label><mixed-citation publication-type="other">Kumar DN, Chowdhary DL, Pathuri T, Katta P, Arya L, editors. AI Enhanced-Smart Genome Editing: Integration of CRISPR-Cas9 with Artificial Intelligence for Cancer Treatment. 2024 5th International Conference for Emerging Technology (INCET); 2024: IEEE.</mixed-citation></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duong</surname><given-names>MT-Q</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>You</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Min</surname><given-names>J-J</given-names></name></person-group><article-title>Bacteria-cancer interactions: bacteria-based cancer therapy</article-title><source>Exp Mol Med</source><year>2019</year><volume>51</volume><issue>12</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s12276-019-0297-0</pub-id><pub-id pub-id-type="pmid">31827064</pub-id><pub-id pub-id-type="pmcid">PMC6906302</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Duong MT-Q, Qin Y, You S-H, Min J-J. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019;51(12):1&#8211;15.<pub-id pub-id-type="pmid">31827064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-019-0297-0</pub-id><pub-id pub-id-type="pmcid">PMC6906302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pernigoni</surname><given-names>N</given-names></name><name name-style="western"><surname>Zagato</surname><given-names>E</given-names></name><name name-style="western"><surname>Calcinotto</surname><given-names>A</given-names></name><name name-style="western"><surname>Troiani</surname><given-names>M</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>RP</given-names></name><name name-style="western"><surname>Cal&#236;</surname><given-names>B</given-names></name><etal/></person-group><article-title>Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis</article-title><source>Science</source><year>2021</year><volume>374</volume><issue>6564</issue><fpage>216</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1126/science.abf8403</pub-id><pub-id pub-id-type="pmid">34618582</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Cal&#236; B, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021;374(6564):216&#8211;24.<pub-id pub-id-type="pmid">34618582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abf8403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>KH</given-names></name><name name-style="western"><surname>Nowicki</surname><given-names>C</given-names></name><name name-style="western"><surname>Giurini</surname><given-names>EF</given-names></name><name name-style="western"><surname>Marzo</surname><given-names>AL</given-names></name><name name-style="western"><surname>Zloza</surname><given-names>A</given-names></name></person-group><article-title>Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><issue>12</issue><fpage>1497</fpage><pub-id pub-id-type="doi">10.3390/vaccines9121497</pub-id><pub-id pub-id-type="pmid">34960243</pub-id><pub-id pub-id-type="pmcid">PMC8707929</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Gupta KH, Nowicki C, Giurini EF, Marzo AL, Zloza A. Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy. Vaccines. 2021;9(12):1497.<pub-id pub-id-type="pmid">34960243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9121497</pub-id><pub-id pub-id-type="pmcid">PMC8707929</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tumorigenic bacteria in colorectal cancer: mechanisms and treatments</article-title><source>Cancer Biology Med</source><year>2022</year><volume>19</volume><issue>2</issue><fpage>147</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2020.0651</pub-id><pub-id pub-id-type="pmcid">PMC8832957</pub-id><pub-id pub-id-type="pmid">34586760</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Li S, Liu J, Zheng X, Ren L, Yang Y, Li W, et al. Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. Cancer Biology Med. 2022;19(2):147.<pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2020.0651</pub-id><pub-id pub-id-type="pmcid">PMC8832957</pub-id><pub-id pub-id-type="pmid">34586760</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedighi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zahedi Bialvaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamblin</surname><given-names>MR</given-names></name><name name-style="western"><surname>Ohadi</surname><given-names>E</given-names></name><name name-style="western"><surname>Asadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Halajzadeh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><issue>6</issue><fpage>3167</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1002/cam4.2148</pub-id><pub-id pub-id-type="pmid">30950210</pub-id><pub-id pub-id-type="pmcid">PMC6558487</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med. 2019;8(6):3167&#8211;81.<pub-id pub-id-type="pmid">30950210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2148</pub-id><pub-id pub-id-type="pmcid">PMC6558487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadem</surname><given-names>E</given-names></name><name name-style="western"><surname>Nafari</surname><given-names>AH</given-names></name><name name-style="western"><surname>Safarzadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Falavand Jozaei</surname><given-names>R</given-names></name><name name-style="western"><surname>Almasian</surname><given-names>M</given-names></name><name name-style="western"><surname>Elyasi</surname><given-names>H</given-names></name></person-group><article-title>The role of bacteria in the treatment of cancer: A comprehensive review</article-title><source>Plant Biotechnol Persa</source><year>2020</year><volume>2</volume><issue>1</issue><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.29252/pbp.2.1.26</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Khadem E, Nafari AH, Safarzadeh A, Falavand Jozaei R, Almasian M, Elyasi H. The role of bacteria in the treatment of cancer: A comprehensive review. Plant Biotechnol Persa. 2020;2(1):26&#8211;34.</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C-B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J-Y</given-names></name></person-group><article-title>Gut microbiota in cancer immune response and immunotherapy</article-title><source>Trends Cancer</source><year>2021</year><volume>7</volume><issue>7</issue><fpage>647</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.01.010</pub-id><pub-id pub-id-type="pmid">33674230</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Zhou C-B, Zhou Y-L, Fang J-Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer. 2021;7(7):647&#8211;60.<pub-id pub-id-type="pmid">33674230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2021.01.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;rska</surname><given-names>A</given-names></name><name name-style="western"><surname>Przystupski</surname><given-names>D</given-names></name><name name-style="western"><surname>Niemczura</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kulbacka</surname><given-names>J</given-names></name></person-group><article-title>Probiotic bacteria: a promising tool in cancer prevention and therapy</article-title><source>Curr Microbiol</source><year>2019</year><volume>76</volume><fpage>939</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s00284-019-01679-8</pub-id><pub-id pub-id-type="pmid">30949803</pub-id><pub-id pub-id-type="pmcid">PMC6586914</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">G&#243;rska A, Przystupski D, Niemczura MJ, Kulbacka J. Probiotic bacteria: a promising tool in cancer prevention and therapy. Curr Microbiol. 2019;76:939&#8211;49.<pub-id pub-id-type="pmid">30949803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00284-019-01679-8</pub-id><pub-id pub-id-type="pmcid">PMC6586914</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name></person-group><article-title>Current status and future directions of bacteria-based immunotherapy</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>911783</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.911783</pub-id><pub-id pub-id-type="pmid">35757741</pub-id><pub-id pub-id-type="pmcid">PMC9226492</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Tang Q, Peng X, Xu B, Zhou X, Chen J, Cheng L. Current status and future directions of bacteria-based immunotherapy. Front Immunol. 2022;13:911783.<pub-id pub-id-type="pmid">35757741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.911783</pub-id><pub-id pub-id-type="pmcid">PMC9226492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Anselmo</surname><given-names>AC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Nanotechnology intervention of the Microbiome for cancer therapy</article-title><source>Nat Nanotechnol</source><year>2019</year><volume>14</volume><issue>12</issue><fpage>1093</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/s41565-019-0589-5</pub-id><pub-id pub-id-type="pmid">31802032</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Song W, Anselmo AC, Huang L. Nanotechnology intervention of the Microbiome for cancer therapy. Nat Nanotechnol. 2019;14(12):1093&#8211;103.<pub-id pub-id-type="pmid">31802032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-019-0589-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name></person-group><article-title>Delivery strategies for macromolecular drugs in cancer therapy</article-title><source>Acta Pharm Sinica B</source><year>2020</year><volume>10</volume><issue>6</issue><fpage>979</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.01.009</pub-id><pub-id pub-id-type="pmcid">PMC7332661</pub-id><pub-id pub-id-type="pmid">32642406</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Guo Q, Jiang C. Delivery strategies for macromolecular drugs in cancer therapy. Acta Pharm Sinica B. 2020;10(6):979&#8211;86.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2020.01.009</pub-id><pub-id pub-id-type="pmcid">PMC7332661</pub-id><pub-id pub-id-type="pmid">32642406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P</given-names></name><name name-style="western"><surname>Marchesi</surname><given-names>F</given-names></name><name name-style="western"><surname>Garlanda</surname><given-names>C</given-names></name></person-group><article-title>Macrophages as tools and targets in cancer therapy</article-title><source>Nat Rev Drug Discovery</source><year>2022</year><volume>21</volume><issue>11</issue><fpage>799</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1038/s41573-022-00520-5</pub-id><pub-id pub-id-type="pmid">35974096</pub-id><pub-id pub-id-type="pmcid">PMC9380983</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discovery. 2022;21(11):799&#8211;820.<pub-id pub-id-type="pmid">35974096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-022-00520-5</pub-id><pub-id pub-id-type="pmcid">PMC9380983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helmink</surname><given-names>BA</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MW</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>V</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>JA</given-names></name></person-group><article-title>The microbiome, cancer, and cancer therapy</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>3</issue><fpage>377</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0377-7</pub-id><pub-id pub-id-type="pmid">30842679</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Helmink BA, Khan MW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377&#8211;88.<pub-id pub-id-type="pmid">30842679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0377-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chrysostomou</surname><given-names>D</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>LA</given-names></name><name name-style="western"><surname>Marchesi</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kinross</surname><given-names>JM</given-names></name></person-group><article-title>Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy</article-title><source>Gastroenterology</source><year>2023</year><volume>164</volume><issue>2</issue><fpage>198</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2022.10.018</pub-id><pub-id pub-id-type="pmid">36309208</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Chrysostomou D, Roberts LA, Marchesi JR, Kinross JM. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology. 2023;164(2):198&#8211;213.<pub-id pub-id-type="pmid">36309208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2022.10.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>WY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>The role of gut microbiota in cancer treatment: friend or foe?</article-title><source>Gut</source><year>2020</year><volume>69</volume><issue>10</issue><fpage>1867</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321153</pub-id><pub-id pub-id-type="pmid">32759302</pub-id><pub-id pub-id-type="pmcid">PMC7497589</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Cheng WY, Wu C-Y, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867&#8211;76.<pub-id pub-id-type="pmid">32759302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-321153</pub-id><pub-id pub-id-type="pmcid">PMC7497589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M-R</given-names></name><name name-style="western"><surname>Jusiak</surname><given-names>B</given-names></name><name name-style="western"><surname>Lu</surname><given-names>TK</given-names></name></person-group><article-title>Engineering advanced cancer therapies with synthetic biology</article-title><source>Nat Rev Cancer</source><year>2019</year><volume>19</volume><issue>4</issue><fpage>187</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">30837696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0121-0</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Wu M-R, Jusiak B, Lu TK. Engineering advanced cancer therapies with synthetic biology. Nat Rev Cancer. 2019;19(4):187&#8211;95.<pub-id pub-id-type="pmid">30837696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0121-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Zang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy</article-title><source>Biomaterials</source><year>2019</year><volume>214</volume><fpage>119226</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119226</pub-id><pub-id pub-id-type="pmid">31174068</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Chen F, Zang Z, Chen Z, Cui L, Chang Z, Ma A, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials. 2019;214:119226.<pub-id pub-id-type="pmid">31174068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119226</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sima</surname><given-names>P</given-names></name><name name-style="western"><surname>Vetvicka</surname><given-names>V</given-names></name><name name-style="western"><surname>Vannucci</surname><given-names>L</given-names></name></person-group><source>J Tumor J Tumor</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>560</fpage><lpage>4</lpage></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Sima P, Vetvicka V, Vannucci L. J Tumor J Tumor. 2020;8(1):560&#8211;4.</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ter&#225;n-Navarro</surname><given-names>H</given-names></name><name name-style="western"><surname>Zeoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Salines-Cuevas</surname><given-names>D</given-names></name><name name-style="western"><surname>Marradi</surname><given-names>M</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>N</given-names></name><name name-style="western"><surname>Gonzalez-Lopez</surname><given-names>E</given-names></name><etal/></person-group><article-title>Gold glyconanoparticles combined with 91&#8211;99 peptide of the bacterial Toxin, Listeriolysin O, are efficient immunotherapies in experimental bladder tumors</article-title><source>Cancers</source><year>2022</year><volume>14</volume><issue>10</issue><fpage>2413</fpage><pub-id pub-id-type="doi">10.3390/cancers14102413</pub-id><pub-id pub-id-type="pmid">35626016</pub-id><pub-id pub-id-type="pmcid">PMC9140107</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Ter&#225;n-Navarro H, Zeoli A, Salines-Cuevas D, Marradi M, Montoya N, Gonzalez-Lopez E, et al. Gold glyconanoparticles combined with 91&#8211;99 peptide of the bacterial Toxin, Listeriolysin O, are efficient immunotherapies in experimental bladder tumors. Cancers. 2022;14(10):2413.<pub-id pub-id-type="pmid">35626016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14102413</pub-id><pub-id pub-id-type="pmcid">PMC9140107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><mixed-citation publication-type="other">Aguilera-Herce J, Garc&#237;a-Quintanilla M, Romero-Flores R, McConnell MJ, Ramos-Morales F. A live Salmonella vaccine delivering PcrV through the type III secretion system protects against Pseudomonas aeruginosa. Msphere. 2019;4(2). 10.1128/msphere. 00116&#8201;&#8211;&#8201;19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mSphere.00116-19</pub-id><pub-id pub-id-type="pmcid">PMC6470209</pub-id><pub-id pub-id-type="pmid">30996108</pub-id></mixed-citation></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troxell</surname><given-names>B</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>M</given-names></name><name name-style="western"><surname>Ali</surname><given-names>R</given-names></name><name name-style="western"><surname>Koci</surname><given-names>M</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>H</given-names></name></person-group><article-title>Attenuated Salmonella enterica serovar typhimurium, strain NC983, is immunogenic, and protective against virulent typhimurium challenges in mice</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><issue>4</issue><fpage>646</fpage><pub-id pub-id-type="doi">10.3390/vaccines8040646</pub-id><pub-id pub-id-type="pmid">33153043</pub-id><pub-id pub-id-type="pmcid">PMC7711481</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Troxell B, Mendoza M, Ali R, Koci M, Hassan H. Attenuated Salmonella enterica serovar typhimurium, strain NC983, is immunogenic, and protective against virulent typhimurium challenges in mice. Vaccines. 2020;8(4):646.<pub-id pub-id-type="pmid">33153043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8040646</pub-id><pub-id pub-id-type="pmcid">PMC7711481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Niu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Su</surname><given-names>X</given-names></name><etal/></person-group><article-title>Bacterial-Mediated tumor therapy: old treatment in a new context</article-title><source>Adv Sci</source><year>2023</year><volume>10</volume><issue>12</issue><fpage>2205641</fpage><pub-id pub-id-type="doi">10.1002/advs.202205641</pub-id><pub-id pub-id-type="pmcid">PMC10131876</pub-id><pub-id pub-id-type="pmid">36908053</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Liu Y, Niu L, Li N, Wang Y, Liu M, Su X, et al. Bacterial-Mediated tumor therapy: old treatment in a new context. Adv Sci. 2023;10(12):2205641.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202205641</pub-id><pub-id pub-id-type="pmcid">PMC10131876</pub-id><pub-id pub-id-type="pmid">36908053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Punetha</surname><given-names>A</given-names></name><name name-style="western"><surname>Punetha</surname><given-names>AK</given-names></name></person-group><source>Microbiome therapeutics for the cancer management</source><year>2023</year><publisher-loc>Microbiome Therapeutics</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>197</fpage><lpage>230</lpage></element-citation><mixed-citation id="mc-CR167" publication-type="book">Punetha A, Punetha AK. Microbiome therapeutics for the cancer management. Microbiome Therapeutics: Elsevier; 2023. pp. 197&#8211;230.</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Bacteria and bacterial derivatives as drug carriers for cancer therapy</article-title><source>J Controlled Release</source><year>2020</year><volume>326</volume><fpage>396</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.07.009</pub-id><pub-id pub-id-type="pmid">32681947</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Cao Z, Liu J. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Controlled Release. 2020;326:396&#8211;407.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2020.07.009</pub-id><pub-id pub-id-type="pmid">32681947</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laliani</surname><given-names>G</given-names></name><name name-style="western"><surname>Sorboni</surname><given-names>SG</given-names></name><name name-style="western"><surname>Lari</surname><given-names>R</given-names></name><name name-style="western"><surname>Yaghoubi</surname><given-names>A</given-names></name><name name-style="western"><surname>Soleimanpour</surname><given-names>S</given-names></name><name name-style="western"><surname>Khazaei</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bacteria and cancer: different sides of the same coin</article-title><source>Life Sci</source><year>2020</year><volume>246</volume><fpage>117398</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117398</pub-id><pub-id pub-id-type="pmid">32032647</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Laliani G, Sorboni SG, Lari R, Yaghoubi A, Soleimanpour S, Khazaei M, et al. Bacteria and cancer: different sides of the same coin. Life Sci. 2020;246:117398.<pub-id pub-id-type="pmid">32032647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.117398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>T</given-names></name><name name-style="western"><surname>Diao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Blum</surname><given-names>NT</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name></person-group><article-title>Engineering bacteria and bionic bacterial derivatives with nanoparticles for cancer therapy</article-title><source>Small</source><year>2022</year><volume>18</volume><issue>12</issue><fpage>2104643</fpage><pub-id pub-id-type="doi">10.1002/smll.202104643</pub-id><pub-id pub-id-type="pmid">34908239</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Yin T, Diao Z, Blum NT, Qiu L, Ma A, Huang P. Engineering bacteria and bionic bacterial derivatives with nanoparticles for cancer therapy. Small. 2022;18(12):2104643.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202104643</pub-id><pub-id pub-id-type="pmid">34908239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avogadri</surname><given-names>F</given-names></name><name name-style="western"><surname>Martinoli</surname><given-names>C</given-names></name><name name-style="western"><surname>Petrovska</surname><given-names>L</given-names></name><name name-style="western"><surname>Chiodoni</surname><given-names>C</given-names></name><name name-style="western"><surname>Transidico</surname><given-names>P</given-names></name><name name-style="western"><surname>Bronte</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cancer immunotherapy based on killing of Salmonella-infected tumor cells</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><issue>9</issue><fpage>3920</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3002</pub-id><pub-id pub-id-type="pmid">15867392</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 2005;65(9):3920&#8211;7.<pub-id pub-id-type="pmid">15867392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-04-3002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S-R</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D-H</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>SW</given-names></name><name name-style="western"><surname>Min</surname><given-names>J-J</given-names></name></person-group><article-title>Bacteria and bacterial derivatives as delivery carriers for immunotherapy</article-title><source>Adv Drug Deliv Rev</source><year>2022</year><volume>181</volume><fpage>114085</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.114085</pub-id><pub-id pub-id-type="pmid">34933064</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Kang S-R, Nguyen D-H, Yoo SW, Min J-J. Bacteria and bacterial derivatives as delivery carriers for immunotherapy. Adv Drug Deliv Rev. 2022;181:114085.<pub-id pub-id-type="pmid">34933064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.114085</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attebury</surname><given-names>H</given-names></name><name name-style="western"><surname>Daley</surname><given-names>D</given-names></name></person-group><article-title>The gut Microbiome and pancreatic cancer development and treatment</article-title><source>Cancer J</source><year>2023</year><volume>29</volume><issue>2</issue><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1097/PPO.0000000000000647</pub-id><pub-id pub-id-type="pmid">36957973</pub-id><pub-id pub-id-type="pmcid">PMC10042586</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Attebury H, Daley D. The gut Microbiome and pancreatic cancer development and treatment. Cancer J. 2023;29(2):49&#8211;56.<pub-id pub-id-type="pmid">36957973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PPO.0000000000000647</pub-id><pub-id pub-id-type="pmcid">PMC10042586</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>M</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S-N</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>VH</given-names></name><name name-style="western"><surname>Park</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Jung</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Effect of Salmonella treatment on an implanted tumor (CT26) in a mouse model</article-title><source>J Microbiol</source><year>2012</year><volume>50</volume><fpage>502</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s12275-012-2090-9</pub-id><pub-id pub-id-type="pmid">22752915</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Yun M, Pan S, Jiang S-N, Nguyen VH, Park S-H, Jung C-H, et al. Effect of Salmonella treatment on an implanted tumor (CT26) in a mouse model. J Microbiol. 2012;50:502&#8211;10.<pub-id pub-id-type="pmid">22752915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12275-012-2090-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Min</surname><given-names>J-J</given-names></name><etal/></person-group><article-title>Comparison of anticancer activities and biosafety between Salmonella enterica serovar typhimurium &#8710;ppGpp and VNP20009 in a murine cancer model</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>914575</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.914575</pub-id><pub-id pub-id-type="pmid">35847095</pub-id><pub-id pub-id-type="pmcid">PMC9277105</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Liu X, Guo Y, Sun Y, Chen Y, Tan W, Min J-J, et al. Comparison of anticancer activities and biosafety between Salmonella enterica serovar typhimurium &#8710;ppGpp and VNP20009 in a murine cancer model. Front Microbiol. 2022;13:914575.<pub-id pub-id-type="pmid">35847095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2022.914575</pub-id><pub-id pub-id-type="pmcid">PMC9277105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaghoubi</surname><given-names>A</given-names></name><name name-style="western"><surname>Khazaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Jalili</surname><given-names>S</given-names></name><name name-style="western"><surname>Hasanian</surname><given-names>SM</given-names></name><name name-style="western"><surname>Avan</surname><given-names>A</given-names></name><name name-style="western"><surname>Soleimanpour</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bacteria as a double-action sword in cancer</article-title><source>Biochim Et Biophys Acta (BBA)-Reviews Cancer</source><year>2020</year><volume>1874</volume><issue>1</issue><fpage>188388</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188388</pub-id><pub-id pub-id-type="pmid">32589907</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Yaghoubi A, Khazaei M, Jalili S, Hasanian SM, Avan A, Soleimanpour S, et al. Bacteria as a double-action sword in cancer. Biochim Et Biophys Acta (BBA)-Reviews Cancer. 2020;1874(1):188388.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2020.188388</pub-id><pub-id pub-id-type="pmid">32589907</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Ramadi</surname><given-names>BK</given-names></name><name name-style="western"><surname>Fernandez&#8208;Cabezudo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>El&#8208;Hasasna</surname><given-names>H</given-names></name><name name-style="western"><surname>Al&#8208;Salam</surname><given-names>S</given-names></name><name name-style="western"><surname>Attoub</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Attenuated bacteria as effectors in cancer immunotherapy</article-title><source>Ann N Y Acad Sci</source><year>2008</year><volume>1138</volume><issue>1</issue><fpage>351</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1196/annals.1414.036</pub-id><pub-id pub-id-type="pmid">18837910</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Al-Ramadi BK, Fernandez&#8208;Cabezudo MJ, El&#8208;Hasasna H, Al&#8208;Salam S, Attoub S, Xu D, et al. Attenuated bacteria as effectors in cancer immunotherapy. Ann N Y Acad Sci. 2008;1138(1):351&#8211;7.<pub-id pub-id-type="pmid">18837910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1414.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weerakkody</surname><given-names>LR</given-names></name><name name-style="western"><surname>Witharana</surname><given-names>C</given-names></name></person-group><article-title>The role of bacterial toxins and spores in cancer therapy</article-title><source>Life Sci</source><year>2019</year><volume>235</volume><fpage>116839</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.116839</pub-id><pub-id pub-id-type="pmid">31499068</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Weerakkody LR, Witharana C. The role of bacterial toxins and spores in cancer therapy. Life Sci. 2019;235:116839.<pub-id pub-id-type="pmid">31499068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2019.116839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>G-F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X-Z</given-names></name></person-group><article-title>Cell primitive-based biomimetic functional materials for enhanced cancer therapy</article-title><source>Chem Soc Rev</source><year>2021</year><volume>50</volume><issue>2</issue><fpage>945</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1039/D0CS00152J</pub-id><pub-id pub-id-type="pmid">33226037</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Luo G-F, Chen W-H, Zeng X, Zhang X-Z. Cell primitive-based biomimetic functional materials for enhanced cancer therapy. Chem Soc Rev. 2021;50(2):945&#8211;85.<pub-id pub-id-type="pmid">33226037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0cs00152j</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#252;nther</surname><given-names>J</given-names></name><name name-style="western"><surname>D&#228;britz</surname><given-names>J</given-names></name><name name-style="western"><surname>Wirthgen</surname><given-names>E</given-names></name></person-group><article-title>Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1801</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01801</pub-id><pub-id pub-id-type="pmid">31417567</pub-id><pub-id pub-id-type="pmcid">PMC6682646</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">G&#252;nther J, D&#228;britz J, Wirthgen E. Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment. Front Immunol. 2019;10:1801.<pub-id pub-id-type="pmid">31417567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01801</pub-id><pub-id pub-id-type="pmcid">PMC6682646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero</surname><given-names>I</given-names></name><name name-style="western"><surname>Castanon</surname><given-names>E</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>M</given-names></name><name name-style="western"><surname>Champiat</surname><given-names>S</given-names></name><name name-style="western"><surname>Marabelle</surname><given-names>A</given-names></name></person-group><article-title>Intratumoural administration and tumour tissue targeting of cancer immunotherapies</article-title><source>Nat Reviews Clin Oncol</source><year>2021</year><volume>18</volume><issue>9</issue><fpage>558</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00507-y</pub-id><pub-id pub-id-type="pmcid">PMC8130796</pub-id><pub-id pub-id-type="pmid">34006998</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Reviews Clin Oncol. 2021;18(9):558&#8211;76.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00507-y</pub-id><pub-id pub-id-type="pmcid">PMC8130796</pub-id><pub-id pub-id-type="pmid">34006998</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J-S</given-names></name><name name-style="western"><surname>Jun</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-S</given-names></name></person-group><article-title>Critical issues in the development of immunotoxins for anticancer therapy</article-title><source>J Pharm Sci</source><year>2020</year><volume>109</volume><issue>1</issue><fpage>104</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2019.10.037</pub-id><pub-id pub-id-type="pmid">31669121</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Kim J-S, Jun S-Y, Kim Y-S. Critical issues in the development of immunotoxins for anticancer therapy. J Pharm Sci. 2020;109(1):104&#8211;15.<pub-id pub-id-type="pmid">31669121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2019.10.037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirzaei</surname><given-names>R</given-names></name><name name-style="western"><surname>Afaghi</surname><given-names>A</given-names></name><name name-style="western"><surname>Babakhani</surname><given-names>S</given-names></name><name name-style="western"><surname>Sohrabi</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hosseini-Fard</surname><given-names>SR</given-names></name><name name-style="western"><surname>Babolhavaeji</surname><given-names>K</given-names></name><etal/></person-group><article-title>Role of microbiota-derived short-chain fatty acids in cancer development and prevention</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>139</volume><fpage>111619</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111619</pub-id><pub-id pub-id-type="pmid">33906079</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Mirzaei R, Afaghi A, Babakhani S, Sohrabi MR, Hosseini-Fard SR, Babolhavaeji K, et al. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother. 2021;139:111619.<pub-id pub-id-type="pmid">33906079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban-Wojciuk</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MM</given-names></name><name name-style="western"><surname>Oyler</surname><given-names>BL</given-names></name><name name-style="western"><surname>F&#229;hraeus</surname><given-names>R</given-names></name><name name-style="western"><surname>Marek-Trzonkowska</surname><given-names>N</given-names></name><name name-style="western"><surname>Nita-Lazar</surname><given-names>A</given-names></name><etal/></person-group><article-title>The role of TLRs in anti-cancer immunity and tumor rejection</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2388</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02388</pub-id><pub-id pub-id-type="pmid">31695691</pub-id><pub-id pub-id-type="pmcid">PMC6817561</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Urban-Wojciuk Z, Khan MM, Oyler BL, F&#229;hraeus R, Marek-Trzonkowska N, Nita-Lazar A, et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol. 2019;10:2388.<pub-id pub-id-type="pmid">31695691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02388</pub-id><pub-id pub-id-type="pmcid">PMC6817561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroll</surname><given-names>AV</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Holay</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Biomimetic nanoparticle vaccines for cancer therapy</article-title><source>Adv Biosystems</source><year>2019</year><volume>3</volume><issue>1</issue><fpage>1800219</fpage><pub-id pub-id-type="doi">10.1002/adbi.201800219</pub-id><pub-id pub-id-type="pmcid">PMC6855307</pub-id><pub-id pub-id-type="pmid">31728404</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Kroll AV, Jiang Y, Zhou J, Holay M, Fang RH, Zhang L. Biomimetic nanoparticle vaccines for cancer therapy. Adv Biosystems. 2019;3(1):1800219.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adbi.201800219</pub-id><pub-id pub-id-type="pmcid">PMC6855307</pub-id><pub-id pub-id-type="pmid">31728404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Guan</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Role of SCFAs in gut Microbiome and Glycolysis for colorectal cancer therapy</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><issue>10</issue><fpage>17023</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1002/jcp.28436</pub-id><pub-id pub-id-type="pmid">30888065</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Wang G, Yu Y, Wang YZ, Wang JJ, Guan R, Sun Y, et al. Role of SCFAs in gut Microbiome and Glycolysis for colorectal cancer therapy. J Cell Physiol. 2019;234(10):17023&#8211;49.<pub-id pub-id-type="pmid">30888065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.28436</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laborda-Illanes</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanchez-Alcoholado</surname><given-names>L</given-names></name><name name-style="western"><surname>Dominguez-Recio</surname><given-names>ME</given-names></name><name name-style="western"><surname>Jimenez-Rodriguez</surname><given-names>B</given-names></name><name name-style="western"><surname>Lavado</surname><given-names>R</given-names></name><name name-style="western"><surname>Comino-M&#233;ndez</surname><given-names>I</given-names></name><etal/></person-group><article-title>Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment</article-title><source>Cancers</source><year>2020</year><volume>12</volume><issue>9</issue><fpage>2465</fpage><pub-id pub-id-type="doi">10.3390/cancers12092465</pub-id><pub-id pub-id-type="pmid">32878124</pub-id><pub-id pub-id-type="pmcid">PMC7565530</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, Jimenez-Rodriguez B, Lavado R, Comino-M&#233;ndez I, et al. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers. 2020;12(9):2465.<pub-id pub-id-type="pmid">32878124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12092465</pub-id><pub-id pub-id-type="pmcid">PMC7565530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senevirathne</surname><given-names>A</given-names></name><name name-style="western"><surname>Lloren</surname><given-names>KKS</given-names></name><name name-style="western"><surname>Aganja</surname><given-names>RP</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Transforming bacterial pathogens into Wonder tools in cancer immunotherapy</article-title><source>Mol Ther</source><year>2025</year><volume>33</volume><issue>3</issue><fpage>866</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2025.01.029</pub-id><pub-id pub-id-type="pmid">39825565</pub-id><pub-id pub-id-type="pmcid">PMC11897747</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Senevirathne A, Lloren KKS, Aganja RP, Kwon J, Lee JH. Transforming bacterial pathogens into Wonder tools in cancer immunotherapy. Mol Ther. 2025;33(3):866&#8211;82.<pub-id pub-id-type="pmid">39825565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2025.01.029</pub-id><pub-id pub-id-type="pmcid">PMC11897747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Din</surname><given-names>SRU</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>SU</given-names></name><name name-style="western"><surname>Arbi</surname><given-names>FM</given-names></name><name name-style="western"><surname>Xuefang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M</given-names></name></person-group><article-title>Bacteria-driven cancer therapy: exploring advancements and challenges</article-title><source>Crit Rev Oncol/Hematol</source><year>2023</year><volume>191</volume><fpage>104141</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2023.104141</pub-id><pub-id pub-id-type="pmid">37742883</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Din SRU, Saeed S, Khan SU, Arbi FM, Xuefang G, Zhong M. Bacteria-driven cancer therapy: exploring advancements and challenges. Crit Rev Oncol/Hematol. 2023;191:104141.<pub-id pub-id-type="pmid">37742883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2023.104141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name></person-group><article-title>Role of the microbiota in cancer growth and necrosis: the challenges and opportunities of bacteriotherapy for cancer and its complications</article-title><source>Reviews Res Med Microbiol</source><year>2018</year><volume>29</volume><issue>1</issue><fpage>20</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1097/MRM.0000000000000120</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Pan W, Kang Y. Role of the microbiota in cancer growth and necrosis: the challenges and opportunities of bacteriotherapy for cancer and its complications. Reviews Res Med Microbiol. 2018;29(1):20&#8211;3.</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>EA</given-names></name><name name-style="western"><surname>Lukomski</surname><given-names>S</given-names></name><name name-style="western"><surname>Boone</surname><given-names>BA</given-names></name></person-group><article-title>Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1217095</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1217095</pub-id><pub-id pub-id-type="pmid">37588093</pub-id><pub-id pub-id-type="pmcid">PMC10425600</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Henderson EA, Lukomski S, Boone BA. Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer. Front Oncol. 2023;13:1217095.<pub-id pub-id-type="pmid">37588093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1217095</pub-id><pub-id pub-id-type="pmcid">PMC10425600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><mixed-citation publication-type="other">Tieu MV, Pham DT, Cho S. Bacteria-based cancer therapy: looking forward. Biochim Biophys Acta Rev Cancer. 2024;1879(4):189112. 10.1016/j.bbcan.2024.189112.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2024.189112</pub-id><pub-id pub-id-type="pmid">38761983</pub-id></mixed-citation></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarahmadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zare</surname><given-names>M</given-names></name><name name-style="western"><surname>Aghayari</surname><given-names>M</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>H</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>GA</given-names></name></person-group><article-title>Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future</article-title><source>Cell Communication Signal</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>239</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01622-w</pub-id><pub-id pub-id-type="pmcid">PMC11040964</pub-id><pub-id pub-id-type="pmid">38654309</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Yarahmadi A, Zare M, Aghayari M, Afkhami H, Jafari GA. Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future. Cell Communication Signal. 2024;22(1):239.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-024-01622-w</pub-id><pub-id pub-id-type="pmcid">PMC11040964</pub-id><pub-id pub-id-type="pmid">38654309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaghoubi</surname><given-names>A</given-names></name><name name-style="western"><surname>Khazaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Hasanian</surname><given-names>SM</given-names></name><name name-style="western"><surname>Avan</surname><given-names>A</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C</given-names></name><name name-style="western"><surname>Soleimanpour</surname><given-names>W</given-names></name></person-group><article-title>Bacteriotherapy in breast cancer</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>23</issue><fpage>5880</fpage><pub-id pub-id-type="doi">10.3390/ijms20235880</pub-id><pub-id pub-id-type="pmid">31771178</pub-id><pub-id pub-id-type="pmcid">PMC6928964</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Yaghoubi A, Khazaei M, Hasanian SM, Avan A, Cho C, Soleimanpour W. Bacteriotherapy in breast cancer. Int J Mol Sci. 2019;20(23):5880.<pub-id pub-id-type="pmid">31771178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20235880</pub-id><pub-id pub-id-type="pmcid">PMC6928964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sultan</surname><given-names>MS</given-names></name></person-group><article-title>Challenges of breast cancer treatment through microbial therapeutic delivery</article-title><source>Microb Bioactives</source><year>2023</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Sultan MS. Challenges of breast cancer treatment through microbial therapeutic delivery. Microb Bioactives. 2023;6(1):1&#8211;15.</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Thi-Thu Ngo</surname><given-names>H</given-names></name><name name-style="western"><surname>Son</surname><given-names>J</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Min</surname><given-names>J-J</given-names></name></person-group><article-title>Exploiting bacteria for cancer immunotherapy</article-title><source>Nat Reviews Clin Oncol</source><year>2024</year><volume>21</volume><issue>8</issue><fpage>569</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/s41571-024-00908-9</pub-id><pub-id pub-id-type="pmid">38840029</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Kwon S-Y, Thi-Thu Ngo H, Son J, Hong Y, Min J-J. Exploiting bacteria for cancer immunotherapy. Nat Reviews Clin Oncol. 2024;21(8):569&#8211;89.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00908-9</pub-id><pub-id pub-id-type="pmid">38840029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mokhtari</surname><given-names>RB</given-names></name><name name-style="western"><surname>Homayouni</surname><given-names>TS</given-names></name><name name-style="western"><surname>Baluch</surname><given-names>N</given-names></name><name name-style="western"><surname>Morgatskaya</surname><given-names>E</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Das</surname><given-names>B</given-names></name><etal/></person-group><article-title>Combination therapy in combating cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>23</issue><fpage>38022</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.16723</pub-id><pub-id pub-id-type="pmid">28410237</pub-id><pub-id pub-id-type="pmcid">PMC5514969</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022.<pub-id pub-id-type="pmid">28410237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.16723</pub-id><pub-id pub-id-type="pmcid">PMC5514969</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Edil</surname><given-names>BH</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Combination therapies for cancer: challenges and opportunities</article-title><source>BMC Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>171</fpage><pub-id pub-id-type="doi">10.1186/s12916-023-02852-4</pub-id><pub-id pub-id-type="pmid">37143031</pub-id><pub-id pub-id-type="pmcid">PMC10161484</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Zhou Z, Edil BH, Li M. Combination therapies for cancer: challenges and opportunities. BMC Med. 2023;21(1):171.<pub-id pub-id-type="pmid">37143031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-023-02852-4</pub-id><pub-id pub-id-type="pmcid">PMC10161484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Molecular-targeted agents combination therapy for cancer: developments and potentials</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><issue>6</issue><fpage>1257</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/ijc.28261</pub-id><pub-id pub-id-type="pmid">23649791</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer. 2014;134(6):1257&#8211;69.<pub-id pub-id-type="pmid">23649791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.28261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiselev</surname><given-names>VI</given-names></name><name name-style="western"><surname>Ashrafyan</surname><given-names>LA</given-names></name><name name-style="western"><surname>Muyzhnek</surname><given-names>EL</given-names></name><name name-style="western"><surname>Gerfanova</surname><given-names>EV</given-names></name><name name-style="western"><surname>Antonova</surname><given-names>IB</given-names></name><name name-style="western"><surname>Aleshikova</surname><given-names>OI</given-names></name><etal/></person-group><article-title>A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>904</fpage><pub-id pub-id-type="doi">10.1186/s12885-018-4792-9</pub-id><pub-id pub-id-type="pmid">30236079</pub-id><pub-id pub-id-type="pmcid">PMC6148762</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Kiselev VI, Ashrafyan LA, Muyzhnek EL, Gerfanova EV, Antonova IB, Aleshikova OI, et al. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer. 2018;18(1):904.<pub-id pub-id-type="pmid">30236079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-018-4792-9</pub-id><pub-id pub-id-type="pmcid">PMC6148762</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Siu</surname><given-names>KTH</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X-Y</given-names></name></person-group><article-title>Exploring treatment options in cancer: tumor treatment strategies</article-title><source>Signal Transduct Target Therapy</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>175</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01856-7</pub-id><pub-id pub-id-type="pmcid">PMC11252281</pub-id><pub-id pub-id-type="pmid">39013849</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Therapy. 2024;9(1):175.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01856-7</pub-id><pub-id pub-id-type="pmcid">PMC11252281</pub-id><pub-id pub-id-type="pmid">39013849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>R</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name></person-group><article-title>Cancer treatment therapies: traditional to modern approaches to combat cancers</article-title><source>Mol Biol Rep</source><year>2023</year><volume>50</volume><issue>11</issue><fpage>9663</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s11033-023-08809-3</pub-id><pub-id pub-id-type="pmid">37828275</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663&#8211;76.<pub-id pub-id-type="pmid">37828275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-023-08809-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirrmacher</surname><given-names>V</given-names></name></person-group><article-title>Cancer vaccines and oncolytic viruses exert profoundly lower side effects in cancer patients than other systemic therapies: A comparative analysis</article-title><source>Biomedicines</source><year>2020</year><volume>8</volume><issue>3</issue><fpage>61</fpage><pub-id pub-id-type="doi">10.3390/biomedicines8030061</pub-id><pub-id pub-id-type="pmid">32188078</pub-id><pub-id pub-id-type="pmcid">PMC7148513</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Schirrmacher V. Cancer vaccines and oncolytic viruses exert profoundly lower side effects in cancer patients than other systemic therapies: A comparative analysis. Biomedicines. 2020;8(3):61.<pub-id pub-id-type="pmid">32188078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines8030061</pub-id><pub-id pub-id-type="pmcid">PMC7148513</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoda</surname><given-names>M</given-names></name></person-group><article-title>Potential alternatives to conventional cancer therapeutic approaches: the way forward</article-title><source>Curr Pharm Biotechnol</source><year>2021</year><volume>22</volume><issue>9</issue><fpage>1141</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2174/1389201021666201016142408</pub-id><pub-id pub-id-type="pmid">33069195</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Hoda M. Potential alternatives to conventional cancer therapeutic approaches: the way forward. Curr Pharm Biotechnol. 2021;22(9):1141&#8211;8.<pub-id pub-id-type="pmid">33069195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389201021666201016142408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsvetkova</surname><given-names>D</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>S</given-names></name></person-group><article-title>Application of approved cisplatin derivatives in combination therapy against different cancer diseases</article-title><source>Molecules</source><year>2022</year><volume>27</volume><issue>8</issue><fpage>2466</fpage><pub-id pub-id-type="doi">10.3390/molecules27082466</pub-id><pub-id pub-id-type="pmid">35458666</pub-id><pub-id pub-id-type="pmcid">PMC9031877</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Tsvetkova D, Ivanova S. Application of approved cisplatin derivatives in combination therapy against different cancer diseases. Molecules. 2022;27(8):2466.<pub-id pub-id-type="pmid">35458666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27082466</pub-id><pub-id pub-id-type="pmcid">PMC9031877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggersmann</surname><given-names>TK</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>T</given-names></name><name name-style="western"><surname>Gluz</surname><given-names>O</given-names></name><name name-style="western"><surname>Wuerstlein</surname><given-names>R</given-names></name><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name></person-group><article-title>CDK4/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib</article-title><source>BioDrugs</source><year>2019</year><volume>33</volume><issue>2</issue><fpage>125</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s40259-019-00337-6</pub-id><pub-id pub-id-type="pmid">30847853</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Eggersmann TK, Degenhardt T, Gluz O, Wuerstlein R, Harbeck N. CDK4/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib. BioDrugs. 2019;33(2):125&#8211;35.<pub-id pub-id-type="pmid">30847853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-019-00337-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lerebours</surname><given-names>F</given-names></name><name name-style="western"><surname>Ciruelos</surname><given-names>E</given-names></name><name name-style="western"><surname>Drullinsky</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruiz-Borrego</surname><given-names>M</given-names></name><name name-style="western"><surname>Neven</surname><given-names>P</given-names></name><etal/></person-group><article-title>RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><issue>4</issue><fpage>489</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00034-6</pub-id><pub-id pub-id-type="pmid">33794206</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489&#8211;98.<pub-id pub-id-type="pmid">33794206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00034-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Videtic</surname><given-names>GM</given-names></name><name name-style="western"><surname>Paulus</surname><given-names>R</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Parker</surname><given-names>W</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer</article-title><source>Int J Radiation Oncology* Biology* Phys</source><year>2019</year><volume>103</volume><issue>5</issue><fpage>1077</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.11.051</pub-id><pub-id pub-id-type="pmcid">PMC6454873</pub-id><pub-id pub-id-type="pmid">30513377</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiation Oncology* Biology* Phys. 2019;103(5):1077&#8211;84.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2018.11.051</pub-id><pub-id pub-id-type="pmcid">PMC6454873</pub-id><pub-id pub-id-type="pmid">30513377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>ED</given-names></name><name name-style="western"><surname>Heidenreich</surname><given-names>A</given-names></name><name name-style="western"><surname>Lawrentschuk</surname><given-names>N</given-names></name><name name-style="western"><surname>Tombal</surname><given-names>B</given-names></name><name name-style="western"><surname>Pompeo</surname><given-names>AC</given-names></name><name name-style="western"><surname>Mendoza-Valdes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations</article-title><source>Prostate Cancer Prostatic Dis</source><year>2019</year><volume>22</volume><issue>1</issue><fpage>24</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/s41391-018-0079-0</pub-id><pub-id pub-id-type="pmid">30131604</pub-id><pub-id pub-id-type="pmcid">PMC6370592</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo AC, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24&#8211;38.<pub-id pub-id-type="pmid">30131604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41391-018-0079-0</pub-id><pub-id pub-id-type="pmcid">PMC6370592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimbach</surname><given-names>JK</given-names></name><name name-style="western"><surname>Kulik</surname><given-names>LM</given-names></name><name name-style="western"><surname>Finn</surname><given-names>RS</given-names></name><name name-style="western"><surname>Sirlin</surname><given-names>CB</given-names></name><name name-style="western"><surname>Abecassis</surname><given-names>MM</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>LR</given-names></name><etal/></person-group><article-title>AASLD guidelines for the treatment of hepatocellular carcinoma</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><issue>1</issue><fpage>358</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/hep.29086</pub-id><pub-id pub-id-type="pmid">28130846</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358&#8211;80.<pub-id pub-id-type="pmid">28130846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29086</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>A-L</given-names></name><name name-style="western"><surname>Brockmueller</surname><given-names>A</given-names></name><name name-style="western"><surname>Fahimi</surname><given-names>N</given-names></name><name name-style="western"><surname>Ghotbi</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>S</given-names></name><name name-style="western"><surname>Sadri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bacteria-mediated modulatory strategies for colorectal cancer treatment</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><issue>4</issue><fpage>832</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10040832</pub-id><pub-id pub-id-type="pmid">35453581</pub-id><pub-id pub-id-type="pmcid">PMC9026499</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Mueller A-L, Brockmueller A, Fahimi N, Ghotbi T, Hashemi S, Sadri S, et al. Bacteria-mediated modulatory strategies for colorectal cancer treatment. Biomedicines. 2022;10(4):832.<pub-id pub-id-type="pmid">35453581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10040832</pub-id><pub-id pub-id-type="pmcid">PMC9026499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><mixed-citation publication-type="other">Saha S, Mollick S, Zaman S. The uses of bacteria in cancer therapy. Brac University; 2021.</mixed-citation></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Synthetic engineered bacteria for cancer therapy</article-title><source>Expert Opin Drug Deliv</source><year>2023</year><volume>20</volume><issue>7</issue><fpage>993</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1080/17425247.2023.2241367</pub-id><pub-id pub-id-type="pmid">37497622</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Gong T, Wu J. Synthetic engineered bacteria for cancer therapy. Expert Opin Drug Deliv. 2023;20(7):993&#8211;1013.<pub-id pub-id-type="pmid">37497622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425247.2023.2241367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshimatsu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mikami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>T</given-names></name></person-group><article-title>Bacteriotherapy for inflammatory bowel disease</article-title><source>Inflamm Regeneration</source><year>2021</year><volume>41</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s41232-020-00153-4</pub-id><pub-id pub-id-type="pmcid">PMC7807454</pub-id><pub-id pub-id-type="pmid">33441186</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Yoshimatsu Y, Mikami Y, Kanai T. Bacteriotherapy for inflammatory bowel disease. Inflamm Regeneration. 2021;41(1):3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41232-020-00153-4</pub-id><pub-id pub-id-type="pmcid">PMC7807454</pub-id><pub-id pub-id-type="pmid">33441186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wawrety</surname><given-names>W</given-names></name><name name-style="western"><surname>Kedziora</surname><given-names>A</given-names></name></person-group><article-title>Role of bacteria in cancers and their therapeutic potential: review of current knowledge</article-title><source>Iran J Basic Med Sci</source><year>2025</year><volume>28</volume><issue>3</issue><fpage>273</fpage><pub-id pub-id-type="pmid">39906620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22038/ijbms.2024.77667.16798</pub-id><pub-id pub-id-type="pmcid">PMC11790194</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Wawrety W, Kedziora A. Role of bacteria in cancers and their therapeutic potential: review of current knowledge. Iran J Basic Med Sci. 2025;28(3):273.<pub-id pub-id-type="pmid">39906620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22038/ijbms.2024.77667.16798</pub-id><pub-id pub-id-type="pmcid">PMC11790194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawant</surname><given-names>SS</given-names></name><name name-style="western"><surname>Patil</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name><name name-style="western"><surname>Kunda</surname><given-names>NK</given-names></name></person-group><article-title>Microbes as medicines: Harnessing the power of bacteria in advancing cancer treatment</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>20</issue><fpage>7575</fpage><pub-id pub-id-type="doi">10.3390/ijms21207575</pub-id><pub-id pub-id-type="pmid">33066447</pub-id><pub-id pub-id-type="pmcid">PMC7589870</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Sawant SS, Patil SM, Gupta V, Kunda NK. Microbes as medicines: Harnessing the power of bacteria in advancing cancer treatment. Int J Mol Sci. 2020;21(20):7575.<pub-id pub-id-type="pmid">33066447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21207575</pub-id><pub-id pub-id-type="pmcid">PMC7589870</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>BS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Bak</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Gut microbiota Eubacterium callanderi exerts anti-colorectal cancer activity</article-title><source>Microbiol Spectr</source><year>2022</year><volume>10</volume><issue>6</issue><fpage>e02531</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1128/spectrum.02531-22</pub-id><pub-id pub-id-type="pmid">36448791</pub-id><pub-id pub-id-type="pmcid">PMC9769849</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Ryu SW, Kim J-S, Oh BS, Choi WJ, Yu SY, Bak JE, et al. Gut microbiota Eubacterium callanderi exerts anti-colorectal cancer activity. Microbiol Spectr. 2022;10(6):e02531&#8211;22.<pub-id pub-id-type="pmid">36448791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/spectrum.02531-22</pub-id><pub-id pub-id-type="pmcid">PMC9769849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>M-Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q-C</given-names></name><name name-style="western"><surname>Hua</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y-Y</given-names></name><etal/></person-group><article-title>The microbiota and Microbiome in pancreatic cancer: more influential than expected</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1008-0</pub-id><pub-id pub-id-type="pmid">31109338</pub-id><pub-id pub-id-type="pmcid">PMC6526613</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Wei M-Y, Shi S, Liang C, Meng Q-C, Hua J, Zhang Y-Y, et al. The microbiota and Microbiome in pancreatic cancer: more influential than expected. Mol Cancer. 2019;18(1):97.<pub-id pub-id-type="pmid">31109338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-019-1008-0</pub-id><pub-id pub-id-type="pmcid">PMC6526613</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>